Glucose Metabolism in High-Risk Prostate Cancer Patients throughout the Acute Disease Trajectory by Di Sebastiano, Kathleen
Glucose Metabolism in High-Risk Prostate Cancer Patients throughout the 
Acute Disease Trajectory 
 
 
 
by 
 
 
Kathleen M. Di Sebastiano 
 
 
A thesis 
presented to the University of Waterloo 
in fulfillment of the 
thesis requirement for the degree of 
Doctor of Philosophy 
in 
Kinesiology 
 
 
 
Waterloo, Ontario, Canada, 2016 
 
 
©Kathleen M. Di Sebastiano 2016 
 
  ii 
AUTHOR'S DECLARATION 
I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including any 
required final revisions, as accepted by my examiners. 
I understand that my thesis may be made electronically available to the public. 
 
  iii 
Abstract 
Background: Hyperglycemia and insulin resistance are associated with obesity, physical inactivity, 
and poor diet, and may be related to hyperinsulinemia, disrupted lipid and adipokine signaling, and 
pro-inflammation. The independent and/or combination of these metabolic perturbations may increase 
prostate cancer risk, exacerbate during acute treatment, and worsen in survivorship.   The interactions 
between prostate cancer, treatment, dysregulation of glucose metabolism, and the associated 
metabolic sequelae are complex and should be evaluated in an integrative manner to discern these 
relationships.  The purpose of this thesis is to employ an integrative approach to examine glucose 
metabolism and related features at diagnosis and during the acute treatment trajectory (up to the first 
6 months of treatment) of prostate cancer patients. Objectives:  The objectives of this thesis were to: 
1) characterize glucose and associated parameters (insulin, C-peptide, IGF-1, IGFBP-3) in relation to 
lipid measures (triglycerides, cholesterols), adipokines (adiponectin, leptin), body composition, 
physical activity, diet, and inflammation  (CRP, IL-1β, IL-4. IL-6, IL-8, IL-10, TNF-α) prior to 
prostate cancer treatment, 2) examine potential changes in this comprehensive metabolic profile 
during the acute prostate cancer treatment trajectory (~6 months following radiation therapy), and 3) 
develop a cell culture model to examine the cellular mechanisms contributing to potential alterations 
in glucose metabolism observed during the treatment trajectory.  Methods:  In Study 1, fasting 
glucose, insulin, C-peptide, IGF-1, IGFBP-3, cholesterol, triglycerides, leptin, adiponectin, CRP were 
measured along with traditional moderators glucose metabolism (body composition, nutrition intake, 
habitual physical activity) to characterize interrelated metabolic features in men undergoing prostate 
biopsy. High-risk prostate cancer patients demonstrate the greatest C-peptide and leptin 
concentrations, as well as the greatest visceral adiposity in Study 1.  In Study 2, more comprehensive 
evaluations, including an oral glucose tolerance test (OGTT), were prospectively performed on a 
separate group of high-risk prostate cancer patients prior to radiation therapy (baseline), as well as 7 
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weeks and 33 weeks following baseline.  Patients were compared to a group of young healthy males 
and a group of age- and BMI-matched males to assess age- and cancer-related differences in glucose 
metabolism. To understand the underlying mechanisms of poor metabolic outcomes in high-risk 
prostate cancer patients, a novel cell culture model was developed in Study 3 where human skeletal 
muscle myoblasts (HSkMM) were incubated with human serum from prostate cancer patients across 
the acute treatment trajectory to examine glucose uptake. Results:  At the time of the prostate biopsy 
(or time of diagnosis for the prostate cancer patients) in Study 1, prostate cancer patients diagnosed 
with aggressive cancer (Gleason ≥4+3) demonstrated greater insulin secretion assessed by C-peptide 
concentrations compared with patients that had less aggressive cancers (Gleason ≥4+3: 2.8±1.1 
ng/mL vs Gleason 3+3 1.4±0.6 mg/mL vs Gleason 3+4: 1.3±0.8 mg/mL; p=0.002).  Insulin 
concentrations and HOMA-IR tended to be greater in patients with the most aggressive cancer 
compared to the others. Greater insulin secretion, measured by C-peptide concentrations, was related 
to greater visceral adiposity, higher leptin and leptin:adiponectin ratio, suggesting these metabolic 
perturbations may relate to obesity.  In Study 2, high-risk prostate cancer patients demonstrated 
impaired glucose tolerance by 2 hours of an OGTT prior to treatment (Normal: <7.8mM, Patients: 
8.62±2.87mM), which improved at 7 weeks post-baseline (6.78±1.48 mM) and was maintained 33 
weeks following baseline (5.69±2.14mM, p=0.007). Insulin, C-peptide, IGF-1, IGFBP-3, adipokines, 
triglycerides, cholesterols, inflammatory markers, physical activity, and nutrition intake did not 
change during the study trajectory. In Study 3, we evaluated the effects of serum from prostate cancer 
patients and matched males on differentiated HSkMM, which showed significantly reduced glucose 
uptake compared with young males; however there were no differences between prostate cancer 
patients and matched males, suggesting an age-related decrease in glucose uptake. Conclusions:  At 
diagnosis, prostate cancer patients demonstrated a cluster of glucose-related metabolic perturbations 
that may contribute to prostate cancer aggressiveness. Significant improvements in glucose 
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metabolism were observed during acute treatment, despite the lack of change in traditional 
moderators of glucose metabolism, suggesting cancer-related effects on host glucose metabolism. 
New models are needed to elucidate the mechanisms driving these metabolic changes and to, 
ultimately, reduce the risk of cancer recurrence, diabetes, and cardiovascular disease in prostate 
cancer survivors.   
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Chapter 1 
Statement of the Problem 
1.1 Introduction 
Prostate cancer is the most common form of cancer in Canadian men, with 1 in 7 men being 
diagnosed in their lifetime (1). Despite the prevalence of prostate cancer, the 5-year survival rate is 
exceptionally high at 96% (2), especially when it is compared to the survival rates for other types of 
cancer, such as pancreatic and lung cancer where the 5-year survival rates are 8% (2) and 14% in 
males, respectively (2).  However, prostate cancer patients are typically at increased risk for 
metabolic diseases, such as metabolic syndrome (3-5), cardiovascular disease (5-8), and diabetes (5-
8), in survivorship likely attributed to treatment. Increased risk of these metabolic diseases as well as 
increased risk of prostate cancer development is typically associated with obesity (9-11) and 
hyperinsulinemia (12, 13), commonly resulting from high fat diets (14, 15) and physical inactivity 
(16, 17). Little is known about the interrelationship between these metabolic and lifestyle 
perturbations and prostate cancer development, as well as the changes in these relationships during 
treatment. From these data, two distinct research questions emerge:  
A) What metabolic factors associate with the development of prostate cancer?   
B) How do metabolic factors change during prostate cancer treatment and contribute to 
quality of life in survivorship?  
1.1.1 What metabolic factors associate with the development of prostate cancer?   
A number of non-modifiable risk factors have been associated with the diagnosis of prostate 
cancer; these include age, family history and ethnicity (18-20).  There are also a number of 
modifiable risk factors that have been associated with developing prostate cancer including, diet, 
physical inactivity, obesity and smoking.  Most of the literature that relates these modifiable lifestyle 
factors, such as obesity, to prostate cancer is inconclusive. Some studies demonstrate positive 
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associations between prostate cancer and lifestyle factors, while others demonstrate no association 
(21-23). However, there is more conclusive evidence to indicate that these lifestyle factors, may 
contribute to the increased risk of aggressive prostate cancer and prostate cancer mortality (24). 
Comparing metabolic and lifestyle features in prostate cancer patients with non-malignant individuals 
may advance our understanding of potential factors that associate with prostate cancer diagnosis.  
1.1.2 How do Lifestyle and Metabolic Factors Influence Prostate Cancer Treatment 
and contribute to Quality of Life in Survivorship? 
Increased prevalence of prostate cancer combined with a 96% 5-year survival rate results in a 
continually increasing number of prostate cancer survivors (2).  There are several definitions for the 
term cancer survivor; for the purpose of this thesis, cancer survivor will be defined as an individual 
who has completed primary treatment, focusing on post-treatment.  A large body of literature 
suggests that prostate cancer patients are at increased risk of cardiovascular disease and diabetes in 
survivorship (25-29).  This relationship is primarily described in patients who undergo androgen 
deprivation therapy (ADT) as part of their cancer treatment.  ADT is a form of chemical castration 
that reduces testosterone and other androgens to extremely low concentrations.  This reduction in 
testosterone, the primary anabolic stimulus in the male body, may result in skeletal muscle loss and 
adipose tissue gains (30). These features of body composition are associated with various unhealthy 
metabolic outcomes (i.e. impaired glucose metabolism; 31) and with the development of the co-
morbidities in survivorship (25-29). There is also a growing body of literature examining how ADT 
influences glucose metabolism and diabetes (28, 32); however, few studies have examined glucose 
metabolism integrating interactions with body composition, physical activity and diet. The metabolic 
profile of prostate cancer patients at the time of cancer diagnosis may relate to risk of more aggressive 
prostate cancer and prostate cancer mortality (24). 
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 ADT is just one of the treatment options available for prostate cancer patients and the studies 
investigating the metabolic effects of ADT usually focus on the long-term (years) consequences of 
treatment (25-29, 32).  Little is known about the metabolic implications of radiation therapy.  Higher 
BMI is associated with increased risk of biochemical recurrence following radiation therapy (33); 
however, the mechanisms and the impact of radiation therapy on the metabolism of prostate cancer 
patients are unknown. Further investigation of the metabolic health of men undergoing acute 
treatment with modalities other than ADT is warranted to elucidate the interaction between prostate 
cancer treatment, metabolic perturbations and the development of secondary diseases in prostate 
cancer survivors.        
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Chapter 2 
Fundamentals of Prostate Cancer 
2.1 Prostate Cancer in Canada 
Prostate cancer is the most common form of cancer in Canadaian men with an estimated 24 
000 new cases diagnosed in 2015, accounting for 23.9% of all male cancer diagnoses (2). Since the 
early 1990’s, the number of cases of prostate cancer has increased due to improvements in prostate 
cancer screening procedures, culminating in two peaks in prostate cancer diagnosis in 1993 and 2001 
following intensified screening using prostate specific antigen (PSA) testing.  However, since 2001, 
the age-standardized incidence rate of prostate cancer has been declining (2).  Despite these declining 
incidence rates, the number of prostate cancer diagnoses is still significantly above those of other 
cancers (an estimated 176 355 Canadian males have been diagnosed with prostate cancer since 1999); 
however, there has been a steady decline in the prostate cancer mortality, with 96% 5-year survival 
rates (2). These reductions in mortality are likely due to improvements in treatment (20), leading to a 
growing number of prostate cancer survivors in Canada. 
2.2 Prostate Cancer Staging 
With the prevalence of prostate cancer and the exceptionally high 5-year survival rates, 
severity of cancer diagnosis is a large determinant of not only survival outcomes, but also treatment 
approaches and outcomes.  Currently, there are 3 tools to diagnose and assess cancer severity: cancer 
stage, PSA level, and Gleason score, together named stage grouping. Digital rectal exams (DRE), 
physical palpation of the rectum to identify abnormalities in the prostate, are also used to assess 
prostate cancer. However, the subjective nature of the DRE prevents its inclusion in stage grouping. 
As with many cancers, TNM (Tumour, Node, Metastasis) staging, which is the cancer staging system 
accepted by the International Union Against Cancer and the American Joint Committee on Cancer 7th 
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edition (34), is used to assess the progression of cancer by classifying size, lymphatic involvement, 
and metastases (34). TNM staging is based on the extent of the tumour (T) (i.e. size and number of 
tumours), whether or not it has spread to the lymph nodes (N), and the presence of distant metastasis 
(M) (i.e. whether the tumour has spread to other locations) (34).  A number is assigned to each letter 
to represent the extent of the disease (Table 2.1).  These factors are assessed through a variety of tests 
including physical exam (DRE), imaging (x-ray, CT, MRI, etc.), biomarker assessment, pathology 
reports, and surgical assessment (34). There are 4 general stages of cancer progression. In Stage 0 the 
carcinoma in situ, while Stages I, II, and III represent more extensive disease and Stage IV represents 
metastatic disease. Additional criteria are used in staging assess tumour grade or cell type. 
 
Table 2.1: TNM Staging Classification System 
 Primary Tumour (T) Regional Lymph Nodes (N) Distant Metastasis (M) 
X Cannot be evaluated Cannot be evaluated Cannot be evaluated 
0 No primary tumour No involvement No metastasis 
In situ Abnormal cells present, 
but not yet cancerous 
- - 
1 Size and extent of primary 
tumour is assessed 
Lymph nodes involved, 
number and extent assessed 
Metastasis present 
2 - 
3 - 
4 - - 
 
The second tool used to diagnose prostate cancer is PSA concentration.  PSA is a serine 
protease that is produced by both normal and malignant prostate glands.  In a non-malignant male, it 
is secreted in seminal fluid and little is released into the blood; however, in malignant tissue 
significant amounts of PSA leaks into the blood stream, raising its circulating levels (35).  Thus, PSA 
is a potent biomarker for prostate cancer.  Healthy circulating PSA levels are < 4 ug/L, while PSA 
levels between 4-10 ug/L are termed the “grey zone” where further investigation is required, and PSA 
levels >10 ug/L are considered significantly elevated (35).   However, the efficacy of PSA testing is 
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often questioned and PSA screening is not currently recommended in Canada (36); however, its use is 
still widespread (37, 38).  
The final tool used to diagnose and assess prostate cancer severity is Gleason score.  This is a 
pathology marker that characterizes the pattern of cells within the tumour.  There are different cell 
patterns that a pathologist evaluates and subsequently assigns 2 scores (each score ranges from 1-5). 
The first score is the most common cell pattern observed in the prostate tissue and the second score is 
the second most common cell pattern observed. These scores are then added together to determine 
Gleason score (a total score ranging from 2-10) (39). Please see Appendix II for a detailed description 
of the individual cell characteristics of Gleason scores. Generally, the higher the Gleason score, the 
more severe the cancer; however, a Gleason score of >7 is often defined in the literature as the cut 
point between moderate and severe prostate cancer diagnosis.   
 These three diagnostic tools, TNM staging, PSA and Gleason score, are used together to 
stratify prostate cancer risk.  The most commonly cited method was developed by D’Amico and 
colleagues (40).  This system stratifies patients into 3 risk categories: low-, intermediate- and high-
risk cancer.  This system predicts the likelihood that the patient will experience PSA or biochemical 
failure (defined as elevation of PSA following prostate cancer treatment) within 5 years and it is 
based on cancer stage, PSA levels at diagnosis and Gleason score. Low-risk patients are staged T1c-
T3a, have PSA < 10 ug/L, and Gleason < 6. They are predicted to have a < 25% chance of PSA 
failure in 5 years.  Intermediate-risk patients have between 25-50% chance of PSA failure in 5 years 
and are staged T2b, with PSA between 10-20 ug/L, and Gleason scores of 7.  Finally, high-risk 
prostate cancer is defined as > 50% chance of PSA failure in 5 years with a staging > T2c, PSA > 20 
ug/L and/or Gleason score > 8 (40).  Understanding of the classification systems of prostate cancer is 
important as low-, intermediate- and high-risk cancer have different risk factors, treatment plans, and 
outcomes.   
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2.3 Prostate Cancer Treatment 
Stage of cancer at diagnosis is a large determinant of the type of treatment a prostate cancer 
patient will receive, as each stage provides its own unique treatment challenges.  There are 5 major 
treatment options for prostate cancer patients:  active surveillance, surgery, radiation therapy, 
hormone therapy, and chemotherapy.  The use of these therapies is highly dependent on the individual 
cancer diagnosis and progression.  Many of these therapies are employed in conjunction with one 
another. 
2.3.1 Active Surveillance 
Active surveillance is a process of close monitoring in low-risk prostate cancers.  Essentially, 
patients with cancers at a very low-risk for progression, are not treated initially, but are instead 
repeatedly evaluated to determine if the cancer is progressing and therefore warrants treatment (41).  
There are no specific guidelines for the use of active surveillance from the Canadian Urological 
Association (CUA), American Urology Association (AUA), or European Association for Urology 
(EAU).  Since no specific guidelines for active surveillance exist, descriptions of active surveillance 
vary; in general, active surveillance constitutes repeated check-ups generally every 3-6 months that 
include DRE, PSA tests, and/or repeat biopsies (42).   
The following eligibility criteria have been proposed by the EUA to identify patients eligible 
for active surveillance: clinically confirmed prostate cancer (T1-T2), Gleason ≤6, ≤3 biopsy cores 
involved with cancer, ≤50% of each core defined with the presence of cancer, and PSA <10 ng/mL 
(43).  Therapy is recommended when there is significant disease progression, which is defined by 
rapid PSA doubling time (cut off between ≤2 and ≤4 years), clinical progression with DRE, or grade 
progression (Gleason ≥7) or tumour volume progression with repeated biopsy (43, 44).   
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2.3.2 Surgery 
Radical prostatectomy is the most common form of surgery for prostate cancer treatment 
(42).  It involves the complete removal of the prostate gland, the seminal vesicles, and ampulla of the 
vas deferens (41).  There are multiple variations of radical prostatectomy including the incision 
location (retropubic vs perineal), as well as laparoscopic and robotic-assisted techniques (41). There 
are also both nerve-sparing and non-nerve sparing options that are chosen based on tumour 
characteristics and sexual function in patients (43). For patients with truly localized disease (found 
only within the prostate gland), radical prostatectomy offers a potentially curative treatment; 
however, for higher risk, non-localized disease, this may not be possible (41). For more advanced 
prostate cancer, radical prostatectomy is performed in conjunction with a pelvic lymphadenectomy, 
removal of the surrounding lymph nodes (43).  For men with high-risk cancer (Stage >cT2b, PSA 
>20ng/dl, Gleason ≥7), multiple-modal treatment is used and surgical methods may be used in 
conjunction with additional treatments (43). 
2.3.3 Radiation Therapy 
Prostate cancer patients can undergo either external beam radiation therapy or brachytherapy, 
though the latter is typically used only in less advanced cases.  Brachytherapy involves inserting 
small radioactive “seeds” directly inside of the prostate to treat the cancerous tissue (41).  The 
isotope, isotope intensity, and number of seeds are determined on a case-by-case basis; however, 
common treatment regimens include 120 Gy of palladium or 140 Gy of iodine-125 (41).  This 
technique has been deemed safe and effective for low-risk prostate cancer patients.  The EAU 
employs the following eligibility criteria for this treatment: stage cT1c-T2z, N0, M0; Gleason ≤6, 
initial PSA ≤10ng/mL, ≤50% biopsy cores involved in cancer; prostate volume <50mL, and a good 
international prostate system score.   
  9 
External beam radiation therapy involves providing radiation to the prostate and surrounding 
tissues via an external device (41). Dosage is dependent on cancer severity, with the EAU suggesting 
at least 74 Gy for low-risk prostate cancer, 76-81 Gy for intermediate prostate cancer patients as these 
dosages have been shown to improve disease-free survival times (45).  However, for high-risk 
prostate cancer patients, the EAU suggests that while escalating doses of external beam radiation 
beyond those recommended for intermediate-risk patients improves disease-free survival, external 
beam radiation is unable to mitigate the risk of systemic relapse (45).  Consequently, radiation 
therapy for high-risk patients is usually used in conjunction with hormonal therapy.  
2.3.4 Hormone Therapy 
Hormone therapy, termed androgen deprivation therapy (ADT), is used in patients for whom 
curative therapy is not possible or appropriate (41).  The aim of ADT is to reduce testosterone to 
castrate levels, as testosterone has been identified as one of the earliest promoters of prostate cancer 
growth (46).  Traditionally, this was achieved through orchiectomy, or surgical removal of the 
testicles, which reduces testosterone level by 90-95%; however, this treatment type is currently rare, 
with most patients undergoing “chemical castration” through the use of various drugs (47).  ADT can 
be used as primary treatment in early-stage prostate cancer or can be administered neo-adjuvantly, 
prior to local treatment, to reduce tumour size and improve treatment outcomes, or adjuvantly, 
following local treatment, as a precaution to treat cancerous cells elsewhere in the body (47). 
Numerous categories of drugs can be used in ADT, including luteinizing hormone-releasing 
hormone (LHRH) agonist, LHRH antagonist, and anti-androgens.  LHRH, also known as 
gonadotropin-releasing hormone, is responsible for the release of both follicle stimulating hormone 
(FSH) and luteinizing hormone (LH) and is considered the first step in the hypothalamic-pituitary-
gonadal axis (48).  LHRH agonist work by essentially depleting the pituitary and down-regulating the 
pituitary LHRH receptor, reducing the pituitary’s ability to respond to LHRH (17). This treatment is 
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associated with an initial testosterone flare when first administered as the pituitary initially releases 
LH prior to its expected down-regulation, which typically occurs approximately 30 days following 
administration (48).  LHRH antagonist work more quickly and do not cause the testosterone flare 
observed with LHRH agonist (48).  The drugs stop LHRH from binding to its receptors in the 
pituitary, reducing LH secretion and ultimately reducing testosterone levels (47).  Anti-androgens are 
often used in conjunction with LHRH agonists as they block the effects of androgens without 
suppressing their production (48).  The combination of these drugs is known as total androgen 
blockade.    
 There are numerous side-effects associated with ADT including hot flashes, decreased libido 
and erectile dysfunction, breast enlargement and tenderness, irritability, depression and emotional 
disturbances, headache, dry skin, itching, and rashes, gastrointestinal distress, testicle shrinkage, 
osteoporosis, anemia, skeletal muscle loss, increased adiposity, and the risk of developing metabolic 
syndrome (a cluster of risk factors that increases the risk of cardiovascular disease and diabetes) (47).   
Skeletal muscle loss and increased adiposity are especially a concern because these body composition 
changes are associated with cardiovascular disease and diabetes in non-malignant populations (49, 
50).  Prostate cancer patients who receive ADT are at increased risk for cardiovascular disease and 
diabetes in survivorship (28). 
2.3.5 Chemotherapy 
Chemotherapy is not used in most cases of prostate cancer and is typically used to treat only 
metastatic and castration resistant prostate cancer.  Docetaxel is the primary chemotherapy agent 
recommended by the CUA for the treatment of castration resistant prostate cancer (51).  The advised 
dosage is 75mg/m2 IV, every 3 weeks (51).  Docetaxel significantly increased survival compared to 
other treatment regimens including mitoxantrone (52).  For disease control, palliation and quality of 
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life, the CUA indicated that there is Level 2, Grade B evidence for the use of weekly docetaxel plus 
prednisone, or mitoxantrone plus prednisone (51).  
2.4 Prostate Cancer Risk Factors 
2.4.1 Non-modifiable Risk Factors 
There are 3 primary non-modifiable risk factors that have been associated with prostate 
cancer: age, ethnicity, and family history.  Age is the strongest known risk factor for prostate cancer.  
In Canada, 97.8% of all prostate cancer diagnoses occur in men over the age of 50, while less than 
1% of cases occur in men under the age of 40 (18).  By age 90, 80% of men have been shown to have 
cancerous cells in their prostate (53).   
 Apart from age, family history has been shown to be one of the strongest risk factors for 
prostate cancer.  The literature suggests that 5 to 10% of all prostate cancer is associated with genetic 
predisposition, and this value increases between 30 to 40% in men diagnosed prior to the age of 55 
years old (19,54).  Risk further increases if a first-degree relative is diagnosed prior to the age of 60 
(55). 
 Ethnicity or race has also been shown to significantly influence prostate cancer risk. There is 
a significant increase in prostate cancer incidence among African American men when compared to 
any other race (20).  The age-adjusted incidence rates per 100 000 men are 248.5 for African 
Americans compared to 156.7 for Caucasians, 93.8 for Asians and 138 for Hispanic populations (20).  
African Americans are also more likely to be diagnosed with advanced disease (56) and are 2 times as 
likely to die of prostate cancer compared with Caucasian men (20, 57). 
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2.4.2  Modifiable Risk Factors 
While the evidence supporting the associations between age, family history, ethnicity and 
prostate cancer development is strong, the literature linking modifiable risk factors such as obesity, 
diet, and physical activity to prostate cancer risk is less clear.   
 Obesity has been linked to increased risk of a number of different types of cancer including 
breast and colorectal; however, the link between obesity and prostate cancer is less clear.  Numerous 
meta-analyses have examined the relationship between obesity, usually assessed via body mass index 
(BMI) and prostate cancer incidence (9, 10, 21-23, 58-60).  Each meta-analysis reported a small but 
significant positive increase in relative risk for prostate cancer.   The general conclusions from these 
analyses are that obesity is associated with increased risk of prostate cancer, and specifically, 
aggressive prostate cancer.  The literature examining the relationship between low-risk or localized 
prostate cancer and obesity remains inconclusive.  Discacciati et al (9) reported a protective effect of 
obesity against localized prostate cancer (RR: 0.94; 95% CI, 0.91-0.97), but an increased risk of 
aggressive prostate cancer with obesity (RR: 1.09; 95% CI, 1.02-1.16).  Most studies used BMI as 
their marker of body composition, which is a crude measure of body composition and obesity; 
therefore, it may not be sensitive enough to determine associations between prostate cancer and 
obesity in individual studies. However, BMI is an effective measure of obesity at a population level, 
thus, the relationship between BMI and prostate cancer incidence becomes clearer in the meta-
analyses when a larger sample size is considered. 
While most meta-analyses reported a positive association between BMI and prostate cancer 
risk and specifically, aggressive prostate cancer, there is great heterogeneity in the literature.  This is 
most likely due to study design and country of origin as obesity rates and prostate cancer screening 
procedures vary greatly from country to country. Geographical regions have been shown to influence 
the relationship between prostate cancer and obesity (61). North American studies reported no effect 
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of obesity on prostate cancer risk (relative risk (RR): 1.04; 95% CI 0.96-1.03), while European and 
Australian cohorts demonstrated a modest positive association between obesity and prostate cancer 
risk (RR: 1.04; 95% CI 1.01-1.07) (61).   These discrepancies are thought to be due to differences in 
PSA screening procedures, as PSA screening is more common in North America and compared to 
Europe; thus, cancer diagnosis occurs at earlier stages in North America versus in Europe.  In 
addition, PSA levels are typically lower in obese men (62), which results in fewer biopsies in this 
population, and consequently, fewer obese men are diagnosed at an earlier stage – this phenomenon is 
known as detection bias hypothesis and will be discussed in detail later in this literature review 
(Section 2.5.2). 
 Two other lifestyles factors, which have been known to contribute significantly to obesity, 
have been examined for their relationship to prostate cancer: diet and physical activity.  The 
relationship between diet and prostate cancer has been examined in a variety of different ways 
including specific macronutrients like fat intake, food group analysis such as fruit and vegetables, 
meat, and dairy, specific foods such as soy and green tea and a number of specific vitamins and 
minerals including, lycopene and selenium (14, 15, 63-65).  The majority of the literature in this area 
remains inconclusive with small-scale studies showing both positive and neutral association between 
these components of diet and prostate cancer risk (14, 15, 63, 64).  
The relationship between diet and prostate cancer is further confounded when obesity and 
metabolic syndrome are considered.  Both obesity and metabolic syndrome have independently been 
implicated in prostate cancer development; however, dietary intake significantly influences both of 
these conditions.  Obesity and metabolic syndrome are associated with high carbohydrate (65, 66) and 
saturated fat intake (67).  The traditional hypocaloric macronutrient distribution of 15% protein, 
<30% fat, and 50-55% carbohydrates to treat obesity and metabolic syndrome has come into question 
of late, with a higher protein distribution of 30% protein, 30% fat and 40% carbohydrates may be 
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more effective in ameliorating the negative implications of diet on body composition and metabolic 
syndrome (68).  However, all of these factors complicate the relationship between diet and prostate 
cancer even further.   
As with diet, the literature examining physical activity as a risk factor remains inconsistent.  
Overall, physical activity is reported to reduce the risk of prostate cancer by 10-20% with increasing 
physical activity levels (16).   One review evaluated 40 epidemiological studies examining physical 
activity as a protective mechanism against prostate cancer (17).  Twenty-two of the studies reported a 
small, but significant protective effect of physical activity and prostate cancer risk, 14 demonstrated 
no association between physical activity levels and prostate cancer risk, while the remaining 4 
demonstrated a negative effect of physical activity on prostate cancer risk (17).  However, many of 
the discrepancies observed in these data may be related to differences in methodological approaches, 
type of exercise reported (including the use aerobic versus resistance training or combined protocols), 
intensity, duration, and frequency of these programs as well as heterogeneity in the populations 
studied.  Another important consideration for all of these modifiable risk factors, obesity, diet, and 
physical activity, all relate to one another, confounding the data even further.   
2.5 Aggressive versus Slow Growing Cancers 
Much of the literature examining risk of prostate cancer and lifestyle factors remain 
inconclusive, especially with regards to the dichotomy between the aggressive or high-risk cancers 
and localized or low-risk cancers.  This phenomenon is most often observed in the literature 
examining obesity and obesity-related risk factors in prostate cancer.  Obesity has been shown to be a 
risk factor for high-risk prostate cancer and prostate cancer mortality, but has not consistently been 
shown to be a risk factor for general prostate cancer diagnosis (69).  Metabolic syndrome has also 
demonstrated this relationship with prostate cancer (70). There are two primary hypotheses that may 
explain this phenomenon: the altered hormone hypothesis and the detection bias hypothesis. 
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2.5.1 Altered Hormone Hypothesis  
 The altered hormone hypothesis is based on the role of testosterone in both normal and 
malignant prostate tissue, and the differences in testosterone levels in obese versus lean men.  In 
healthy prostate tissue, testosterone stimulates tissue growth; however, testosterone cannot distinguish 
between healthy and malignant tissue.  Thus, when a tumour is present testosterone stimulates tumour 
growth along with healthy prostate cell growth.  Obese men typically have lower testosterone levels 
compared to lean men (71).  Consequently, there is a smaller tumour growth stimulus from 
testosterone in obese patients.  However, in advanced prostate cancer, tumours often become 
testosterone independent – they grow without a testosterone stimulus – thus, obese patients with 
lower testosterone levels would be more likely to develop the more aggressive type of tumour (72).  
2.5.2 Detection Bias Hypothesis 
 Detection bias hypothesis suggests that prostate cancer is more difficult to detect in obese 
patients.  Obesity obscures the accuracy of the primary screening tools employed by physicians to 
detect prostate cancer. First, digital rectal exams are more difficult to perform in obese patients, 
limiting the physician’s ability to accurately assess the prostate (72).  Second, obese individuals have 
naturally lower PSA levels due to hemodilution (72).  Thus, this biomarker is less likely to be 
elevated in obese patients.   Finally, obese patients have larger prostate volumes, implying that there 
is increased likelihood that small, early stage tumours may be missed with a prostate biopsy (72).  A 
typical prostate biopsy extracts 12 biopsy cores to be examined by a pathologist to provide a Gleason 
score.  The larger the prostate, the increased chance that one of the 12 cores will miss a small tumour 
(72).  These three factors work together to hinder a physician’s ability to detect prostate cancer in 
obese patients.  Therefore, prostate cancer is diagnosed at later stages in obese patients (72).   
 Both the altered hormone hypothesis and the detection bias hypothesis remain controversial 
and require further investigation.  Some researchers suggest that a combination of factors from both 
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the altered hormone hypothesis and the detection bias hypothesis may explain the discrepancy in the 
relationship between obesity and risk of low-grade versus high-grade prostate cancer. 
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Chapter 3 
Literature Review 
3.1 Insulin and Glucose Metabolism in Prostate Cancer 
As with much of the literature examining metabolic factors and their association with prostate 
cancer, the relationship between glucose metabolism and prostate cancer remains unclear.  Few 
studies have examined glucose metabolism as a risk factor for prostate cancer, and those that have, 
demonstrate inconsistent results (73, 74).  As well, the literature examining glucose metabolism in 
prostate cancer treatment and survivorship is only focused on ADT use.    
3.1.1 Insulin as a Risk Factor for Prostate Cancer 
 Insulin has been implicated in a number of processes in tumour growth.  Increased insulin 
secretion occurs with many cancers, which results in a decreased sensitivity in peripheral tissues and 
leading to insulin resistance in healthy tissues.  Consequently, this increase in secretion and decrease 
in peripheral tissue sensitivity may result in systemic hyperinsulinemia, further exacerbating cancer 
growth (76-77).  Some studies have demonstrated positive association between hyperinsulinemia and 
prostate cancer risk (12, 78-80), while other studies examined hyperinsulinemia as a risk factor for 
prostate cancer and found no association between elevated insulin and prostate cancer risk. (73, 74).  
Abnormal insulin levels are not the only potential risk factors for prostate cancer, fasting insulin 
levels near the upper end of the healthy ranges have also been positively associated with prostate 
cancer in a case-cohort study (80).  In contrast, late stage diabetes – specifically, when insulin levels 
begin to decline due to β-cell burnout - is negatively associated with prostate cancer risk (81-83). 
Metformin, a common drug used to control blood sugar in type 2 diabetics, is associated with 
decreased risk of prostate cancer (84, 55).   Despite this data, in a meta-analysis that examined insulin 
therapy and prostate cancer risk, no significant associations were found between insulin therapy and 
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prostate cancer risk (86).  Taken together, this suggests that insulin may stimulate prostate cancer 
growth but it is uncertain whether insulin therapy will reduce the risk of prostate cancer.   
3.1.2 Mechanisms of Insulin Action in Prostate Cancer 
There is a large body of literature to support insulin as a potent growth factor in prostate 
cancer (Reviewed: 87-91). Insulin is also associated with growth of aggressive prostate tumour 
growth and more advanced disease (92).  Higher grade (aggressive) prostate tumours have also been 
shown to have increased numbers of insulin receptors on their membrane (91).   The binding of 
insulin to its receptor activates the intrinsic tyrosine receptor domain stimulating both the 
PI3K/Akt/mTOR pathway as well as the MAP/ERK-kinase pathway (92).  Activation of these 
pathways ultimately results in cell proliferation, migration, and differentiation, as well as the 
inhibition of apoptosis (92).  Thus, elevated circulating insulin concentrations combined with 
increased number of insulin receptors on aggressive prostate tumours supports the hypothesis of 
insulin as a significant contributor to prostate cancer growth.    
Beyond insulin itself, other factors that contribute to glucose metabolism have been 
implicated in the development of prostate cancer.  Insulin-like growth factor-1 (IGF-1) works through 
the same signalling pathways as insulin and has been shown to increase prostate cancer risk (93, 94), 
while its primary transport binding protein insulin-like growth factor binding protein-3 (IGFBP-3), 
which when would to IGF_1 forms a stable complex,.  is inversely associated with prostate cancer 
risk (24). As well, elevated fasting C-peptide, a marker of insulin secretion due to it simultaneous 
release for the pancreas with insulin and its short half-life, has been associated with prostate cancer 
risk (95). Its measurement allows for the distinction between increase insulin secretion or decrease 
clearance as the mechanism for hyperinsulinemia.  However, most of the literature focuses on fasting 
insulin, and C-peptide values, which may mask the body’s ability to respond to a glucose challenge. 
Only 2 studies have employed an oral glucose tolerance test (OGTT) in prostate cancer patients to 
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evaluate responses to a bolus of glucose (96, 97).  Zamboni et al (96) demonstrated normal 2-hour 
glucose concentrations following OGTT in prostate cancer patients with varying severity of disease. 
Here, patients had higher fasting insulin and homeostatic model assessment insulin resistance 
(HOMA-IR) compared with non-malignant controls.  Despite the plethora of data that one could 
obtain from an OGTT, Zamboni and colleagues only evaluated fasting and 2-hour glucose 
measurements were considered in addition to fasting insulin. They did not measure 2-hour insulin and 
C-peptide concentrations during the OGTT, which would better examine the body’s ability to clear 
glucose.  Since insulin may have a role in aggressive prostate cancer growth, it would also be 
important to distinguish glucose responses during an OGTT based on severity of disease. 
Tekdogan et al (97) examined insulin, IGF-1 and IGFBP-3 during and OGTT in prostate 
cancer patients compared to patients with benign prostate hyperplasia (BPH).  There were no 
differences in IGF-1 and IBGBP-3 during the OGTT between the prostate cancer patients and the 
BPH patients; however, they noted elevated insulin levels in both groups, though the patients with 
BPH had significantly higher insulin concentrations than the cancer patients (97).   The use of 
methodology beyond fasting metabolites and hormone concentrations is clearly important since 
fasting measures may mask impairments that would be revealed through an OGTT or other 
comprehensive approaches.  Further investigation into the role of glucose metabolism during a 
glucose challenge may be more reflective of the tissue exposure to insulin and its related hormones 
and may facilitate the understanding of the complex relationship between prostate cancer and glucose 
metabolism.  
3.1.3 Glucose Metabolism and Prostate Cancer Treatment 
 ADT is a common treatment approach for high-risk prostate cancer and its use is associated 
with diabetes as a secondary disease state (27).  Impaired insulin sensitivity occurs within the first 3 
months of ADT use (98, 99). In an OGTT following 12 weeks of ADT, glucose response was 
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identical following ADT relative to baseline; however, insulin levels were significantly elevated 
following the 12 weeks of treatment during the OGTT, suggesting decreased insulin sensitivity (99). 
As well, decreases in the insulin sensitivity index and increased glycated hemoglobin (a marker of 
long term perturbations in glucose metabolism) were also observed in prostate cancer patients 
undergoing 12 weeks of ADT (98). Fasting serum insulin levels (98, 100, 102) and fasting glucose 
levels have also been shown to increase following ADT (102).  Despite this evidence, there are few 
large-scale studies examining longitudinal changes and incidence of ADT- related metabolic 
disorders (103). 
The mechanisms underlying the relationship between ADT and the development of insulin 
resistance are poorly characterized.  The main hypothesis suggests that the interaction between 
cytokines and testosterone influence the development of insulin resistance (103). Adipose tissue 
derived pro-inflammatory cytokines like interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), 
elevated in chronic low-grade inflammation, have been associated with type II diabetes (104, 105).  
Low testosterone concentrations have been shown to contribute to insulin resistance in hypogonadal 
men with metabolic syndrome. In contrast, testosterone administration can lower plasma insulin 
concentrations and HOMA-IR (106), which may occur through inhibition of these inflammatory 
markers (106, 107). It is possible that cross-talk between sex steroids and pro-inflammatory cytokines 
during ADT may influence the development of insulin resistance in the patients (103). However, it is 
unknown whether increased pro-inflammatory cytokine levels cause insulin resistance or are a 
consequence of ADT use and altered sex hormone levels.  Further, investigation into the mechanisms 
behind these associations is warranted to elucidate these complex interactions.  
Beyond ADT, there is some evidence that treatments other than ADT may increase diabetes 
risk in prostate cancer survivors.  Thong et al (108) examined incidence of diabetes following a 
prostate cancer diagnosis and demonstrated that 50.2% of patients had received radical 
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prostatectomy, 21.4% received radiation therapy, 16.3% were undergoing active surveillance 
and only 12.1% received hormone therapy as their primary treatment type (108).  These data 
suggest that all prostate cancer patients, not just those receive ADT, are at risk of developing 
diabetes in survivorship.  Remarkably, the vast majority of research has focused on the 
metabolic effects of hormone therapy. Clearly, there are other mechanisms driving the 
relationship between insulin and prostate cancer that warrant further study.  
 
3.2 Body Composition and Prostate Cancer 
Obesity has been implicated in the development of disrupted glucose metabolism, insulin 
resistance and eventually diabetes (109).  However, it has also been implicated in the development of 
prostate cancer.  It is one of the major modifiable risk factors for prostate cancer.  In Section 2.4.2 
(Modifiable Risk Factors), I discussed the influence of obesity on prostate cancer risk.  Beyond risk, 
obesity may also significantly affect treatment and survivorship following a prostate cancer diagnosis. 
3.2.1 Obesity and Prostate Cancer Treatment 
Obesity may influence outcomes of the 3 primary categories of prostate cancer treatment: 
radical prostatectomy, radiation therapy, and androgen deprivation therapy (ADT).  Obesity has been 
shown to significantly increase biochemical recurrence (a rise in blood PSA following surgery or 
radiation treatment) and prostate cancer specific mortality (23). A systematic review and dose-
response meta-analysis by Hu et al (58) examined the relationship between BMI and biochemical 
recurrence following multiple treatment types. Across all treatment types a 5 kg/m2 increase in BMI 
was associated with a 16% increase in biochemical recurrence (RR: 1.16; 95% CI: 1.08-1.24).  
Analysis of individual treatment types revealed a 17% increase in biochemical recurrence with radical 
prostatectomy (RR: 1.17; 95% CI: 1.07-1.28; Hu et al, 2014). Similarly, Cao and Ma (23) observed a 
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21% increase in biochemical recurrence (RR: 1.21; 95% CI: 1.11-1.31) and a 15% increase in 
prostate-specific mortality (RR: 1.15; 95% CI; 1.06-1.25) per 5 kg/m2 increase in BMI following 
radical prostatectomy (23). The relationship between increased BMI and biochemical recurrence is 
stronger in more recently treated men, and populations of PSA-detected cancer (110). However, 
obesity increases the risk of biochemical recurrence following radical prostatectomy in long-term 
survival as well (111). This relationship may also be influenced by the difficulty of operating on 
obese patients (112); however, when poor surgical technique is adjusted for, obesity is still associated 
with increased biochemical recurrence and prostate-specific mortality (23, 113). Taken together, these 
data suggest poorer survival outcomes for obese patients compared to normal weight patients. 
 The literature examining the relationship between obesity and radiation therapy is limited – to 
date, 2 studies have examined brachytherapy and 4 have investigated external beam radiation therapy 
in relation to biochemical recurrence. In patients treated with external beam radiation therapy, obesity 
was significantly associated with increased risk of biochemical recurrence in 3 of 4 studies (ES 
Range: 1.16-1.61) (114-116).  The fourth study reported no significant associations in risk of 
biochemical recurrence in obese men (Effect Size (ES): 1.02, 95% CI: 0.68-1.54; 117).   In the studies 
examining brachytherapy, neither showed a significant effect of treatment on biochemical recurrence 
(118, 119).  When these data were combined in a meta-analysis, Hu et al (58) indicated no association 
between obesity and brachytherapy (RR: 0.91; 95% CI: 0.64-1.28); however, external beam radiation 
therapy was associated with a 19% increased risk of biochemical recurrence per 5 kg/m2 increase in 
BMI (RR: 1.19; 95% CI: 1.10-1.28) (58). 
 ADT chemically reduces testosterone to castrate levels to combat the proliferative effects of 
testosterone on many prostate tumours.  The impact of obesity on ADT is poorly characterized.  
Patients receiving ADT lose significant amount of muscle and gain adipose tissue (29), which has 
been associated with increased incidence of cardiovascular disease and diabetes in survivorship (27).  
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However, a study by Keto and colleagues (120) found that during ADT, obese patients had increased 
risk of castrate-resistance prostate cancer, metastases, and prostate cancer specific mortality compared 
to non-obese patients.  The literature also demonstrates that testosterone levels are higher in obese 
men on ADT, suggesting incomplete testosterone suppression (121).  Although ADT prescription is 
currently not dependent on body size, it might be important to consider body composition on patients 
receiving ADT as obese patients may be under-dosed (121).   
3.2.2 Obesity and High-Risk Prostate Cancer 
Overall, the literature reports a 15-20% increase in prostate cancer specific mortality per 5 
kg/m2 increase in BMI (23).  Detection bias (as described in Section 2.5.2) alone cannot explain this 
association and there are 3 proposed primary underlying biological mechanisms driving this 
relationship (122).   Increased insulin and IGF-1 concentrations, which are associated with obesity 
(123, 124), result in elevated circulating growth factors causing increased tumour proliferation, 
reduced tumour apoptosis and transitioning of prostate tumour cells to an androgen resistant state 
(60).  Accelerated tumour growth in prostate cancer xenograph models has been reported as a result 
of diet-induced hyperinsulinemia (125, 126). Conversely, later stages of diabetes, where insulin levels 
begin to decline, has been associated with reduced prostate cancer risk (127).  Similarly, higher serum 
C-peptide concentrations have been associated with increased prostate cancer specific mortality 
(128). Elevated circulating IGF-1 has also been linked to increased prostate cancer incidence (22, 
129). Up-regulation of the IGF-1 receptor has been observed in studies where there is a transition of 
androgen dependent cell lines to androgen independent cells, as well as prostate cancer progression in 
vivo (130).  Taken together, these findings support the hypothesis that increased insulin and IGF-1 
levels, which are associated with obesity, result in elevated circulating growth factors that stimulate 
tumour proliferation and reducing tumour apoptosis (60).   
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Obese men have lower testosterone levels (as discussed in Section 2.5.1), which creates an 
environment conducive to the growth of more aggressive prostate tumour – testosterone-independent 
tumours (71).   Lower testosterone levels, such as those observed in obese men, will result in the 
slower the growth of testosterone-dependent tumours - less aggressive prostate tumours (71). Thus, 
testosterone concentrations, as per body phenotype, may also influence tumour characteristics, 
independent of the effects of hormone treatments.  
 The final mechanism hypothesized to explain the link between obesity and aggressive 
prostate cancer is chronic subclinical inflammation via altered adipokine levels.  Inflammation and 
altered adipokine signalling has also been linked to the development of insulin resistance (131).  
Leptin is elevated in obesity and has been shown to increase prostate cancer cell line proliferation and 
inhibit apoptosis in both androgen sensitive (LNCaP) and androgen resistant (PC-3 and DU145) cell 
lines (132-134).  However, there is a stronger proliferative response to leptin in PC-3 and DU145, 
androgen resistant cell lines (132, 133), which occurs through inactivation of FOXO1 (135). In vitro 
studies have demonstrated robust relationship between leptin and prostate cancer aggressiveness; 
however the epidemiological evidence is inconsistent, where positive (136, 137) and null 
relationships are demonstrated (112, 138-140).  Conversely to leptin, adiponectin is purported to have 
anti-tumour effects (140). Serum adiponectin concentrations are reduced in obese individuals (141, 
142).  Prostate cancer patients have demonstrated lower serum adiponectin (140, 143) and there is an 
inverse relationship observed between histological grade and disease stage, and plasma adiponectin 
levels (143). Numerous pathways have been hypothesized to explain the protective effect of 
adiponectin against carcinogenesis including AMPK, NF-κB, PPAR-α, and MAPK signalling, as well 
as the downstream moderator JNK and STAT3 (144, ).  Taken together, these data suggest an 
important role for adipokines and risk of aggressive prostate cancer; however, further investigation is 
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required to elucidate the complex interactions between adipokines, obesity and prostate cancer and 
how these factors contribute to insulin resistance.     
3.2.3 Skeletal Muscle in Prostate Cancer 
Obesity addresses only one component of body composition – adipose tissue. It does not 
consider skeletal muscle and its potential role in prostate cancer.  Unlike obesity, which has a large 
body of literature investigating its relationship to prostate cancer risk and treatment outcomes, there is 
no literature that examines skeletal muscle mass and prostate cancer risk and treatment outcomes.  
The majority of the literature examining skeletal muscle in prostate cancer examines the relationship 
between ADT and skeletal muscle loss. Androgens are the primary anabolic stimulus in skeletal 
muscle in men, and consequently, ADT causes significant muscle loss (145) and adipose tissue gain 
(29, 146). In non-malignant populations, these body composition characteristics are associated with 
the development of insulin resistance and metabolic syndrome (147, 148). Hypogonadism is 
independently predictive of hyperinsulinemia and metabolic syndrome (149-151).  It may also be 
related to increased saturated fat intake (152), inactivity (153) as well as unhealthy changes in body 
composition (154) during the treatment time-course in prostate cancer patients.  The literature 
demonstrates a clear relationship between ADT use and skeletal muscle loss; however, there is a 
significant gap in our understanding of skeletal muscle in prostate cancer as to date no one has 
investigated skeletal muscle at prostate cancer diagnosis.  This is especially important in men with 
high-risk prostate cancer who receive ADT and are at increased risk of cardiovascular disease and 
diabetes as a result of treatment.   
3.3 Metabolic Syndrome and Prostate Cancer 
More recently, investigators have begun to examine metabolic syndrome as a potential risk 
factor for prostate cancer.  Many of the studies that suggest potential mechanisms to explain the 
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complex relationship between obesity and prostate cancer implicate components of metabolic 
syndrome, such as insulin resistance.  
 There are 3 definitions of metabolic syndrome commonly cited in the literature: the National 
Cholesterol Education Program – Adult Treatment Panel III (NCEP-ATP III; 155), the World Health 
Organization (WHO; 156) definition, and the International Diabetes Federation (IDF; 157).  The 
NCEP-ATP III definition and the IDF definition are the two most highly cited in the literature; 
however, for the purpose of this thesis the IDF definition of metabolic syndrome will be used as it has 
been used previously in the prostate cancer literature (70).  The European Group for the Study of 
Insulin Resistance (EGIR; 158) and the American Heart Association (AHA; 159) have also published 
definitions (Table 3.1). The IDF definition is now the consensus worldwide definition of metabolic 
syndrome.  
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Table 3.1:  Metabolic Syndrome Definitions 
 IDF, 20061 
(157) 
NCEP, 20018 
(155) 
WHO, 19999 
(156) 
EGIR, 199910 
(158) 
AHA, 2004 
(159) 
Central Obesity 
WC 
     Men (cm) 
     Women (cm) 
Waist to Hip  
Ratio  
     Men (AU) 
     Women (AU) 
BMI (kg/m2) 
 
 
>942 or >903 
>80 
 
 
- 
- 
≥304 
 
 
≥102 
≥88 
 
 
 
 
 
 
>0.90 
>0.85 
>30 
 
 
≥94 
≥80 
 
 
>102 
>88 
Triglycerides 
(mg/dL)  
>1505 ≥150 >150 >1775 ≥150 
HDL Cholesterol 
(mg/dL) 
     Men 
     Women 
 
 
<40 
<506 
 
 
<40 
<50 
 
 
<35 
<39 
<395  
 
<40 
<50 
Raised Blood 
Pressure (mmHg) 
     Systolic 
     Diastolic 
 
 
>130 
>856 
 
 
>130 
>855 
 
 
>140 
≥90 
 
 
≥140 
≥906 
 
 
≥130 
≥856 
Raised Fasting 
Glucose (mM) 
>5.67 >6.1 - 6.1 ≥5.611 
Microalbumin 
(ug/min) 
- - ≥20 - - 
1 Metabolic syndrome is Central Obesity with ≥2 other risk factors 
2 Europids, Sub-Saharan African, Eastern Mediterranean and Middle Eastern Populations 
3 South Asian, Chinese, Japanese 
4 If BMI is >30 kg/m2 central obesity can be assumed 
5 Or treatment for this abnormality 
6 Or previous diagnosis or treatment for this abnormality 
7 Or diagnosis of type 2 diabetes 
8 Metabolic syndrome is identified with at least 3 risk factors 
9 Metabolic syndrome requires the presence of one of the following: diabetes, impaired glucose 
intolerance, impaired fasting glucose or insulin resistance and 2 other risk factors 
10 Metabolic syndrome requires insulin resistance (top 25% fasting insulin values among 
nondiabetics) and ≥2 other risk factors 
11 Or use of medication for hyperglycemia 
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3.3.1 Metabolic Syndrome and Prostate Cancer Risk 
To understand the role of metabolic syndrome in the prostate cancer trajectory, I will start by 
discussing the evidence that associates metabolic syndrome with risk of prostate cancer development. 
Much of the literature examining metabolic syndrome as a risk factor for prostate cancer is 
inconclusive with positive and null associations demonstrated.   In a meta-analysis, Esposito and 
colleagues (160) demonstrated no significant association between metabolic syndrome and prostate 
cancer risk (160). Some studies reported a positive association between prostate cancer and metabolic 
syndrome (RR: 1.56-3.36; 161-164), while others demonstrated no association (RR: 0.65-1.29; 95, 
163-173).  Severity of disease may contribute to this relationship as De Nunzio and colleagues (70) 
reported a significant association between patients with aggressive prostate cancer (Gleason score > 
7) and metabolic syndrome (Odds Ratio (OR): 3.82, 95% CI 1.33-10.9; 70). Metabolic syndrome is a 
multi-factorial condition and each component may influence prostate cancer risk.  When the 
individual components of metabolic syndrome (waist circumference, hypertension, hyperglycemia, 
dyslipidemia) were considered, only hypertension and waist circumference were demonstrated to be 
significantly associated with increased risk of prostate cancer (Hypertension: RR 1.15; 95% CI: 1.01-
1.30; Waist Circumference >102cm: RR 1.56; 95% CI: 1.15-2.15; 160).  
Increased risk of prostate cancer has also been reported for African Americans with metabolic 
syndrome (RR: 1.71; 95% CI: 0.97-3.01; 172), while no association (Hazard Ratio (HR): 0.81, 95% 
CI: 0.2-3.3;168) and reduced risk (RR: 0.77; 95% CI: 0.51-1.05; 163) is reported for other ethnic 
groups with metabolic syndrome. One hypothesis to explain the observed variations in these studies is 
geographic region.  Specifically, ethnic profile may influence the outcomes of these results as the US 
studies have a large number of African Americans (who are at increased risk of prostate cancer 
relative to other ethnic profiles) and Hispanic participants; whereas the Scandinavian and Italian 
cohorts are almost entirely Caucasian (70, 161-163, 167, 169). As well, obesity rates differ greatly in 
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these countries.  The Scandinavian cohorts are slimmer with only 12-15% of the population being 
obese and have lower metabolic syndrome rates at only19-22% of the population (161-163, 167,169). 
In the Italian cohort, 44% of the population was classified as obese (70), while 24-40% in the US 
populations are identified as obese (163, 168, 170, 172).   
 Because of the multifactorial nature of metabolic syndrome, there is much speculation as the 
mechanisms driving increased prostate cancer risk in patients with metabolic syndrome.  De Nunzio 
and colleagues (174)  suggest that increased inflammation, changes in adipokine concentrations, 
insulin resistance, and alterations in hormone status, all of which are observed in metabolic syndrome, 
contribute to more aggressive prostate tumour biology.  Metabolic syndrome is associated with 
chronic low-grade inflammation, which may lead to uncontrolled proliferation in rapidly dividing 
cells such as cancer cells (175).  As previously discussed in Section 3.2.2, leptin has been shown to 
stimulate the growth prostate cancer cells in vitro while increased serum leptin is associated with 
larger, high-grade tumours (112, 140, 176).  Adiponectin has been demonstrated to have 
antiangiogenetic and antitumour properties (112, 140, 176), while low serum adiponectin is 
associated with more advanced prostate cancer (112, 140, 176). 
3.3.2  Metabolic Syndrome in Prostate Cancer Treatment and Survivorship 
When examining the relationship of metabolic syndrome beyond risk, the majority of the 
literature investigates the relationship between ADT and metabolic syndrome.  A meta-analysis 
investigating the relationship between metabolic syndrome and ADT demonstrated a 75% increased 
risk of developing metabolic syndrome with ADT use (RR: 1.75; 95% CI: 1.27-2.41; 3).  In an 
observational, multicentre, prospective study, Morote et al (177) demonstrated that after only 6 
months of ADT use almost all components of metabolic syndrome (waist circumference, BMI, total 
cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, glucose 
and HbA1c) significantly increased and these changes persisted with 12 months of ADT use (177).  
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Androgen suppression use has been shown to decrease insulin sensitivity (98), increase fasting insulin 
levels (100, 101), and deleteriously change serum lipoprotein levels (100, 101).  An epidemiological 
study by Haffner et al (149) also demonstrated that low serum testosterone levels are associated with 
increased total cholesterol, LDL cholesterol, and triglycerides (149). It is unclear whether these 
consequences arise as a result of ADT use or tumour presence (or lingering effects of the tumour if 
post-treatment). However, hypogonadism, independent of a cancer diagnosis, has been shown to be 
an independent predictor of metabolic syndrome in males (151), suggesting that ADT itself has 
profound effects on metabolism.  
There are a few key differences between prostate cancer patients diagnosed with metabolic 
syndrome who are receiving ADT compared with individuals who have metabolic syndrome but 
never been diagnosed with prostate cancer.  The first difference is that ADT is associated with 
increased HDL cholesterol - an increase of approximately 8-20% in the first 3-12 months of ADT 
(100, 178,179).  Secondly, adipose tissue gains as a result ADT occur in subcutaneous fat not visceral 
fat (99, 179). Central obesity, which measures visceral adiposity, is the key component of metabolic 
syndrome. Visceral adiposity has negative implications on fasting glucose, insulin, cholesterol and 
triglyceride concentrations compared with subcutaneous adiposity (180).  Thirdly, ADT is associated 
with increased adiponectin and normal C-reactive protein (CRP) concentrations (179, 181), while 
metabolic syndrome is associated with low adiponectin (182) and increased CRP (183).  This 
suggests that the metabolic perturbations observed in prostate cancer patients, especially those 
receiving ADT, should be considered differently from non-malignant populations as they may have a 
different pathology that leads to metabolic syndrome (184). 
3.3.3 Dyslipidemia and Prostate Cancer 
 Dyslipidemia, including increased triglyceride and decreased HDL cholesterol 
concentrations, is a key component of metabolic syndrome; however, cholesterol and lipid 
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metabolism may be of particular importance in the development and proliferation of prostate cancer.  
The literature examining lipid profiles in prostate cancer is limited and divided into two primary 
categories: risk and ADT use. Evidence for dyslipidemia as a risk factor for prostate cancer is mixed.   
Decreased HDL cholesterol has been observed in prostate cancer patients compared with age and 
BMI matched non-malignant controls (26, 185), which aligns with data from non-malignant males 
with have metabolic syndrome.  Prostate cancer patients also demonstrate higher LDL cholesterol 
compared with age-matched controls (185), which results in increased total cholesterol levels (26).   
In an examination of lipid profiles in aggressive (Gleason > 8) versus non-aggressive 
(Gleason <8) prostate cancer, Prabhat et al (79) showed that aggressive cancer is associated with 
lower HDL cholesterol, higher triglyceride and very low-density lipoprotein (VLDL) cholesterol 
concentrations, but no significant differences where observed in total cholesterol and LDL cholesterol 
(79).  Conversely, two cohort studies have demonstrated no significant changes in any lipid 
parameters in newly diagnosed prostate cancer patients (186, 187). The results of these studies are 
inconsistent, and therefore inconclusive. These discrepancies may be explained by the differences in 
study design (cohort versus case-control) and the small sample sizes of the studies as well as by the 
heterogeneity of the body composition profiles of the patients within the studies.   
A recent epidemiological investigation in the SEARCH database evaluated the association 
between dyslipidemia and risk of prostate cancer recurrence in a group of patients who underwent 
surgery as their primary treatment type.  Allott et al (188) demonstrated that for every 10 mg/dl 
increase in serum triglycerides there was a 3% increase in risk of prostate cancer recurrence (HR: 
1.03; 95% CI: 1.01-1.05) (189).  While the authors noted no significant associations between total, 
LDL, and HDL cholesterol and cancer recurrence across all men, in men with dyslipidemia, every 10 
mg/dl increase in total cholesterol was associated with a 9% increased risk of cancer recurrence (HR: 
1.09; 95% CI 1.01-1.17) and every 10 mg/dl increase in HDL cholesterol was associated with a 39% 
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reduction in the risk of recurrence (HR: 0.61; 95% CI: 0.41-0.91).  It has also been observed that 
statin use, a class of cholesterol-lowering drug, has been associated with decreased risk of prostate 
cancer (189). 
 The literature examining lipid profiles during ADT demonstrate more consistent findings.  
Multiple studies have demonstrated increased total cholesterol, triglycerides and HDL cholesterol 
with ADT use (100, 178, 179).  Total cholesterol has been shown to increase between 9 and 11%, 
HDL increases between 8 and 11%, while triglycerides increase by approximately 27% 100,  179). 
HDL cholesterol and total cholesterol levels rise relatively quickly, within the first 3 months of ADT 
administration (100).  However, in more recent studies, changes observed in lipid profile resembled 
more traditional dyslipidemia with increases in total cholesterol, LDL cholesterol and triglycerides 
and decreases in HDL cholesterol following 1 year of ADT use (102) and compared with a control 
group (190). While the observed changes in dyslipidemic patterns are poorly understood, there is 
indirect evidence that link these patters to length of ADT use.   
3.4  Conclusions and Perspectives  
Much of the literature examining obesity, metabolic syndrome, glucose metabolism and 
prostate cancer has revealed some interesting associations.  However, most studies in these research 
domains focus on two distinct time points in the prostate cancer disease trajectory: 1) prior to cancer 
diagnosis or risk factors and, 2) the long-term implications of ADT - the only treatment investigated.  
Little is known about prostate cancer patients as they progress through the disease trajectory.  
Moreover, many mechanisms have been proposed, with little investigation, to explain the potential 
integrative relationship between obesity, metabolic syndrome, insulin resistance and prostate cancer, 
including alteration in sex hormones, adipokines, and pro-inflammatory cytokines.  Thus, the use of 
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different methodological approaches is warranted to help elucidate the nature of the complex 
mechanisms of interaction between body composition, glucose metabolism and prostate cancer.  
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Chapter 4                                                                                         
Thesis Rationale and Study Design 
4.1 Justification 
Glucose-related metabolic perturbations, such as hyperinsulinemia, are emerging as important 
risk factors for aggressive prostate cancer (73, 74, 78).  However, these metabolic disturbances do not 
occur in isolation, but rather work in conjunction with numerous other metabolic perturbations, 
including dyslipidemia, changes in the adipokine profile and inflammation to create a metabolic 
environment conducive to prostate cancer (174). These same perturbations are associated with the 
development of secondary disease states, including cardiovascular disease and diabetes (27), as well 
as cancer recurrence in survivorship (191).  Despite these associations, little is known about glucose 
metabolism in prostate cancer patients during the acute treatment trajectory.  Most of the available 
literature fails to characterize glucose and related parameters (i.e. insulin C-peptide, IGF-1), as well 
as lipid parameters, adipokines, cytokines and lifestyle factors for prostate cancer patients in an 
integrative manner; instead, most studies focus on few components in large populations, which have 
led to inconsistencies in the literature. The aims of this thesis were to: 1) understand the metabolic 
features including glucose and related parameters (insulin, C-peptide, IGF-1, IGFBP-3), lipid related 
markers (triglycerides, cholesterols, adiponectin, leptin) and lifestyle factors (body composition, 
physical activity, nutritional intake) that may be related to prostate cancer diagnosis and severity of 
disease, 2) to evaluate how these factors change during the acute prostate cancer treatment trajectory, 
and 3) to investigate potential mechanisms contributing to potential alterations in this metabolic 
profile observed during the treatment trajectory. 
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4.2 Overall Thesis Purpose and Objectives 
4.2.1 Overall Thesis Purpose 
The purpose of this thesis is to examine metabolic features (as mentioned in Section 4.1) of 
prostate cancer patients at diagnosis and changes in theses parameters throughout the acute treatment 
trajectory.  It will also investigate the mechanisms underlying the potential changes in these metabolic 
features, specifically in glucose metabolism. Also, it will examine lifestyle factors that may contribute 
to potential changes in glucose metabolism that may occur during treatment, such as body 
composition, diet and exercise. 
4.2.2 Overall Thesis Objectives 
1. To identify potential perturbations in glucose metabolism in newly diagnosed prostate 
cancer patients and to understand the influence of other metabolic parameters, such as 
lipids, adipokines, cytokines, body composition, nutrition intake and physical activity, on 
glucose metabolism of these prostate cancer patients.  
2. To understand how glucose and other related metabolic parameters differ between 
prostate cancer patients and men of similar age and body size who do not have prostate 
cancer.  
3. To examine potential changes that may develop in glucose and related parameters in 
prostate cancer patients during the acute prostate cancer treatment trajectory (immediately 
and ~ 6 months following radiation therapy). 
4. To examine the potential mechanisms that may contribute to the potential alterations in 
metabolism and specifically glucose metabolism during the treatment trajectory. 
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4.3 Study 1: C-peptide, abdominal obesity, and adipokines are associated with 
higher Gleason scores in prostate cancer  
4.3.1 Rationale 
Metabolic syndrome, defined in Section 3.3 as a cluster of metabolic perturbations including 
obesity, hypertension, hyperglycemia, and dyslipidemia, has recently emerged as an important risk 
factor for prostate cancer (191). Its presence increases the risk of cardiovascular disease and diabetes, 
and has been associated with numerous other metabolic perturbations including inflammation (192), 
insulin resistance (193) and changes in the sex hormone profile (194).  These metabolic sequelae have 
been associated with prostate cancer and specifically aggressive prostate cancer development (174); it 
creates an environment conducive to tumour growth and angiogenesis.  Metabolic syndrome, by 
definition, is as multifactorial condition and it is associated with numerous other metabolic 
perturbations (192-194), together this suggests a complex metabolic profile that may facilitate 
prostate cancer growth (195); however, the literature lacks studies that integrate these factors.  This 
study aims to develop an integrative approach to elucidate the complex interactions between 
metabolic syndrome and glucose-related metabolic perturbations and prostate cancer growth.  We 
also aim to examine lifestyle factors (physical inactivity, nutrition intake, obesity) that may contribute 
to the development of these metabolic perturbations observed in prostate cancer.  
The purpose of this study was to evaluate the presence of metabolic syndrome as well as 
specific features of glucose metabolism, lipid profile, body composition, nutrition intake and physical 
activity levels in individuals who were referred for a prostate biopsy (to assess the presence of 
prostate cancer). Moreover, we sought to identify specific components that associated with 
aggressiveness of prostate cancer, based on Gleason score obtained from pathology reports. 
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4.3.2 Objectives and Hypotheses 
4.3.2.1 Objectives 
In men who have been prospectively referred for a prostate biopsy: 
1. To identify proportion of individuals with metabolic syndrome and evaluate the relationship 
between its presence and prospective prostate biopsy Gleason scores as a surrogate for cancer 
aggressiveness.  
2.  To evaluate the components of metabolic syndrome, additional metabolic measures (i.e. 
cytokines, adipokines, C-peptide, insulin, etc.) and lifestyle factors (i.e. activity levels, nutrition 
intake) that may explain the presence of metabolic syndrome and to how it may related to 
prospective prostate biopsy Gleason scores  
3. To associate metabolic features (body composition, glucose- and lipid-related markers, 
inflammation) and lifestyle factors (habitual physical activity levels, functional capacity, 
nutritional intake) with the prospective prostate biopsy Gleason scores. 
4.3.2.2 Hypotheses 
1. Participants diagnosed with prostate cancer will be more likely to have metabolic syndrome as 
well as elevated HbA1C, fasting, glucose, insulin, and C-peptide compared with those who are 
not diagnosed with prostate cancer. Patients diagnosed with prostate cancer will likely be 
overweight or obese and possess lower than normal lean mass compared with participants not 
diagnosed with prostate cancer.  
2. Participants with higher Gleason scores are more likely to present with features of metabolic 
syndrome, including obesity, glucose impairments, and dyslipidemia, compared with 
participants diagnosed with earlier stage prostate cancer and those not diagnosed with cancer. 
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4.4 Study 2: Prostate cancer patients experience impaired glucose tolerance 
following diagnosis, which is improved with radiation therapy independent of 
changes in traditional moderators of glucose metabolism 
4.4.1 Rationale 
Metabolic perturbations (metabolic syndrome, hyperglycemia, hyperinsulinemia, 
dyslipidemia, inflammation) are associated with prostate cancer, and specifically aggressive prostate 
cancer (12, 196-199). However, despite these associations, significant gaps exist in the literature in 
identifying the potential mechanisms that relate metabolic perturbations and prostate cancer 
diagnosis.  It has been suggested that increased insulin, IGF-1, inflammatory cytokines, estradiol and 
leptin as well as decreased adiponectin, work together to create a more aggressive prostate cancer 
tumour biology in those with metabolic syndrome; however, these hypotheses remain untested (174).  
Results from Study 1 of this thesis suggest a cluster of metabolic perturbations, including elevated C-
peptide, increased visceral adiposity, elevated leptin, and lower adiponectin , are associated with 
prostate cancer diagnosis.  Increased C-peptide concentrations are indicative of increased insulin 
release from the pancreas (200).  Since insulin is a potent cancer promoter (75-77), further 
investigations into the glucose metabolism of prostate cancer patients are warranted to further 
elucidate these findings.   
As well, the relationship between the metabolic perturbation described by De Nunzio and 
colleagues (174) and prostate cancer development is most pronounced in high-risk prostate cancer 
patients (191).  Findings from Study 1 of this thesis lend further support to this hypothesis whereby 
patients with the highest Gleason scores demonstrated the worst metabolic profile (elevated C-
peptide, increased visceral adiposity, elevated leptin, lower adiponectin) compared to patients with 
lower Gleason scores. Thus, high-risk prostate cancer patients were chosen for Study 2 for more in-
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depth evaluations of their glucose metabolism and related metabolic health because metabolic 
disturbances in these patients will be the most pronounced.   
 The metabolic health of high-risk prostate cancer patients is clinically important. Firstly, 
high-risk prostate cancer patients undergo numerous treatment options including radiation therapy 
(RT), prostatectomy, and androgen deprivation therapy (ADT) (40-42).  However, little is known 
about the influence of these treatment types on host glucose and lipid metabolism.  This is especially 
concerning since the ~26% of prostate cancer patients who develop diabetes following prostate cancer 
treatment undergo radiation therapy as their initial treatment, while ~45% undergo prostatectomy 
(108).  Secondly, high-risk patients are most likely to receive ADT, which reduces testosterone to 
castrate levels and consequently decreases lean tissue and increases fat mass (29). Significant 
metabolic perturbations have been observed in these patients following long-term ADT use and these 
patients are at increased risk of diabetes and cardiovascular disease in survivorship (27); however, 
little is known about the acute treatment trajectory.  
 The purpose of the current study is to investigate and describe the potential changes in 
glucose metabolism and how they relate to body composition, other metabolic factors (i.e. 
inflammation), nutrition intake, and exercise characteristics in high-risk prostate cancer patients prior 
to treatment and during the acute phase of treatment (radiation therapy with or without ADT). 
Patients were examined prior to the start of treatment (baseline), immediately following the 
completion of either type of radiation therapy (~7 weeks), and after 6 months following completion of 
radiation therapy (~33 weeks).   
In addition, glucose metabolism and related parameters (including insulin, C-peptide, lipid 
metabolism) become more impaired with aging. These 2 factors are associated with impaired glucose 
tolerance in non-malignant individuals (147, 148).   Given that prostate cancer occurs in older men 
with increased body mass index (BMI) (17, 201), it is necessary to compare age- and BMI-matched 
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males to identify potential impairments in glucose metabolism that may be attributed to age and BMI. 
A comparison to a young healthy group of males may also identify the extent of any potential 
impairments in patients and matched males.  
4.4.2 Objectives and Hypotheses 
4.4.2.1 Objectives 
1. To describe the metabolic profile, including glucose metabolism and related markers, body 
composition, lipid metabolism, inflammation, nutrition intake, physical activity, in high-risk 
prostate cancer patient prior to treatment initiation and to compare this profile to men of the 
same age and body size (matched males) and a young healthy comparison group (young 
males) to discern both age- and prostate cancer-related metabolic perturbations.  
2. To describe potential changes in metabolism including glucose metabolism and related 
markers (body composition, lipid metabolism, inflammation, nutrition intake, physical 
activity) during the acute treatment trajectory (at 7 and 33 weeks from treatment initiation). 
4.4.2.2 Hypotheses 
1. Compared with age- and BMI-matched males, prostate cancer patients will have greater peak 
glucose, greater 2-hour glucose concentrations as well as greater area under the glucose curve 
following an oral glucose tolerance test (OGTT).  Prostate cancer patients will also present 
with dyslipidemia, greater body fat mass, less muscle mass, and pro-inflammation compared 
with matched and young males. 
2. During the course of treatment (~7 weeks) and 6 months following the end of treatment (~33 
weeks), prostate cancer patients will present with further impairments in glucose metabolism 
and its related markers compared to pre-treatment.  Prostate cancer patients will also 
demonstrate fat gains, lean tissue losses and increases in pro-inflammatory markers. 
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4.5 Study 3: Serum from high-risk prostate cancer patients does not induce 
cancer specific changes in glucose uptake in differentiated human skeletal 
muscle myotubes: developing a novel model to examine mechanisms of 
metabolic change in cancer patients  
4.5.1 Rationale 
One of the defining features of metabolic syndrome, an emerging independent risk factor for 
prostate cancer, is impaired glucose metabolism (157).  The results of Study 2 demonstrated that, 
prior to treatment initiation, high-risk prostate cancer patients have normal fasting glucose 
concentrations (4.9±1.2mM). However, during an OGTT, patients exhibited impaired glucose 
tolerance with 2-hour glucose concentrations (the time point clinically used to determine impairments 
in glucose tolerance) >7 mM (8.7±2.9mM).  Following 7 weeks of radiation therapy glucose tolerance 
was improved, as 2-hour glucose concentrations were <7 mM (6.8±1.5mM) and this improvement 
was maintained 37 weeks from baseline (2-hour glucose: 5.7±2.1mM).  There were also no 
significant changes in physical activity levels or nutrition intake, which suggests improvements in 
glucose tolerance were independent of lifestyle changes .  No significant changes were noted in 
insulin and C-peptide throughout the treatment trajectory, which suggested increased peripheral 
insulin sensitivity .  This implies that there may be a systemic influence at the level of the muscle and 
possibly other peripheral tissues (liver, adipose).    The presence of prostate cancer may influence 
glucose tolerance in these patients, independent of changes in glucose related hormones, such as 
insulin and C-peptide, and lifestyle determinants of glucose metabolism.   
It has been suggested that metabolic perturbations associated with metabolic syndrome, such 
as increased inflammatory cytokines, increased insulin and IGF-1, altered the adipokine profile 
(increased leptin and decreased adiponectin) and increased estradiol, work together to create a more 
aggressive prostate cancer tumour biology in high risk-prostate cancer patients (174).  These 
  42 
perturbations may exacerbate impairments in glucose metabolism observed at diagnosis, such as in 
Study 2 ; however, the underlying mechanisms explaining these interactions are unclear. Cell culture 
and animal model studies are an appropriate starting point for these investigations, given the limited 
knowledge in this area and the difficulty of conducting invasive metabolic testing in a cancer patient 
population.  
To investigate this response further, a novel in vitro cell culture model was developed, as cell 
culture allows complete control of the environment surrounding the cell. Skeletal muscle accounts for 
80% of whole body post-prandial glucose disposal (202), and human skeletal muscle myotubes in 
culture respond to insulin in vitro allowing comparison between glucose uptake in both basal and 
insulin stimulated conditions (203,204); therefore, they were selected as a the model in which to 
observed changes in glucose metabolism. The use of skeletal muscle will allow us to investigate if 
there is a systemic signal driving the changes in glucose metabolism observed in vivo. The myotubes 
were exposed to serum collected from prostate cancer patients, prior to treatment to induce any 
cancer-related changes in glucose metabolism.  Fasting serum was used to account to variability in 
hormone levels in the post-prandial state.  Myotubes were also exposed to fasting serum from age- 
and BMI-matched males and young healthy males, to help explain for cancer- and age-related 
changes in glucose uptake.  Serum from post-treatment (7 weeks and 33 weeks post-treatment 
initiation) was also used in the culture model to examine how glucose uptake may change during the 
acute treatment trajectory.  This model allowed the investigation of systemically driven cancer-related 
changes in glucose uptake in skeletal muscle, the tissue that accounts for most glucose disposal of any 
tissue in vivo.  These potentially unknown factors released from tumours to induce whole body 
changes in host glucose metabolism have previously been identified in pancreatic cancer patients 
(206).  Basso and colleagues identified a 2030MW putative pancreatic cancer-associated factor that 
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was present in the serum of patients and was also capable of impairing glucose metabolism in 
hepatocytes in an in vitro model (206).     
 The purpose of this study was to investigate the capability of this novel method to measure 
impairments in glucose uptake in human skeletal muscle cells when exposed to serum from prostate 
cancer patients and compare this with serum from an age- and BMI-matched and a young healthy 
group of males.  Moreover, the effects of patient serum collected throughout the treatment trajectory 
(baseline - prior to treatment, following ~7 weeks of RT, and ~37 weeks from baseline) on glucose 
uptake in cultured skeletal muscle myotubes was also investigated.  
4.5.2 Objectives and Hypotheses 
4.5.2.1 Objectives 
1. To examine the effects of serum, collected from prostate cancer patients, on glucose uptake in 
cultured human skeletal muscle myoblasts compared with serum from age- and BMI-matched 
non-malignant males and a young healthy comparison group.  
2. To examine the differences in glucose uptake in cultured human skeletal muscle cells incubated 
with serum collected from prostate cancer patients at baseline, following ~7 weeks of radiation 
therapy, and ~37 weeks following baseline evaluations.  
4.5.2.2 Hypotheses 
1.  Glucose uptake will be decreased in human skeletal muscle cells cultured with prostate cancer 
serum as compared with an age- and BMI-matched comparison group and a young healthy 
comparison group. 
2.  Glucose uptake will be lower in prostate cancer patients prior to the initiation of cancer 
treatment.  Following 7 weeks of radiation therapy, glucose uptake will increase and this 
improvement will be maintained at ~33 weeks following baseline. 
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5.3 Abstract 
Purpose: Prostate cancer development has been associated with numerous lifestyle factors (obesity, 
physical activity, nutrition intake) and metabolic perturbations. We aimed to characterize an 
integrative metabolic profile of men undergoing diagnostic prostate biopsies. 
Materials and Methods: We prospectively evaluated 51 consecutive men for body composition, 
metabolic syndrome, glucose- and lipid-related measures and lifestyle factors prior to prostate biopsy. 
These factors were related to biopsy outcomes for: 1) presence or absence of cancer, and 2) where 
cancer was present, Gleason score. 
Results: Serum C-peptide concentrations were significantly greater in participants with Gleason 
scores ≥4+3 (2.8±1.1 ng/mL) compared to those with Gleason 3+3 (1.4±0.6 ng/mL) or Gleason 3+4 
(1.3±0.8 ng/mL). There were no significant differences in fasting glucose concentrations; however, 
insulin and insulin resistance (HOMA-IR) tended to be greater participants with Gleason ≥4+3, 
suggesting greater insulin secretion, compared to participants with Gleason 3+3 and 3+4. Central 
adiposity, measured by waist circumference, was significantly greater in participants with Gleason 
≥4+3 compared to those with lower Gleason scores (Gleason ≥4+3: 110.1±7.4 cm vs Gleason 3+4: 
102.0±9.5 cm). Men with Gleason ≥4+3 had significantly greater leptin concentrations than those 
with lower Gleason scores (Gleason ≥4+3: 15.6±3.3 ng/mL vs Gleason 3+4: 811±8.1 ng/mL, p<0.05) 
and leptin: adiponectin ratio (Gleason ≥4+3: 2.4±2.1 AU vs Gleason 3+4: 2.9±3.2 AU, p<0.05). 
Conclusions:  This is the first study to integratively show that serum C-peptide, visceral adiposity, 
serum leptin and leptin: adiponectin ratio are associated with high Gleason scores, suggesting a 
cluster of obesity-related metabolic perturbations that may contribute to aggressiveness in prostate 
cancer. 
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5.4 Introduction 
Lifestyle factors including obesity (201), physical inactivity (206), and high-fat diets (207) 
are associated with prostate cancer.  These factors are also associated with metabolic syndrome, an 
emerging risk factor for prostate cancer (160, 174, 208). Metabolic syndrome, a cluster of interrelated 
risk factors, is purported to increase risk of diabetes and cardiovascular disease (157).  Despite the 
numerous definitions that exist for metabolic syndrome, the International Diabetes Federation (IDF) 
definition will be used here: central obesity (waist circumference (WC) >94 cm in males), with at 
least 2 other risk factors, including hypertension (SBP ≥130mmHg, DBP ≥85mmHg), raised fasting 
glucose (≥5.6 mM), raised triglycerides (TG, ≥1.7mM), and/or reduced high-density lipoprotein 
cholesterol (HDL, <1.0mM; 157). Of these components, central obesity and impaired glucose 
metabolism have been specifically associated with prostate cancer development (160, 174).  
Abnormal metabolic features like obesity and insulin resistance may not affect prostate 
cancer in isolation, but instead work together to create a metabolic environment favourable for 
prostate cancer growth (174).  Physical inactivity and high-fat diets contribute to obesity (210), and 
may contribute to metabolic perturbations associated with prostate cancer development (174). A 
comprehensive metabolic phenotype of prostate cancer patients will elucidate interactions between 
these features and identify potential predictors of prostate cancer development and aggressiveness.  
To our knowledge, the integrative examination of these metabolic and clinical characteristics 
employed here is novel. The primary objective of this prospective observational study was to 
characterize the proportion of participants with metabolic syndrome, concurrently evaluating other 
metabolic parameters that might explain the presence or absence of criteria of the metabolic 
syndrome (WC, glucose, blood pressure, TG and HDL) including body composition (hip-
circumference (HC), fat mass (FM), fat free mass (FFM), % body fat), glucose-related measures 
(insulin, C-peptide, insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 
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(IGFBP-3), lactate), additional features of lipid metabolism (total cholesterol, low-density lipoprotein 
cholesterol (LDL)), C-reactive protein (CRP), adiponectin, and leptin.  To interpret these metabolic 
findings, lifestyle factors (habitual physical activity, functional capacity, nutrition intake) were also 
assessed. Our secondary objective was to associate these metabolic features with the surrogate 
measures of cancer aggressiveness using Gleason scores resulting from the prospective biopsy. 
5.5 Methods 
5.5.1 Participants 
We consecutively and prospectively screened 139 men, with 51 men completing the study 
(Figure 5.1). Men were referred to a single uro-oncologist (JHP) with a clinical suspicion of prostate 
cancer presenting with elevated prostate specific antigen (PSA) levels and/or abnormal digital rectal 
exam (n=36). A second group (n=15) of low-risk prostate cancer patients under active surveillance 
were recruited prior to their surveillance biopsy. Exclusion criteria included previous diagnosis of 
cancer (other than basal cell carcinoma) not in remission for at least 3 years, current anti-neoplastic 
treatment, use of corticosteroids and chronic anti-pain medication for any reason. Participants’ 
clinical characteristics are summarized in Tables 5.1 and 5.2. This study was reviewed and cleared by 
the University Of Waterloo Office Of Research Ethics and by Hamilton Health Sciences/Faculty of 
Health Sciences Research Ethics Board. 
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Figure 5.1: Participant recruitment flow diagram. This consort diagram describes the recruitment, 
enrolment, follow-up and analysis for the current study. 
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 Unable to contact for follow-up (n=4) 
 Biopsy not performed (n=11) 
Follow-up Consented (n=80) 
Recruitment 
Analysis 
Enrollment 
Excluded (n=52) 
   Declined to participate (n=25) 
   Unable to contact (n=26) 
   Died (n=1) 
 
Eligible (n=132) 
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5.5.2 General Study Design 
Participants were recruited prior to their prostate biopsy; the biopsy ultimately confirmed a 
positive or negative cancer diagnosis. To limit clinic visits and reduce participant burden, all study 
procedures were conducted prior to the biopsy on a single day. However, when this was not possible 
(n=2), study assessments were scheduled within 2 weeks of the biopsy date. Following data 
collection, biopsy pathology reports were used to stratify participants into 4 Gleason score categories: 
No cancer, Gleason 3+3, Gleason 3+4, and Gleason ≥4+3. 
5.5.3 Biopsy Protocol 
A single uro-oncologist (JHP) performed all transrectal ultrasound-guided biopsies.  For 
patients with prostate cancer positive biopsies, a minimum of 16 cores were obtained (n=15) 
including 3 cores from the base, 3 cores from the mid, and 2 cores from both the right and left apex, 
including the far lateral aspects of these zones (211). Twenty-one patients had 26 core saturation 
biopsies, including the same 16 core template plus 2 cores from the transitional zone and 3 cores from 
both the left and right anterior (211).  
5.5.4 Clinical Data 
Medical history was assessed using chart review and participant self-report methods.  Family 
history of cancer (in general and prostate cancer), active surveillance prior to current biopsy, PSA 
levels, treatment received following biopsy, and presence of bone metastases was collected via chart 
review.  Previous diagnosis of cancer, other medical conditions (i.e. hypertension, high cholesterol, 
diabetes), current medications, and smoking status were collected using a medical screening 
questionnaire. Blood pressure was measured with a sphygmomanometer. 
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5.5.5 Blood Sampling 
Blood was withdrawn after an overnight fast (8-12 hours with no food or drink except for 
water). Glycated hemoglobin (HbA1c) was analyzed using fresh whole blood.  The remaining sample 
was allowed to clot, spun and serum was collected, aliquoted and stored until analyzed for glucose-
related measures (glucose, insulin, C-peptide, IGF-1, IGFBP-3, lactate), lipid profiles (TG, total 
cholesterol, LDL, HDL), CRP, and adipokines (adiponectin, leptin).   
5.5.6 Biochemical Analysis 
HbA1c was analyzed using the commercially available A1CNow+ (Bayer, Sunnydale, CA). 
Glucose and lactate were assessed using spectrophotometric methods, as previously described (212). 
Insulin and C-peptide were analyzed using commercially available radioimmunoassay kits (Siemans 
Healthcare Diagnostics; Deerfield, IL). Lipid profiles including TG, total cholesterol, HDL, and LDL 
were analyzed spectrofluorophotometrically using commercially available regents (Pointe Scientific; 
Canton, MI). Leptin, adiponectin, IGF-1, IGFBP-3, and CRP were assessed using sandwich enzyme-
linked immunosorbant assays (R&D Systems Inc, Minneapolis, MN).  
5.5.7 Insulin Resistance Calculations 
Insulin resistance was assessed using fasting glucose and insulin values and the homeostatic 
model assessment for insulin resistance (HOMA-IR) equation (213). 
5.5.8 Metabolic Syndrome Assessments 
The IDF definition was used to define metabolic syndrome as follows: central obesity (WC 
>94 cm in males), with at least 2 other risk factors, including hypertension (SBP ≥ 135mmHg, DBP 
≥85), raised fasting glucose (≥5.6 mM), raised TG (≥1.7 mM), and/or reduced HDL (<1.0 mM; 8).   
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5.5.9 Body Composition 
BMI (kg/m2) was calculated from weight and height recorded from medical charts. WC, 
taken (in cm) at the top of the iliac crests, and hip circumference (HC, in cm), at the level of greatest 
gluteal prominence (214), were used to assess waist-to-hip ratio, surrogate measures of visceral 
adiposity.  
Single frequency-bioelectrical impedance analysis (SF-BIA; BIA-101S, RJL Systems, 
Clinton TWP, MI) was used to calculate FFM, FM, % body fat, SMM and SMI.  Fasted participants 
lay supine while electrodes were placed below the knuckles on the prone side of the right hand and 
right wrist, and behind the toes of the right foot and right ankle.  Reactance and resistance values 
were generated and used to estimate FFM with the equation described by Kyle et al (215). FFM was 
then used to estimate FM and % body fat.  SMM was calculated using the equation described by 
Janssen et al (216). This value was then divided by height squared (m2) to determine SMI (kg/m2).   
5.5.10 Functional Assessments and Questionnaires 
Functional assessments included 6-minute walk test (6MWT), hand-grip strength test and the 
Godin Leisure Time Activity Questionnaire. The Godin Leisure Time Activity Questionnaire 
provided an evaluation of habitual activity (217). For the 6MWT, participants walked as quickly as 
possible on a 50m course for 6 minutes and distance travelled was recorded (218).  Hand-grip 
strength was assessed using a Takie A5001 analogue hand-grip dynamometer. Participants held their 
elbow against their body at 90o with a neutral wrist position.  They squeezed the hand dynamometer 
as hard as possible with their dominant hand and maximum force was recorded. Three trials separated 
by 1-minute breaks were recorded with the highest result deemed maximal strength (219).  
5.5.11 Nutrition Intake 
Participants completed a 3-day food diary over 2 weekdays and 1 weekend day during the 
week of their assessments (220).   Participants were instructed to record all food and beverages 
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consumed each day and the location the food was consumed.  Participants were also asked to record 
any supplement take and whether the recorded eating pattern matched their usual eating patterns.  
Caloric intake and macronutrient breakdown (% fat, % carbohydrate and % protein) was determined 
from these records using ESHA Food Processor software and the Canadian Nutrient Files where 
available and the USDA National Nutrient Database for Standard Reference when Canadian 
information was not available. 
5.5.12 Statistical Analysis 
Values are presented as mean±SD.  Statistical calculations were performed on Sigma Plot ® 
version 11.2 (Systat Software Inc.; San Jose, CA).  As the data met the assumptions of parametric 
statistics, a one-way Analysis of Variance (ANOVA) was used for comparisons between the 4 groups 
(no cancer, Gleason 3+3, Gleason 3+4, Gleason ≥4+3) for all measures using Tukey’s post-hoc 
analysis for pairwise comparisons. Linear regression was used to model the relationship between 
cancer severity and metabolic, lifestyle and body composition measures using the best subset 
regression approach to select the model.  To limit repeated comparisons and parameters investigated, 
only measures that were statistically significant or approaching significance (p<0.100) among the 
group comparisons were considered for linear regression.  When a regression variable included 
multiple components (i.e. HOMA-IR is calculated from glucose and insulin), individual components 
as well as the multiple component variable were considered in the regression analysis (i.e. glucose, 
insulin, and HOMA-IR were considered).  Significance was identified at p<0.050. 
5.6 Results 
Overall, participants were 66±7 years old (Range: 53-82 years old), with a BMI of 28.2±4.4 
kg/m2 (Table 5.1). Of the 51 patients, 38 patients (75%) were diagnosed with prostate cancer, 17 with 
Gleason 3+3, 14 with Gleason 3+4, 5 with Gleason 4+3 and 2 patients with a Gleason Score >7.  For 
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the purpose of analysis in this study, patients with Gleason 4+3 and Gleason >7 have been grouped 
together (Gleason ≥4+3).  Treatment distribution is outlined in Table 5.2. Interestingly, patients 
without cancer were significantly younger than patients with Gleason ≥4+3 (62±7 vs 72±2 years, 
p=0.008; Table 5.2).  Further analysis demonstrates that patients with Gleason ≥4+3 (61-76 years) 
have a narrower age range compared to all other groups. As expected, PSA levels were elevated 
(defined as >4.0 ug/L; 20) across the entire cohort (6.2±2.9 ug/L, Table 5.2); patients with Gleason 
≥4+3 had significantly higher PSA levels compared to the no cancer group (p=0.019, Table 5.2). 
 
Table 5.1: Participant Characteristics (n=51) 
Age (years) 66 ± 7 
Systolic Blood Pressure (mmHg) 135 ± 14 
Diastolic Blood Pressure (mmHg) 85 ± 8 
Height (cm) 175.7 ± 6.4 
Weight (kg) 89.3 ± 14.9 
BMI (kg/m2) 
     Underweight: BMI <18.5 kg/m2 (n) 
     Normal: BMI 18.5 – 24.9  kg/m2 (n) 
     Overweight: BMI 25.0 – 29.9 kg/m2 (n) 
     Obese: BMI 30.0 – 34.9 kg/m2 (n) 
     Obese: BMI >35.0 kg/m2  (n) 
28.9 ± 4.4 
0 (0%) 
8 (17.0%) 
21 (44.7%) 
13 (27.7%) 
5 (10.6%) 
 
 
Metabolic syndrome was identified in 32 of 51 (63%) participants based on IDF criteria (8), 
21 (66%) of which were diagnosed with cancer (Table 5.3).  Remarkably, all 51 patients had at least 
one metabolic syndrome risk factor (Table 5.3). Also, 24 participants self-identified as hypertensive 
and were prescribed medication, 24 participants self-identified with lipid abnormalities 
(hypercholesterolemia) and were prescribed medication, and 9 participants self-identified as diabetic 
or prediabetic (Table 5.3). Interestingly, a large proportion of participants still had metabolic 
syndrome, despite receiving medical treatment to manage elements of this condition.  
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Table 5.2: Clinical Characteristics 
 All 
participants 
(n=51) 
No Cancer 
(n=13) 
Gleason 
3+3 
(n=17) 
Gleason 
3+4 
(n=14) 
Gleason 
≥4+3 
(n=7) 
Patient Outcomes 
Age (years) 
Range  
66 ± 7 
53-82 
62 ± 6 
53-82 
65 ± 7  
53-76 
67 ± 7 
53-76 
71 ± 5* 
61-76 
PSA (ng/mL) 6.1 ± 3.3 4.3 ± 2.0 6.2 ± 2.9 6.7 ± 2.2 8.2 ± 4.2* 
Active Surveillance Prior to Current 
Biopsy (n) 
15 - 9 4 2 
Treatment 
    Active Surveillance (n) 
    Radiation Therapy (n) 
    Androgen Deprivation Therapy (n) 
    Radical Prostatectomy (n) 
 
17 
5 
2 
13 
 
- 
- 
- 
- 
 
15 
1 
0 
1 
 
2 
0 
1 
10 
 
0 
4 
1 
2 
Bone Metastases (n) 2 - 0 1 1 
Number of Positive Biopsy Cores (n) 5 ± 4 - 3 ± 2 8 ± 3 7 ± 3 
Percent Tissue Involved (%) 7.0 ± 10.7 - 3.4 ± 8.0 7.3 ± 7.0 20 ± 20 
Medical History 
Family History of Cancer (n) 24 8 10 3 3 
Family History of Prostate Cancer 
(n) 
9 3 4 1 1 
Previous Cancer (n) 
      Basel Cell Carcinoma (n) 
      Colorectal (n) 
      Bladder (n) 
      Kidney (n) 
      Testicular (n) 
      Male Breast Cancer (n) 
12 
7 
1 
1 
1 
1 
1 
3 
2 
0 
0 
0 
0 
1 
2 
1 
0 
1 
0 
0 
0 
6 
4 
1 
0 
1 
0 
0 
1 
0 
0 
0 
0 
1 
0 
Hypertension (n) 24 9 3 8 4 
High Cholesterol (n) 24 5 9 5 5 
Diabetes (n) 9 2 2 3 2 
Smoking 
     Current (n) 
     Ex (n) 
     Never (n) 
 
7 
25 
19 
 
4 
4 
6 
 
1 
12 
4 
 
2 
3 
8 
 
0 
6 
1 
* indicates significantly different from all other groups 
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Table 5.3: Assessment of the components of metabolic syndrome  
 All 
participants 
(n=51) 
No Cancer 
(n=13) 
Gleason 
3+3 
(n=17) 
Gleason 
3+4 
(n=14) 
Gleason 
≥4+3 
(n=7) 
Metabolic syndrome (n) 
  Central Obesity + 1 Risk Factor (n) 
   At least 1 Risk Factor (n) 
32 (63%) 
39 (76%) 
51 (100%) 
11 (84%) 
13 (100%) 
13 (100%) 
12 (70%) 
14 (82%) 
17 (100%) 
3 (17%) 
5 (36%) 
14 (100%) 
6 (86%) 
7(100%) 
7 (100%) 
Central Obesity (n) 39 (76%) 12 (92%) 14 (82%) 5 (36%) 7 (100%) 
Hypertension (n) 46 (90%) 13 (100%) 15 (88%) 11 (79%) 6 (86%) 
Abnormal Fasting Glucose (n) 18 (35%) 7 (54%) 4 (23%) 4 (29%) 3 (43%) 
Abnormal TG (n) 8 (15%) 5 (38%) 0 (0%) 2 (14%) 1 (14%) 
Abnormal HDL (n) 22 (43%) 5 (38%) 8 (47%) 3 (17%) 5 (71%) 
Using Lipid Altering Medications (n) 24 (47%) 5 (38%) 9 (52%) 5 (36%) 5 (71%) 
 
5.6.1 Glucose and Insulin Metabolism 
Fasting C-peptide concentrations (indicative of insulin secretion) were significantly greater in 
Gleason ≥4+3 patients versus Gleason 3+3 and Gleason 3+4 (Gleason ≥4+3: 2.8±1.1 ng/mL; Gleason 
3+3 1.4±0.6 mg/mL; Gleason 3+4: 1.3±0.8 mg/mL, p=0.002; Figure 5.2C), despite no differences in 
fasting glucose (p=0.101, Figure 5.2A), lactate (p=0.885, Table 5.4) and HbA1c values (p=0.834, 
Table 4.4). Fasting insulin was 17.5±10.0 uIU/mL in Gleason ≥4+3 patients compared to 7.5±4.6 
uIU/mL in Gleason 3+4, 8.6±3.9 uIU/mL in Gleason 3+3 and, 11.7±10.2 uIU/mL in the No cancer 
group (p=0.087; Figure 5.2B).  Insulin resistance, measured by HOMA-IR, was highest in patients 
with Gleason ≥4+3 though this did not reach statistical significance (p=0.07, Figure 5.2D).  Despite 
that IGF-1 shares a signalling cascade with insulin, no differences were observed in IGF-1 (p=0.546), 
IGFBP-3 (p=0.432) or IGF-1:IGFBP-3 ratio between any of the groups (p=0.123, Table 5.4).  
Collectively, these data suggest emerging insulin resistance in Gleason ≥4+3 patients.  
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5.6.2 Body Composition 
Given that obesity is associated with abnormal insulin signaling (222), body composition may 
elucidate the relationship between increased insulin secretion and aggressive cancers.   
Approximately, 80% of participants were overweight (BMI 25.0–29.9 kg/m2, n=21) or obese (BMI 
>30.0 kg/m2, n=20), while no participants were underweight (BMI <18.5 kg/m2) (Table 5.1). 
Although it was not statistically significant, patients with Gleason ≥4+3 had the largest BMI 
(p=0.090, Table 5.5). On average, WC was 102.8±11.7 cm, indicative of abdominal obesity (IDF cut-
point: >102 cm; Table 5.5).  Patients with Gleason ≥4+3 had significantly larger WC when compared 
to patients with Gleason 3+4 (112.4±6.7 cm vs 97.5±13.7 cm, p=0.028, respectively, Figure 5.3A).  
Similarly, Gleason ≥4+3 patients had significantly greater HC than Gleason 3+4 patients (110.1 ± 7.4 
cm vs 102.0 ± 9.5 cm, p=0.034, respectively, Figure 5.3B).  As well, there was a main effect for 
waist-to-hip ratio, though no interactions were identified (p=0.048, Figure 5.3C).  Though not 
statistically significant, patients with Gleason ≥4+3 had the highest estimates of FM, FM Index, % 
body fat, and SMM compared to the other groups (FM: p=0.090; FM Index: p=0.087; % body fat: 
p=0.058, Table 5.5).  There were no significant differences were observed in FFM, however, 
estimated SMM was highest in participants no cancer, though this did not reach significance 
(p=0.080).  Body fat, specifically visceral adiposity, may contribute to aggressive prostate cancer 
development based on these data.   
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Table 5.5: Anthropometric and BIA derived body composition measures 
 All 
participants 
No Cancer 
(n=13) 
Gleason 
3+3 
(n=17) 
Gleason 
3+4 
(n=14) 
Gleason 
≥4+3 
(n=7) 
Height (cm) 175.7 ± 6.4 177.5 ± 6.2 176.8 ± 
5.5 
175.4 ± 6.9 169.6 ± 
5.4 
Weight (kg) 89.3 ± 14.9 93.7 ± 13.5 89.4 ± 
14.8 
83.9 ± 17.4 92.9 ± 9.7 
BMI (kg/m2) 28.9 ± 4.4 29.7 ± 3.3 28.6 ± 4.3 27.3 ± 5.0 32.2 ± 2.8 
Fat Free Mass 
(kg) 
66.4 ± 10.1 70.7 ± 7.9 65.8 ± 9.5 65.8 ± 12.4 61.3 ± 8.9 
Fat Free Mass 
Index (kg/m2) 
21.4 ±2.8 22.4 ± 2.1 20.9 ± 2.6 21.1 ± 3.7 21.3 ± 2.6 
Fat Mass (kg) 24.0 ± 9.6 23.0 ± 7.2 24.3 ± 7.2 20.8 ± 13.3 31.6 ± 7.8 
Fat Mass Index 
(kg/m2) 
7.8 ± 3.1 
 
7.2 ± 2.0 7.8 ± 2.4 6.7 ± 4.0 11.0 ± 2.8 
% Body Fat 26.0 ± 8.1 24.1 ± 4.9 26.6 ± 4.7 23.3 ± 11.6 33.9 ± 8.0 
Skeletal Muscle 
Mass (kg) 
33.5 ± 6.4 36.0 ± 4.2 33.8 ± 7.1 32.0 ± 7.3 31.0 ± 4.0 
SMM Index 
(kg/m2) 
10.8 ± 1.8 11.4 ±1.0 10.7 ± 2.0 10.4 ± 2.2 10.8 ± 1.2 
† indicates significantly different from Gleason 3+4; ‡ indicates main effect 
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5.6.3 Adipokines, C-reactive Protein, and Lipid Metabolism 
Adipokines are the signalling molecules linking obesity to insulin resistance (223).  Gleason 
≥4+3 patients had higher leptin levels compared with Gleason 3+4, but not other groups (Gleason 
≥4+3: 15.6±3.3 ng/mL, Gleason 3+4; 8.1±8.1 ng/mL, Gleason 3+3: 8.5±5.4ng/mL, No cancer: 
7.9±4.0 ng/mL, p=0.013; Figure 5.4A).  Adiponectin concentrations were lower in Gleason ≥4+3 
patients compared with the other groups, but this did not reach statistical significance (No cancer: 
5.87±3.69 pg/mL; Gleason 3+3: 9.65±6.91 pg/mL; Gleason 3+4: 8.05±5.93 pg/mL; Gleason ≥4+3: 
5.05±5.10, pg/mL, p=0.069, Figure 5.4B).  Thus, leptin: adiponectin ratio was highest in Gleason 
≥4+3 patients (Gleason 3+3: 2.4±2.1 AU, Gleason 3+4; 2.9±3.2, Gleason ≥4+3: 9.7±6.1 AU, 
p=0.013, Figure 5.4C).  There were no significant differences observed in CRP between any of the 
groups (p=0.265, Table 5.4).   
There were no significant differences in the lipid profile (total cholesterol, HDL, LDL, TG) 
between any of the groups (Table 5.5).  However, only patients with Gleason ≥4+3 had HDL levels 
(0.9 ± 0.4 mM) below the IDF cut point (1.0mM; 157).   
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5.6.4 Functional Assessment, Habitual Physical Activity Levels, and Dietary Intake 
Traditional lifestyle factors that moderate of glucose metabolism, functional capacity, 
habitual physical activity, nutritional intake, and macronutrient distribution, were not significantly 
different between any of the groups (Table 5.6).  Patients walked 546.5±88.7m in 6 minutes, which 
was 104±16% of their predicted walking distance (218).   Average handgrip strength was 44.5±8.6 kg 
(Reference 40±8.3; 219) and habitual physical activity measured by Godin Score was 28±23 AU 
(Reference: 38±34; 217).  On average participants consumed 2363±631 kcal per day, consisting of 
43±8% carbohydrate, 19±4% protein and 35±5% fat (Table 5.6).  
 
Table 5.6: Functional Measures and Nutritional Intake  
 All 
participants 
No Cancer 
(n=13) 
Gleason 
3+3 
(n=17) 
Gleason 
3+4 
(n=14) 
Gleason 
≥4+3 
(n=7) 
Reference 
Value 
Functional Measures 
6-minute 
Walk Test (m) 
546.5 ± 
88.7 
583.4 ± 
46.9 
528.8 ± 
93.4 
574.3 ± 
102.8 
493.6 ± 
65.2 
104 ± 
16% of 
predicted 
Handgrip 
Strength (kg) 
44.5 ± 8.6 45.9 ± 8.4 43.9 ± 10.2 45.8 ± 7.9 39.9 ± 5.5 ~40  
Godin Score 
(AU) 
28 ± 23 23 ± 22 24 ± 21 38 ± 28 27 ± 21 ~38 
Nutritional Intake 
Total Calories 
(kcal) 
2363 ± 631 2540 ± 
1001 
2292 ± 409 2368 ± 407 2095 ± 
346 
~1900 
Carbohydrates 
(%) 
43 ± 8 41 ± 8 45 ± 7 45 ± 9 40 ± 11.5 45-60 
 
Protein (%) 19 ± 4 20 ± 5 17 ± 4 18 ± 5 22 ± 2 15-20 
Fat (%) 35 ± 5 36 ± 4 35 ± 5 34 ± 4 36 ± 7 20-35 
 
5.6.5 Linear Regression Analysis 
Multiple linear regression revealed age, PSA, leptin: adiponectin ratio, and HC were 
significantly related to Gleason scores.  Leptin: adiponectin ratio and HC were correlated; thus, 
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including both in the model was unnecessary.  The following model was found to modestly but 
significantly explain the variation in Gleason score: 
𝐺𝑙𝑒𝑎𝑠𝑜𝑛 𝑆𝑐𝑜𝑟𝑒 = (0.0456 × 𝐴𝑔𝑒 (𝑦𝑒𝑎𝑟𝑠) + (0.103 ×  𝑃𝑆𝐴 (
𝑛𝑔
𝑚𝐿
))
+ (0.000138 ×  𝐿𝑒𝑝𝑡𝑖𝑛: 𝐴𝑑𝑖𝑝𝑜𝑛𝑒𝑐𝑡𝑖𝑛 (𝐴𝑈)) − 2.630 
This model provides an r 2 value of 0.398.  Age, PSA, and leptin to adiponectin ratio were statistically 
significant in the model (p=0.013, p=0.021 and p=0.027, respectively).   
5.7 Discussion 
This is the first study, to our knowledge, to comprehensively integrate and evaluate the 
metabolic characteristics of men, prospectively and consecutively recruited following referral to an 
uro-oncologist for prostate biopsy. After obtaining biopsy outcomes, these characteristics were 
associated with corresponding Gleason scores.  
C-peptide concentrations were highest in participants with Gleason ≥4+3 compared with 
other Gleason scores, in line with tendencies exhibited in fasting insulin concentrations and HOMA-
IR. Central adiposity (measured by WC) is associated with insulin resistance (222) and was 
significantly larger in Gleason ≥4+3 patients. Gleason ≥4+3 patients also had significantly greater 
leptin and leptin: adiponectin ratios compared with all other groups. These adipokine perturbations 
may be associated with insulin resistance (223) and visceral adiposity (223, 224).  Collectively, these 
data suggest adiposity-related metabolic sequelae that contribute to aggressive prostate cancer. 
5.7.1 Impaired Markers of Glucose Metabolism are Associated with Higher Gleason 
Scores 
Despite similar fasting glucose concentrations across Gleason score categories, C-peptide 
concentrations were greatest in men with Gleason ≥4+3 suggesting more insulin secretion in this 
group. Previous work has demonstrated both positive (138) and neutral (225) associations between 
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prostate cancer aggressiveness and C-peptide concentrations.   Higher baseline C-peptide 
concentrations have also been shown to increase the likelihood of prostate cancer-specific death 
(128).  
  Elevated C-peptide concentrations aligned with fasting insulin concentrations and the 
HOMA-IR that approached significance in participants with Gleason ≥4+3. Hyperinsulinemia is 
hypothesized to link obesity to prostate cancer development, whereby insulin creates a metabolic 
milieu favourable for cancer growth. Insulin receptors are found in abundance on human prostate 
tumours27, allowing activation of Akt and MAPK pathways, ultimately resulting in proliferation and 
apoptosis inhibition (88). IGF-1 is also proposed to stimulate prostate cancer cell growth through the 
same mechanisms (226). Increased IGFBP-3 binding, the major binding protein of IGF-1, prohibits 
IGF-1 binding to the prostate cancer cell, ultimately reducing proliferation (226).  We found no 
differences across Gleason scores for IGF-1, IGFBP-3, and IGF-1:IGFBP-3 ratio; however, it may 
not be possible to detect differences across Gleason scores in these measures (227). 
5.7.2 Visceral Adiposity, a feature of metabolic syndrome, is related to insulin 
resistance 
The majority of the study participants (63%) had metabolic syndrome, and all participants 
had a least one risk factor of metabolic syndrome. Metabolic syndrome by definition is a 
multifactorial diagnosis; however, central obesity measured by WC is required criteria for all patients 
diagnosed with this syndrome (157). Patients with Gleason ≥4+3 had larger WC and waist-to-hip 
ratio than those with lower Gleason scores. WC >94 cm, the metabolic syndrome cut-point, may be 
an independent risk factor for prostate cancer (160), with both positive (160) and neutral (228) 
associations demonstrated. WC is a measure of visceral adiposity, a key factor numerous disease 
states including metabolic syndrome, diabetes and cardiovascular disease (223). Increased visceral 
adiposity is associated with increased basal insulin and C-peptide levels (228), supporting the 
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elevations in C-peptide and insulin observed here. Similarly, HC and waist-to-hip ratio were 
significantly greater in patients with the Gleason ≥4+3. Few studies consider waist-to-hip ratio as a 
marker of visceral adiposity in prostate cancer, but like WC positive (229) and neutral (228) 
associations have been demonstrated.  
  This variability may be related to study design and participants because geographic and 
cultural differences lead to different metabolic, dietary and activity profiles. However, considerations 
of visceral adiposity may need to include other metabolic features including glucose- (insulin, C-
peptide) and lipid-related parameters, such as adipokines, as visceral adiposity is associated with 
increased leptin and decreased adiponectin levels (223). 
5.7.3 Adipokines are Associated with Visceral Adiposity and Hyperinsulinemia 
Leptin and leptin: adiponectin ratios were significantly higher in patients with Gleason ≥4+3. 
Both leptin and adiponectin are independently associated with prostate cancer development (132, 
230).  Leptin can stimulate cancer cell growth and angiogenesis (132), while adiponectin may have 
anti-proliferative functions (230).  Leptin: adiponectin ratio is emerging as an important predictor of 
prostate cancer risk, with Burton et al reporting elevated leptin, decreased adiponectin, and higher 
leptin: adiponectin ratios in aggressive prostate cancer (198).  
Adiponectin and leptin are hypothesized to link adiposity to the development of insulin 
resistance. Increased adiposity is associated with higher leptin and decreased adiponectin levels and 
hyperinsulinemia may result from changes in circulating adipokines, potentially stimulating prostate 
cancer proliferation beyond the independent effects of leptin and adiponectin (223).  We observed 
increased visceral adiposity, leptin and C-peptide levels in patients with Gleason ≥4+3.  This suggests 
a cluster of metabolic disturbances working via numerous pathways, creating a metabolic 
environment conducive to aggressive prostate cancer development.   
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5.7.4 Age is an Important Risk Factor for Prostate Cancer 
Age is the strongest known risk factor for prostate cancer.  In Canada, 97.8% of all prostate 
cancer diagnoses occur in men over the age of 50 (17) and by age 90, 80% of men have been shown 
to have cancerous cells in their prostate (52).  Increased age is also associated with more aggressive 
cancers (231), and therefore, it is unsurprising that in the current study patients with the most 
aggressive cancers are significantly older than those with no cancer.  However, age is also associated 
with increased insulin resistance (232) and obesity (233).  Consequently, as patients with the most 
aggressive cancers (Gleason score ≥4+3) were significantly older than patients with less aggressive 
cancers, some of the differences in C-peptide and central obesity may be explained by the increased 
age of this group. 
 
5.7.5 The Metabolic Sequelae of Aggressive Cancer may Impact Prostate Cancer 
Survivorship 
We describe a cluster of metabolic perturbations related to aggressive prostate cancer; 
however, this cluster may also pose significant risk for prostate cancer survivors.  Obesity (234), 
hypertension (234), impaired fasting glucose (235), and dyslipidemia (235), features of metabolic 
syndrome, have been associated with increased risk of prostate cancer recurrence.  However, 
recurrence is not the only concern for aggressive prostate cancer patients, as they are more likely to 
receive ADT. ADT causes significant metabolic perturbation (236) and is associated with diabetes 
and cardiovascular disease in survivorship (27).  The negative effects of ADT may be exacerbated in 
patients with aggressive prostate cancer as they exhibit metabolic perturbations at diagnosis.  
5.7.6 Study Considerations 
The prospective study design allowed investigators to be blinded to biopsy outcomes and 
facilitated the inclusion of the no cancer group. Though, no cancer was confirmed by a negative 
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extended prostate biopsy (≥16 cores), this group may differ from men who have never had a prostate 
biopsy. This single-institution cohort is relatively small, consequently, a limited number of variables 
were considered in the linear regression analysis.  However, the small sample size allowed for 
characterization of a comprehensive metabolic profile, resulting in the novel integration of the 
metabolic and clinical characteristics of these men. These data will serve as the foundation for future, 
larger-scale studies to further examine these interactions. 
5.8 Conclusions 
Overall, this investigation revealed a cluster of adiposity related abnormalities in participants 
with high Gleason scores, when compared to participants with lower Gleason scores.  Specifically, 
patients with Gleason ≥4+3 had increased C-peptide concentrations, increased visceral adiposity, 
lower than normal HDL, increased leptin, and leptin: adiponectin ratio.  These finding suggest 
aggressive prostate cancer is associated with a set of adiposity driven metabolic perturbations.  
Further investigations into these metabolic sequelae and their association with high-risk disease is 
warranted to elucidate the mechanisms driving this development and to identify interventions to 
combat this profile. 
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6.3 Abstract 
Background: Obesity and age, key risk factors for aggressive prostate cancer, are associated with 
insulin resistance. Glucose-related parameters in aggressive prostate cancer patients were compared 
with 2 reference groups: men of similar age and body mass index (BMI) without cancer and healthy 
young men. Acute changes in these parameters following radiation treatment were also evaluated.  
 Methods: Nine high-risk prostate cancer patients underwent metabolic assessments prior to treatment 
(baseline), 7 and 33 weeks post-baseline (post-treatment initiation). Baseline measures were 
compared with the 2 reference groups. Evaluations included: 1) fasting and oral glucose tolerance test 
(OGTT) blood samples for glucose, C-peptide, and insulin, 2) fasting blood samples for triglycerides, 
cholesterols, leptin, adiponectin, IL-6, and TNF-α, 3) body composition, 4) nutrition intake, and 5) 
physical activity.    
Results: At baseline, patients had normal fasting glucose concentrations (<5.6mM; 4.9±1.2mM) but 
impaired 2-hours OGTT glucose concentrations (>7.8mM; 8.7±2.9mM).  Both reference groups had 
normal fasting (matched males: 4.2±0.5mM; young males: 3.7±0.4mM) and 2-hour OGTT glucose 
concentrations (matched males: 5.6±1.8mM; young males: 3.1±0.1mM) that were significantly lower 
than patient values.   During the OGTT, patients had higher insulin (120 minutes) and C-peptide (45, 
60, 90, 120 minutes) concentrations compared to the matched males. At 7 weeks, 2-hour OGTT 
glucose concentrations in patients improved to healthy ranges without changes in insulin, C-peptide, 
IGF-1, IGFBP-3 or other metabolic parameters. 
Conclusions: At baseline, high-risk prostate cancer patients demonstrated impaired glucose tolerance 
compared with men of similar age and body size. Following treatment, glucose tolerance improved in 
absence of changes in expected modifiers of glucose metabolism. These improvements may be 
related to treatment.  
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6.4 Introduction 
Age is the strongest known non-modifiable risk factor for prostate cancer whereby 97.8% of 
all Canadian prostate cancer diagnoses occur in men over 50 years old, while <1% of cases occur in 
men under the age of 40 (17). Obesity (201) and metabolic syndrome (160, 174) have emerged as key 
modifiable risk factors for prostate cancer development.  Impaired insulin and adipokine signalling 
develop with aging (237) and obesity (238, 239).  Prostate cancer patients typically exhibit 
hyperinsulinemia (12, 196), elevated C-peptide concentrations (128), dyslipidemia (196, 188), 
adipokine perturbations (198), and/or pro-inflammation (199) that contribute to tumour development 
and influence the presence of comorbidities. To further complicate these interrelationships, prostate 
cancer diagnosis is independently associated with increased number of cardiovascular events (240). 
Given the prevalence of insulin resistance and prostate cancer in older men, it is important to 
distinguish whether these metabolic perturbations are related to the cancer or underlying co-
morbidities that often accompany older men with prostate cancer. Understanding the underlying 
mechanisms of these interrelated metabolic deviations, independent of age and body size, is also 
important in preventing/managing comorbidities and cancer recurrence in survivorship.   
 Different treatment regimens may possess unique metabolic disturbances that may contribute 
to development of CVD and diabetes or exacerbate existing metabolic conditions. Androgen 
deprivation therapy (ADT) has been associated with increased risk of diabetes and cardiovascular 
disease (CVD) in prostate cancer survivors (27, 241), and it is thought that these risks are related to 
muscle loss and adipose tissue gains during ADT. In prostate cancer patients who developed diabetes 
after diagnosis, 50.2% had received a prostatectomy, 21.4% received radiation therapy (RT) 12.1% 
received hormonal therapy, and 16.3% underwent active surveillance as their primary treatment type 
(108). Interestingly, RT is often used in conjunction with prostatectomy and ADT, yet the specific 
  72 
metabolic consequences (i.e. glucose, insulin, C-peptide, adipokine metabolism) of these treatments, 
including RT, are largely unknown.  
 The purpose of this study was to examine the metabolic consequences of prostate cancer 
diagnosis and potential changes during the acute treatment trajectory (primarily RT with secondary 
ADT). Since age and body size influence the development of CVD and diabetes in non-malignant and 
prostate cancer populations, our first objective was to characterize and describe differences in glucose 
metabolism as well as lipids, body composition, cytokines, dietary intake, and physical activity 
between newly diagnosed prostate cancer patients, men of the same age and body size (matched 
males), and a young healthy comparison group (young males). Moreover, RT is intended to have 
localized effects on the tumour, which may directly or indirectly lead to metabolic perturbations on 
host-metabolism. Hence, our second objective was to describe potential changes in these measures 
during the acute treatment trajectory (~33 weeks from treatment initiation).  
6.5  Methods  
6.5.1 General Study Design 
High-risk prostate cancer patients were recruited for this study. Treatment plan was either 
conventional radiation treatment with upfront ADT (n=4) or hypofractionated radiation therapy with 
salvage ADT (n=5). To distinguish metabolic effects observed in prostate cancer patients related to 
aging and body size, 2 separate comparison groups were used: a group of males age- and BMI-
matched to the prostate cancer participants (matched males) and a young healthy group of males 
(young males). 
For prostate cancer patients, clinical and metabolic assessments were conducted over 2 days 
that were >48 hours apart but no more than 1 week apart. Assessments on prostate cancer patients 
were performed at: Baseline (prior to treatment initiation), ~7 weeks (end of RT), and ~33 weeks 
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from baseline (6 months following the end of RT). Assessing patients following diagnosis and prior 
to treatment will distinguish between metabolic changes that lead to the development of prostate 
cancer and provide a true baseline for the examination of metabolism during the acute trajectory.  
Assessments included the following measures: 1) fasting blood samples followed by an OGTT, 2) 
body composition analysis (weight, BMI, Single Frequency-Bioelectrical Impedance Analysis (SF-
BIA)), 3) systolic and diastolic blood pressure and resting heart rate, 4) physical activity measures 
(VO2peak, repeated 1-RM, physical activity questionnaire), and 5) dietary intake (by 3-day food diary). 
This study was reviewed by the University of Waterloo Office of Research Ethics (all groups) and by 
Tri-Hospital Research Ethics Board (prostate cancer patients only). 
6.5.2 Participants 
6.5.2.1 Prostate Cancer Patients 
Nine high-risk (Gleason score >8, PSA >20ng/mL, or Stage >T3A) prostate cancer patients 
were recruited from the Grand River Regional Cancer Centre (Kitchener, ON) following their cancer 
diagnosis, but prior treatment initiation. Patients included in the study were of any age (≥18 years 
old), BMI, and fitness level.  However, patients were excluded from participation if their fasting 
glucose was >7.0 mM or if they had any diagnosis of metabolic disease (cardiovascular disease, 
diabetes).   
6.5.2.2 Non-Malignant Reference Groups 
Men without cancer were recruited from the community and we sought to individually match 
them to corresponding prostate cancer patients in terms of age (±5 years) and BMI (±3 kg/m2). 
Matched males were also required to be weight stable over the last 6 months, have a fasting blood 
glucose <7.0mM, and no history of metabolic disease (diabetes, cardiovascular disease).  
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To evaluate the extent of potential impairment in glucose and lipid metabolism, prostate 
cancer patients and the individuals in the matched males group were compared with the young male 
group who were between the ages of 20-30 years old, weight stable with normal BMI (18.5-24.9 
kg/m2), active with VO2peak >45 mL/kg/min, without metabolic disease and had fasting blood glucose 
<5.6mM.   
6.5.3 Blood Sampling 
Blood was sampled following an overnight fast (8-12 hours with no food or drink except for 
water). A sterile catheter was inserted into an antecubital vein of the participant’s preferred arm and 
25 mL of blood was drawn (Timepoint: -30).  Following 30 minutes (Timepoint 0) a second fasting 
sample of 5 mL was drawn, to account for variability in measures such as fasting blood glucose.  An 
OGTT was subsequently performed to investigate the body’s response to a glucose challenge. 
Participants consumed a 75g glucose drink (Trutol Glucose Tolerance Beverage, ThermoFisher 
Scientific; East Providence, RI) within 10 minutes. Post-prandial blood samples (5 mL) were drawn 
15, 30, 45, 60, 90, and 120 minutes following consumption of the drink the timer was set and 5 mL of 
blood was drawn at (total time of OGTT = 150 minutes).   Blood samples were obtained from 8 of 9 
prostate cancer patients due to sampling difficulties; thus n=8 for all blood measures.  
Fasting blood samples were analyzed for glucose-related parameters (glucose, insulin, C-
peptide), lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, TG), adipokines (leptin, 
adiponectin), inflammatory markers (IL-1β, IL-4, IL-6, IL-8, IL-10, TNF-α, CRP) as well as 
testosterone, IGF-1, and IGFBP-3.  Blood samples collected at all other time-points during the OGTT 
were assessed for glucose, insulin, and C-peptide.  
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6.5.4 Biochemical Analysis 
Blood samples were allowed to clot for 30 minutes, centrifuged and serum collected for 
metabolite analysis. Glucose was analyzed using spectrofluorometric methods (212). Insulin and C-
peptide were analyzed using commercially available kits (Insulin: Human Insulin Specific RIA kit, 
EDM Millipore, St. Charles, MO; C-peptide Double Antibody RIA Kit, Siemans Healthcare 
Diagnostics; Deerfield, IL). Triglycerides, total cholesterol, HDL and LDL cholesterol were analyzed 
using a spectrofluorophotometer and commercially available reagents (Pointe Scientific; Canton, MI).  
Cytokines (IL-1β, IL-4, IL-6, IL-8, IL-10, TNF-α) were analyzed using BD Cytometric Bead Array 
and BD FACSCalibur flow cytometer (BD Biosciences; Mississauga, ON).  Leptin, adiponectin, IGF-
1, IGFBP-3, and C-reactive protein were assessed using sandwich enzyme-linked immunosorbant 
assay (R&D Systems Inc, Minneapolis, MN).  Testosterone was measured using a Parameter assay 
(R&D Systems Inc, Minneapolis, MN).  
6.5.5 Body Composition 
Anthropometric measures included height, weight, and calculated BMI. Weight was 
determined using a balance beam scale (Detecto Scales Inc, Brooklyn, NY) and recorded to the 
nearest 0.1 kilogram.  Height was determined using a stadiometer and recorded to the nearest 0.1 cm. 
These values were used to calculate BMI.  
Fat free mass (FFM), fat mass (FM), percent body fat, skeletal muscle mass (SMM) and 
skeletal muscle index (SMI) were determined via SF-BIA.  Reactance and resistance values were 
generated and used to estimate FFM using the equation describe by Kyle et al (215).  
FM was estimated from calculated FFM and % body fat was calculated as FM divided by 
total weight multiplied by 100.  Skeletal muscle mass (SMM) was calculated using the equation 
described by Janssen et al (216).  
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SMI (kg/m2) was determined by dividing SMM by height squared (m2).  Estimated SMI was 
compared to sarcopenic cut points from the literature defined as SMI ≤8.5 kg/m2 in men (242).  
6.5.6 Physical Activity Assessment 
Prior to the exercise tests, resting blood pressure was assessed using a sphygmomanometer 
and stethoscope and was recorded to the nearest 2 mmHg. Participants were excluded from 
participation in the exercise assessment if systolic blood pressure ≥150 mmHg or diastolic pressure of 
≥90 mmHg on the day of the assessment. 
VO2peak tests were conducted on a treadmill (Bodyguard Fitness, St. Georges, QC) using the 
Vmax breath-by-breath system (Vmax; SensorMedics, Yorba Linda, CA). Three (3) minutes of 
resting data were collected while sitting in a chair and in standing position.  Patients and matched 
males warmed-up by walking at 2 mph (no incline) for 3 minutes.  Treadmill speed and grade was 
increased based on a modified Balke protocol (243) for patients and matched. The University of 
Waterloo Treadmill Protocol was used for the young males. Following resting measures, young males 
warmed-up by walking at 3.5 mph (no incline) for 2 minutes. The speed of the treadmill was then 
increased to a pre-determined speed between 7-8 mph (no incline) and this speed was maintained for 
the entire test. The treadmill grade was increased by 2% every 2 minutes until the participant reached 
exhaustion. Blood pressure, using a manual sphygmomanometer, and Borg’s rating of perceived 
exertion were recorded at every stage of the test. Predicted tests (patients and matched males) were 
terminated when participants reached >85% of their age-predicted maximal heart rate , or when the 
participant requested to stop (244).  
Strength was assessed using predictive 1RM tests for upright bench press and leg extension 
using the American College of Sport Medicine (245) procedure. 1RM was predicted using the 
O’Connor et al equation (246). 
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Habitual physical activity levels were evaluated using the Godin Leisure Time Physical 
Activity Questionnaire. This questionnaire provides a physical activity score, which can be compared 
to a healthy reference group and has been used in a population of prostate cancer patient 
previously(247).  
6.5.7 Nutrition Intake 
During the week of the exercise and metabolic assessments, participants completed a 3-day 
food diary over the 2 weekdays and 1 weekend day (220). Participants were instructed to record all 
foods, beverages and supplements in detail. Daily caloric intake and macronutrient breakdown (% fat, 
% carbohydrate and % protein) were determined using ESHA Food Processor software and the 
Canadian Nutrient Files where available. The USDA National Nutrient Database for Standard 
Reference was used when Canadian information was not available.  
6.5.8 Calculations 
Area under the curve (AUC) was calculated using the incremental area method for glucose, 
insulin, and C-peptide (248).  HOMA-IR (213), QUICKI (249), and Mastuda Index (250) were 
calculated as previously described. Molar ratio for IFG-1: IGFBP-3 and for leptin: adiponectin were 
calculated as previously described using the following molecular masses: IGF-1: 7.5kDa (251); 
IGFBP-3: 30.5kDa (251), leptin: 16kDa (252), adiponectin: 30kDa (252).   
6.5.9 Statistical Analysis 
Values are presented as mean±SD.  All statistical calculations were completed using Sigma 
Plot ® version 11.2 (Systat Software Inc.; San Jose, CA). Statistical significance was determined at 
p<0.05.  One-way repeated-measures ANOVAs were used to determine differences in measurements 
between each of the time points (baseline, 7, and 33 week post-baseline) with Tukey’s post-hoc 
analysis for pairwise comparisons.  Two-way repeated-measures ANOVAs with Tukey’s post-hoc 
  78 
analysis was also be used to compare average fasting glucose, insulin, C-peptide, and lactate to values 
obtained 15, 30, 45, 60, 90, and 120 min of the OGTT for all groups. Comparison between multiple 
groups (prostate cancer patients, matched males, young males) were determined using One-way 
ANOVAs with Tukey’s post-hoc analysis.  
6.6 Results 
Patients were, on average, 71±6 (60-77) years old and had a BMI of 28.2±6.1 (21.0-37.7) 
kg/m2. On average, patients were classified as overweight as per BMI, with 5 of 9 patients being 
overweight or obese (BMI ≥25.0 kg/m2) and average BIA-derived % body fat characterized these 
patients as obese (>30%; Table 6.1). For matched males, 353 individuals who were >40 years old and 
did not have prostate cancer were assessed for eligibility for the matched reference group. Of these, 
71 were eligible and 32 were interested in participating, and were screened. We chose 9 participants 
who best met our criteria to participate in the study (Figure 6.1). For 3 patients who had a BMI >33.0 
kg/m2, we were unable to find eligible matches. These patients were matched with the screened 
individual with the closest age and BMI criteria to the patients and who met all other inclusion 
criteria; as such, data were then analyzed as groups. There were no significant differences between 
patients and matched males in age (72±5 years old, p=0.582) or BMI (27.0±4.0 kg/m2, p=0.634; 
Table 5.1) or other body composition assessments (Table 6.1).  For the young male reference group, 
participants were 26+3 years old, had BMI 23.5±1.6kg/m2 and had lower fat mass (12.1±4.1 kg) and 
percentage body fat (16.5±4.7%) than the prostate cancer patients. Patients, matched males and 
younger males had normal muscularity based on BIA calculations (Table 6.1). 
 
 
 
 
  79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Participant recruitment flow diagram. This consort diagram describes the recruitment, 
enrolment, follow-up and analysis for the current study. 
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Table 6.1A: Physical and Clinical Characteristics 
Characteristic Prostate Cancer Patients Non-Malignant  Comparison 
Groups 
 Baseline 
(n=9) 
7 Weeks 
(n=9) 
33 Weeks 
(n=9) 
Matched Males 
(n=9) 
Young Males 
(n=10) 
Age (years) 71±6   72±5 26±3*† 
Systolic Blood 
Pressure 
(mmHg) 
164 ±20 147±12a 148±16a 135±19* 119±9* 
Diastolic Blood 
Pressure 
(mmHg) 
85±11 77±14a 80±12 83±13 76±6 
Resting Heart 
Rate (bpm) 
72 ±10 73±9 72±10 73±13 70±12 
Testosterone 
(ng/mL) 
29.4±3.3 17.8±10.8a 18.2±8.1a 17.6±12.1* 23.7±4.8 
Table 6.1B: Body Composition Characteristics 
Characteristic Prostate Cancer Patients Non-Malignant  Comparison 
Groups 
 
 Baseline 
(n=9) 
7 Weeks 
(n=9) 
33 Weeks 
(n=9) 
Matched Males 
(n=9) 
Young Males 
(n=10) 
Height (cm) 173.8±0.08   174.0±5.2 175.8±4.7 
Weight (kg) 86.1±23.6 85.6±22.3 85.8±20.6 81.8±12.8 72.7±6.5 
Body Mass 
Index (kg/m2) 
28.2±6.1 28.1±5.7 28.1±5.2 27.0±4.0 23.5±1.6 
BIA-Derived Estimates of Body Composition 
Fat Free Mass 
(kg) 
58.8±14.4 63.7±12.2 60.4±10.1 61.3±6.0 60.5±5.9 
Fat Mass (kg) 27.3±13.4 21.8±15.4 25.4±11.9 20.6±8.6 12.1±4.1* 
% Body Fat 30.6±10.9 23.4±15.2 28.4±7.8 24.4±7.0 16.5±4.7† 
Skeletal 
Muscle Mass 
(kg) 
29.1±7.3 29.6±7.5 29.9±5.3 31.9±3.8 34.4±3.8 
Skeletal 
Muscle Mass 
Index (km/m2) 
9.5 ±1.7 9.7±1.9 9.8±0.97 10.5±0.90 11.1±1.2 
Letters represent significance between Repeated Measures (Baseline, 7 Weeks, 33 Weeks). a indicates 
significant difference from Baseline; b indicates significant difference between 7 Weeks and 33 
Weeks. Letters represent significance between Baseline assessments in Patients and comparison 
groups.  * indicates significant difference between Patients and comparison group; † indicates 
significant difference between Matched Males and Young Males; § indicates a main effect  
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6.6.1 Clinical Characteristics of Prostate Cancer Patients versus Comparison Groups 
At baseline, all patients met the stage IIB requirements, 6 prostate cancer patients were 
classified as tumour stage T1C, 2 patients were classified as T2C and 1 was classified as T3C.  
Patients had average baseline PSA levels of 17.4±17.8 ng/dL while pathology revealed 3 patients had 
Gleason scores of 7 and 6 patients had Gleason scores of 8. Patients were on average classified as 
hypertensive (SBP>140mmHg) despite that 4 were prescribed hypertensive medication. In contrast, 
matched and young males had mean SBP that was in the normal range. Four matched males were 
taking hypertensive medication. Patients exhibited significant improvements in SBP at 7 and 33 
weeks post-baseline but SBP remained >140mmHg (Table 6.1).  Baseline testosterone concentrations 
were significantly higher in the prostate cancer patients compared with the matched males (p=0.013, 
Table 6.1). 
6.6.2 Prostate cancer patients exhibited impaired glucose tolerance and related 
parameters at baseline compared with matched males 
At baseline, patients had normal fasting glucose values of <5.6mM (4.9±1.2mM, Figure 
6.2A) but exhibited impaired glucose concentrations at 2 hours following an OGTT (Impaired OGTT 
defined as >7.8mM by WHO/IFD (157); 8.62±2.87mM, Figure 6.2A). While fasting glucose 
concentrations were similar to matched males (4.2±0.5 mM, p=0.683), 2-hour glucose concentrations 
during the OGTT were significantly lower (5.5±2.2 mM, p=0.015, Table 6.2). Despite this, prostate 
cancer patients and matched males demonstrated similar peak glucose concentrations (11.9±1.9mM 
and 9.8±3.2mM, respectively) and glucose AUC (Figure 6.2B). Young males demonstrated lower 
fasting (3.7±0.4 mM), peak (7.2±1.6mM), 2-hour (3.1±0.99 mM, p<0.001; Table 6.2) glucose 
concentrations and glucose AUC (Figure 6.2B) than prostate cancer patients. Peak glucose also 
occurred at an earlier time point (27.0±14.2 minutes) than in prostate cancer patients (63.8±23.7 
minutes; Table 6.2).  
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Fasting insulin and C-peptide concentrations in prostate cancer patients did not differ with the 
comparison groups (Figures 6.2B and 6.2C). However, during the OGTT, prostate cancer patients 
exhibited greater serum insulin concentrations at 120 minutes compared with the matched males and 
at 45, 60, 90 and 120 minutes compared with the young males (Figure 6.2C).  C-peptide 
concentrations in prostate cancer patients were also significantly greater than both the matched and 
young males at 45, 60, 90, and 120 minutes into the OGTT (Figure 6.2D).  HOMA-IR and Matsuda 
Index revealed lower insulin sensitivity in the prostate cancer patients compared to the matched males 
(Table 6.2). As expected, young males were significantly more insulin sensitive than the prostate 
cancer patients when using the HOMA-IR and QUICKI (Table 6.2). IGF-1 was similar across the 3 
groups but prostate cancer patients and matched males had significantly lower concentrations of 
IGFBP-3 compared with young males (Table 6.2). 
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Table 6.2: Glucose and Related Hormones 
Characteristic Prostate Cancer Patients Non-Malignant  Comparison 
Groups 
 Baseline 
(n=8) 
7 Weeks 
(n=8) 
33 Weeks 
(n=8) 
Matched 
Males 
(n=9) 
Young Males 
(n=10) 
Glucose Response during OGTT 
Fasting 
Glucose (mM) 
4.9±1.2 4.6±0.99 4.5±0.3 4.2±0.5  3.7±0.4* 
2-hour Glucose 
(mM) 
8.7±2.9 6.8±1.5 5.7±2.1a 5.6±1.8* 3.1±0.99*† 
Peak Glucose 
Concentration 
(mM) 
11.9±1.9 9.4±1.9a 9.8±1.5a 9.8±3.2 7.2±1.6* 
Time to Peak 
Glucose (min) 
63.8±23.7 65.6±26.5 
 
56.3±15.5 43.3±21.8 27.0±14.2* 
Glucose-related Measures and Calculations 
Fasting Insulin 
(µIU/mL) 
14.6±5.4 17.8±7.8 14.7±6.1 10.1±4.3 6.2±2.5 
Fasting C-
peptide 
(ng/mL) 
3.3±0.96 2.9±1.0 3.3±0.78 1.8±0.43 0.65±0.31† 
HOMA-IR 3.3±1.7 3.9±2.1 3.1±1.4 2.0±0.64* 1.1±0.50* 
QUICKI 0.32±0.02 0.32±0.02 0.33±0.02 0.35±0.02 0.39±0.03*† 
Matsuda Index 2.7±1.0 3.3±1.9 3.2±1.1 1.2±0.47* 2.8±0.8† 
 
IGF-1 (ng/mL) 107.6±52.8 99.2±48.8 89.6±38.7a 97.8±28.4 143.1±39.2 
IGFBP-3 
(ng/mL) 
2534.1±748.1 2416.1±530.0 2417.1±727.0 2367.8±265.8 3326.3±507.2
*† 
IGF-1: IGFBP-
3 Ratio (AU) 
0.15±0.05 0.15±0.06 0.14±0.04 0.15±0.04 0.16±0.05 
Letters represent significance between Repeated Measures. a indicates significant difference from 
Baseline; b indicates significant difference between 7 Weeks and 33 Weeks. Letters represent 
significance between Baseline assessments in Patients and comparison groups.  * indicates significant 
difference between Patients and comparison group; † indicates significant difference between 
Matched Males and Young Males; § indicates a main effect  
 
  85 
6.6.3 Lipids, Cytokines, and Adipokines in Prostate Cancer Patients Compared with 
Matched and Young Males 
Considering that 2 patients had been prescribed lipid-altering medications, on average, 
prostate cancer patients had total cholesterol, LDL and HDL cholesterol, as well as triglyceride 
concentrations in normal ranges at baseline. Triglycerides were greater in prostate cancer patients, 
otherwise, all other parameters were similar to concentrations in matched males (considering that 4 
matched participants were taking lipid-altering medication). Total cholesterol and triglyceride levels 
were greater and LDL cholesterol were greater in prostate cancer patients compared with young 
males though this did not reach statistical significance (Table 6.3). 
 
Table 6.3: Lipid-Related Metabolic Markers 
Characteristic Prostate Cancer Patients Non-Malignant  Comparison 
Groups 
 Baseline 
(n=8) 
7 Weeks 
(n=8) 
33 Weeks 
(n=8) 
Matched 
Males 
(n=9) 
Young Males 
(n=10) 
Lipid Profile 
Total 
Cholesterol 
(mM) 
4.7±0.9 4.9±1.0 4.9±1.5 4.6±1.0 3.3±0.7*† 
LDL (mM) 2.6±1.7 3.0±1.0 2.9±1.4 2.8±0.9 1.8±0.7†‡ 
HDL (mM) 1.2±0.5 1.3±0.4 1.2±0.5 1.1±0.3 1.3±0.8 
Triglycerides 
(mM) 
1.7±1.3 1.6±0.9 1.6±0.9 0.9±0.6§ 0.8±0.3* 
Adipokines 
Leptin (ng/mL) 7.9±6.0 9.1±7.3 9.4±5.8 7.5±4.5 2.2±2.2*† 
Adiponectin  
(ng/mL) 
6743.8±2759
.6 
6172.0±2796.3 6998.2±3175.9 8823.6±4212.4 6320.7±2385.4 
Leptin: 
Adiponectin 
Ratio (AU) 
0.79±0.70 0.95±1.2 
 
0.54±0.45 0.87±0.66 2.8±2.8§ 
Letters represent significance between Repeated Measures. a indicates significant difference from 
Baseline; b indicates significant difference between 7 Weeks and 33 Weeks. Letters represent 
significance between Baseline assessments in Patients and comparison groups.  * indicates significant 
difference between Patients and comparison group; † indicates significant difference between 
Matched Males and Young Males; § indicates a main effect  
 
  86 
 
Leptin and adiponectin, which are typically linked to obesity and insulin resistance, were not 
different between prostate cancer patients and matched males. As expected, based on adiposity and 
OGTT results, leptin concentrations were significantly greater in the prostate cancer patients as 
compared with the young males. We also observed a main effect for the leptin: adiponectin ratio 
(Table 6.3).  
Increased pro-inflammatory markers have been linked to insulin resistance (253) and obesity 
(254).  CRP, TNF-α, IL-6 and IL-8 were greater in prostate cancer patients and matched males 
compared with young males and IL-1β was similar across the groups (Table 6.4). Anti-inflammatory 
cytokines IL-4 and IL-10 were significantly greater in prostate cancer patients compared with young 
males, and only IL-10 was significantly greater in prostate cancer patients than matched males (Table 
6.4). 
6.6.4 Nutrition Intake and Physical Activity in Prostate Cancer Patients Compared with 
Matched and Young Males 
Prostate cancer patients and matched males consumed significantly less protein compared 
with young males (Table 6.5), which align with the lower body fat measurements observed in the 
young males. There were no differences in habitual activity levels, VO2peak, leg extension and vertical 
bench press between prostate cancer patients and matched males (Table 6.5). Prostate cancer patients 
and matched males had significantly lower VO2peak, leg extension and vertical bench press results than 
young males (Table 6.5). 
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Table 6.4: Inflammatory Markers 
Characteristic Prostate Cancer Patients Non-Malignant Comparison 
Groups 
 Baseline 
(n=8) 
7 Weeks 
(n=8) 
33 Weeks 
(n=8) 
Matched Males 
(n=9) 
Young Males 
(n=10) 
C-Reactive 
Protein 
(ng/mL) 
2.3±1.3 2.8±1.1 3.2±1.6c 2.0±1.5 0.61±0.44*† 
TNF (pg/mL) 12.4±1.8 11.9±2.6 12.6±3.0 7.7±1.6 4.9±0.84*† 
IL-1β (pg/mL) 7.4±1.1 
(n=7) 
8.7±1.36 
(n=7) 
7.6±0.86 
(n=6) 
6.8±1.2 
(n=6) 
7.7±1.0 
IL-4 (pg/mL) 11.2±1.5 10.9±1.3 10.7±1.7 6.2±1.2 
(n=5) 
1.7±0.40* 
IL-6 (pg/mL) 11.9±1.2 13.1±3.4 12.7±0.78 7.6±2.5 1.3±0.23*† 
(n=8) 
IL-8 (pg/mL) 26.6±3.6 27.2±2.8 26.3±5.2 15.1±5.7 8.2±0.81*† 
IL-10 (pg/mL) 11.0±0.84 11.2±1.8 11.1±1.2 7.5±1.1* 3.8±0.92*† 
 
Table 6.5: Lifestyle Factors 
Characteristic Prostate Cancer Patients Non-Malignant  Comparison 
Groups 
 Baseline 
(n=9) 
7 Weeks 
(n=9) 
33 Weeks 
(n=9) 
Matched Males 
(n=9) 
Young Males 
(n=10) 
Physical Activity 
Godin Score 
(AU) 
25.9±20.9 19.4±15.9 19.4±12.1 41.7±22.0 63.9±18.2* 
VO2peak 
(mL/kg/min) 
27.5±9.2 
(n=5) 
24.8±4.6 
(n=7) 
28.5±7.8 
(n=5) 
31.5±3.4 
(n=7) 
61.2±5.4*† 
Leg Extension 
(kg) 
31.4±10.1 30.5±8.4 28.6±9.7 
(n=8) 
35.5±5.0 
(n=7) 
52.5±12.7*† 
Vertical Bench 
Press (kg) 
42.7±17.4 39.4±17.9 39.5±15.5 
(n=8) 
47.9±5.2 109.0±28.9*† 
Nutrition Intake 
Total Calories 
(kcal) 
2245.6±348.4 2132.0±420.8 2211.6±356.2 2571.8±543.4 2461.1±628.1 
Carbohydrates 
(%) 
45.4±7.9 48.1±5.9 44.2±8.0 43.5±6.7 47.5±10.1 
Fat (%) 35.2±5.1 32.0±5.3 34.8±5.7 33.4±4.0 29.2±7.8 
Protein (%) 15.8±2.6 16.6±3.8 16.4±3.9 16.8±2.4 21.8±6.0*† 
Letters represent significance between Repeated Measures.a indicates significant difference from 
Baseline; b indicates significant difference between 7 Weeks and 33 Weeks. Letters represent 
significance between Baseline assessments in Patients and comparison groups.  * indicates significant 
difference between Patients and comparison group; † indicates significant difference between 
Matched Males and Young Males; § indicates a main effect  
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6.6.5 Prostate cancer patients demonstrated longitudinal improvements in glucose 
and related parameters  
Prostate cancer patients continued to have healthy fasting glucose concentrations at 7 and 33 
weeks following baseline (Baseline: 4.9±1.2mM, 7 weeks: 4.6±1.0mM, 33 weeks: 4.5±0.3mM; 
p=0.792; Table 6.2); however, 2-hour glucose values during the OGTT demonstrated improvements 
during the acute treatment trajectory, returning to normal ranges of < 7.8mM by 7 and 33 weeks 
(Baseline: 8.62±2.87mM; 7 weeks: 6.78±1.48mM and 33 weeks: 5.69±2.14mM, respectively; 
p<0.007; Table 6.2).  Peak glucose concentrations during the OGTT were also significantly lower at 7 
and 33 weeks compared with baseline (Baseline: 11.9±1.9mM, 7 Weeks: 9.4±1.9mM, 33 weeks: 
9.8±1.9; p<0.001; Table 6.2). Prostate cancer patients also demonstrated significant decreases in AUC 
at both 7 and 33 weeks (396.7±111.9 mMxmin and 354.6±174.3 mMxmin, respectively) from 
baseline (585.5±193.6 mMXmin; p=0.002; Figure 6.2B).  
Fasting and OGTT insulin and C-peptide concentrations did not change across the study 
trajectory in prostate cancer patients (Figures 6.2C and 6.2D). HOMA-IR, QUICKI, and Matsuda 
Index did not change across the prostate cancer trajectory (Table 6.2). IGF-1 decreased by 33 weeks 
in prostate cancer patients, but IGFBP-3 did not change over 33 weeks in the cancer patients. 
These changes in glucose metabolism were not related to body composition (Table 6.1), lipid 
parameters (Table 6.3), or adipokines (Table 6.3) as these measures did not change during the 33-
week study trajectory.  
 Testosterone concentrations significantly decreased by 33 weeks in prostate cancer patients 
(Table 6.3), which also does not explain the improvements in glucose metabolism. The reduction in 
average testosterone, however, were likely driven by 3 patients who received ADT during the study 
and showed significantly decreased testosterone at 7 and 33 weeks (Baseline: 30.9 ± 3.6 ng/mL; 7 
weeks: 5.4 ± 2.8 ng/mL, p<0.001; 33 weeks: 10.8 ± 7.2 ng/mL, p<0.001) while the other 5 patients 
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demonstrated decreased testosterone that approached significance (n=5; Baseline: 28.6 ± 3.2 ng/mL; 
7 weeks: 25.3 ± 1.9 ng/mL, p=0.387; 33 weeks: 22.6 ± 4.8 ng/mL, p=0.065).   We compared patients 
receiving ADT (n=3) with those not receive ADT throughout the trajectory and observed no 
significant differences in any glucose-related parameters between the 2 treatment regimens (data not 
shown).  
Interestingly, CRP tended to increase over 33 weeks in prostate cancer patients (Table 6.4), 
which would typically result in impaired glucose metabolism. Nutritional intake, physical activity and 
fitness measures did not change from baseline to 33 weeks in prostate cancer patients, suggesting that 
these modifiable risk factors did not contribute to the improved glucose metabolism that was 
observed post-treatment.  
6.7 Discussion 
This was the first study, to our knowledge, to investigate glucose metabolism in prostate 
cancer patients in a manner that accounts for age and body size. This is also a novel, integrative 
evaluation of changes in glucose metabolism and related parameters during the acute treatment 
trajectory. In the current study, we observed higher peak glucose concentrations and impaired glucose 
tolerance tests in prostate cancer patients at baseline (prior to treatment) compared with matched 
males.  This is supported by greater insulin and C-peptide concentrations at 2 hours during an OGTT 
as well as worse HOMA-IR and Matsuda Index in patients compared with matched males.  Given that 
matched males were similar age and body size, these data suggest impaired glucose tolerance at 
prostate cancer diagnosis is likely related to the presence of the cancer rather than age and body size. 
Prostate cancer patients also exhibited greater testosterone, triglycerides, and IL-10 compared with 
matched males, which may lend further support to the idea that impaired glucose metabolism is 
related to high-risk prostate cancer.   
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While glucose response during the OGTT’s returned to normal ranges by 7 weeks, there were 
no changes in related hormone responses (i.e. insulin, C-peptide curves) or insulin sensitivity 
(HOMA-IR, Matsuda Index. The observed improvements in glucose response to the OGTT could not 
be explained by inflammatory mediators or lifestyle parameters (i.e. body composition, physical 
activity, nutrition intake) as these did not change over the 33-week period. Based on our findings, it is 
possible that the improvements in glucose metabolism observed over 33 weeks were related to 
treatment, potentially supporting the relationship between host glucose metabolism, treatment and 
aggressive tumour presence/mitigation. 
6.7.1 Prostate cancer patients demonstrate impaired glucose metabolism compared 
to matched males, despite similar age and body size 
While impaired OGTT was exhibited in prostate cancer patients at baseline compared with 
matched males, there were no differences in body composition measures, nutrition intake, and 
physical activity level. Matched males had normal glucose response during the OGTT but it was 
significantly worse compared with young males. These findings are consistent with impairments in 
glucose tolerance exhibited with aging (255).  Since prostate cancer patients had greater impairments 
in glucose tolerance during the baseline OGTT compared with matched males, it is likely that these 
impairments are related to the tumour presence.  
There is little literature that uses OGTT in prostate cancer patients to better understand the body’s 
ability to clear a bolus of glucose. Zamboni et al (96) demonstrated normal 2-hour glucose 
concentrations following OGTT in prostate cancer patients with varying severity of disease; however, 
patients had higher fasting insulin and HOMA-IR compared with non-malignant controls (96).  This 
study only used fasting and 2-hour glucose measurements and they did not measure 2-hour insulin 
concentrations. The use of methodology beyond fasting glucose concentrations is clearly important 
since fasting measures may mask impairments that would be revealed through an OGTT or other 
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comprehensive approaches.  We also found significantly higher insulin and C-peptide concentrations 
at 45, 60, and 120 minutes of the OGTT in the prostate cancer patients compared with the matched 
males, suggesting that prostate cancer patients may experience higher post-prandial circulating 
insulin. Increased circulating insulin levels have been shown to increase tumour size (126), 
consequently, reducing fasting and post-prandial concentrations of insulin maybe essential for 
mitigating the potential for tumour proliferation.  
Prostate cancer patients at baseline had significantly greater IL-10, testosterone, and 
triglyceride concentrations compared with matched males. The anti-inflammatory mediator, IL-10, 
was significantly greater in prostate cancer patients compared with matched males; however, no 
significant differences were observed in any other inflammatory markers between the 2 groups.  IL-
10 is hypothesized to have tumour-promoting potential by allowing tumour cells to evade the host’s 
immune surveillance (256); however, animal and in vitro models suggest IL-10 may decrease tumour 
growth and angiogenesis (256).  Consequently, observational studies examining IL-10 in prostate 
cancer remain inconclusive.  IL-10 has also been shown to have insulin sensitizing properties and 
may attenuate diet-induced insulin resistance (257).  Presence of glucose intolerance in patients in this 
study suggests that IL-10 did not contribute to insulin resistance. These data imply that elevated 
concentrations of IL-10 in high-risk patients were related to the presence of the tumour, potentially 
contributing to tumour growth and aggressiveness. Future work is needed to characterize the 
interactions between IL-10, insulin sensitivity and tumour growth in prostate cancer patients to 
delineate the role of IL-10 in prostate cancer.  Despite seeing no significant differences in the 
remaining 5 cytokines that were examined, it is important to consider that various other cytokines 
may influence the role of IL-10, and importantly, the relationship between prostate cancer and 
glucose tolerance.  Cytokines also demonstrate pleiotropic actions as well as autocrine and paracrine 
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effects.  Here we used a whole body measure of a limited number of cytokines, thus further 
investigations into these complex interactions are warranted. 
Testosterone is thought to facilitate prostate cancer growth via the androgen receptor (AR), 
stimulating numerous genes that increase PSA, cell growth and survival (258), while low testosterone 
associates with insulin resistance (259). Increased adiposity and age are associated with lower 
testosterone but these factors are also related to insulin resistance. Here, adiposity and age were 
similar between prostate cancer patients and matched males, and testosterone was greater in the 
patient group. Since none of these relationships explain impaired glucose tolerance in the patient 
group, these lack of findings imply that glucose impairments in our study may relate to the presence 
or absence of the tumour rather than age.     
  The relationship between hyperinsulinemia and dyslipidemia is cyclical, with dyslipidemia 
shown to contribute to hyperinsulinemia (260) and hyperinsulinemia shown to contribute to both 
hypertriglyceridemia and increased LDL cholesterol (261). Prostate cancer patients had normal 
ranges of total cholesterol, HDL and LDL concentrations at baseline, but triglyceride levels were 
greater than matched males.  Greater circulating triglycerides may contribute to the observed 
impairments in glucose tolerance in the prostate cancer patients through activation of the IKK 
pathway [262].  Elevated triglycerides are also associated with increased risk of prostate cancer (263, 
264) and prostate cancer recurrence (188); consequently, managing the lipid profile of prostate cancer 
survivors is warranted to counter the risk of impaired glucose metabolism and recurrence in 
survivorship.  
Despite the association between elevated leptin, decreased adiponectin and increased risk of 
prostate cancer and prostate cancer recurrence via the IRS-1–PI3K–Akt signalling cascade (132), we 
did not observe differences in these adipokines between prostate cancer patients and the matched 
males. This phenotype of adipokines has typically been used to explain the development of insulin 
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resistance attributed to obesity. Since adipokines and body composition were similar between 
matched males and prostate cancer patients, these features may not relate to tumour presence and are 
unlikely to explain impaired glucose tolerance in the prostate cancer patients relative to the matched 
males.   
6.7.2 Impairments in glucose metabolism improve during the acute treatment 
trajectory in prostate cancer patients 
During the study trajectory, prostate cancer patients demonstrated decreased peak glucose 
concentrations (7 and 33 weeks) as well as decreased glucose concentrations at 2 hours (33 weeks) 
during the OGTT compared with baseline. These improvements occurred in absence of changes in 
lifestyle factors, such as nutritional intake (e.g. fat) and physical activity, as well as body 
composition. No significant changes in insulin and C-peptide concentrations occurred at any point 
during the OGTT (fasting and post-prandial) at 7 or 33 weeks compared with baseline, together with 
decreased 2-hour OGTT glucose concentrations suggest greater insulin sensitivity in peripheral 
tissues. Similarly, IGF-1 decreased at 33 weeks post-baseline aligning with the idea that low IGF-1 
concentrations may enhance insulin sensitivity (as observed in this study). However, it is important to 
note that if IGF-1 concentrations are too low, glucose clearance may become impaired (265, 266).  
Interestingly, CRP approached significance by 33 weeks in the prostate cancer trajectory.  Elevated 
CRP concentrations are typically associated with insulin resistance and have been correlated with 
several markers of insulin resistance including fasting glucose, insulin and HOMA-IR in non-diabetic 
patients (267).  Despite no changes in glucose tolerance or hormonal response, this may suggest a 
shift toward insulin resistance at this time point and warrants further investigation. 
Changes in glucose tolerance may be attributed to the removal of the tumour following 
radiation therapy.  In vitro studies have demonstrated a more glycolytic profile in aggressive prostate 
cancer cell lines (PC3, DU145) compared with less aggressive cell lines (LNCaP; 268), suggesting a 
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greater reliance on anaerobic glucose metabolism as the primary fuel source in these cell lines to 
satisfy the metabolic demand of these cells. Therefore, there is potential that, in vivo, the presence of 
the tumour may have the ability to disrupt host metabolism.  Consequently, removal of the tumour 
may result in a return to normal glucose metabolism in the host.  
 
6.8 Conclusions 
 This was the first study to integratively investigate the metabolic changes of prostate cancer 
patients independent of age and body size during the acute treatment trajectory.  While caution is 
needed to interpret the findings of this study due to its small sample size, we observed impaired 
glucose tolerance in the prostate cancer patients as compared to the matched males that significantly 
improved during the acute treatment trajectory independent of changes in the traditional moderators 
of glucose metabolism, including hormone response, adipokines, cytokines, body composition, 
physical activity, and nutritional intake.  We also noted significant decreases in testosterone and IGF-
1, known prostate cancer promoters, during the treatment trajectory, while lipid profile, adipokine, 
and inflammatory markers remained unchanged. These improvements in glucose tolerance may be 
due to mitigation of the tumour itself. Future, larger scale studies will advance these findings to better 
understand the influence of the tumour on host glucose metabolism.  
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Chapter 7                                                                                        
Serum from high-risk prostate cancer patients does not induce 
cancer specific changes in glucose uptake in differentiated human 
skeletal muscle myotubes: developing a novel model to examine 
mechanisms of metabolic change in cancer patients  
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7.3 Abstract 
Background: We have demonstrated that prostate cancer patients have impaired glucose tolerance at 
diagnosis compared with men of the same age and body size, but glucose tolerance improves over the 
acute treatment trajectory. Methodology to investigate the mechanisms to explain the findings 
observed in glucose metabolism is limited in cancer patients. Thus, here we developed a novel in 
vitro method to evaluate glucose uptake in human muscle cells that were exposed to human serum, 
and used it to assess this technique’s ability to explain our previous findings.  
Methods: Human skeletal muscle myoblasts were differentiated and incubated with human serum 
from 3 groups: prostate cancer patients prior to treatment, males of the same age and body size 
(matched males), and young males. Muscle cells exposed to serum from patients prior to treatment 
(baseline) were also compared with cells exposed to serum collected 7 and 33 weeks following 
baseline, reflecting the acute treatment trajectory.  A 2-[3H]-deoxy-D-glucose uptake assay with 
insulin stimulation was used to assess differences in glucose uptake between the groups. 
Results: Glucose uptake in myotubes incubated with the serum of prostate cancer patients at baseline 
was significantly lower compared to cells incubated with serum from young males (114.0±6.3% vs 
134.5±9.3% respectively, p<0.001), but not different from cells incubated with serum from matched 
males (114.8±4.5%, p=0.972).  There were no significant differences in the glucose uptake among 
cells incubated with serum from prostate cancer patients across the treatment trajectory (Baseline: 
114.0±6.3%; 7 Weeks; 117.5±10.5%; 33 Weeks: 119.2±9.2%, p=0.366).   
Conclusions: In this novel model, serum from aged individuals (prostate cancer patients and matched 
males) significantly decreases the ability of the skeletal muscle cells to respond to insulin and take up 
glucose.  Cancer-related alterations in glucose uptake were not observed with this method.   
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7.4 Introduction 
Insulin resistance may contribute to aggressive prostate cancer as insulin and IGF-I have been 
shown to stimulate in vitro growth of both androgen sensitive and independent cells (125, 126). Both 
hyperinsulinemia and high IGF-I levels have been associated with increased prostate cancer risk (125-
127).  Interestingly, prostate cancer risk decreases with increased time after a diagnosis of type 2 
diabetes, when insulin levels begin to decline following decreased beta cell function (127)  
Hyperinsulinemia and related metabolic parameters are typically associated with age and 
obesity (269). Our work (Study 2, Chapter 6) suggests that high-risk prostate cancer patients have 
greater impairments in glucose tolerance at the time of cancer diagnosis compared with men of the 
same age and body size.  Following acute treatment (primarily radiation therapy), patients 
demonstrated significantly improved glucose tolerance, independent of changes in insulin, C-peptide, 
inflammation, body composition, diet, and physical activity levels. Skeletal muscle may contribute to 
these changes in glucose metabolism because it accounts for 80% of total glucose disposal (202). 
Isolated skeletal muscle cells from pancreatic cancer patients is less responsive to physiological 
concentrations of insulin compared with non-malignant controls, which was attributed to changes in 
glucose transport across the sarcolemma, and PI3K activity (270).  However, there are no studies that 
have examined changes in muscle glucose uptake across the prostate cancer trajectory.   
 Here, we developed a novel method to explore glucose uptake and insulin signalling using 
cultured human skeletal muscle cells in order to better understand glucose metabolism in high-risk 
prostate cancer patients. The objectives of this study were to: 1) compare glucose uptake in human 
skeletal muscle cells exposed to serum from prostate cancer patients, serum from age- and BMI-
matched non-malignant males as well as serum from a young healthy comparison group, and 2) 
compare glucose uptake in human skeletal muscle cells cultured with serum collected from prostate 
cancer patients at baseline (near diagnosis), and following treatment at 7 weeks and 33 weeks from 
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baseline.  In concordance with our previous work (Study 2, Chapter 6), we hypothesized that glucose 
uptake would be decreased in human skeletal muscle cells exposed to serum from prostate cancer 
patients compared with both serum from age- and BMI-matched males and serum from a young 
healthy group. We also hypothesized that glucose uptake would be elevated in muscle cells exposed 
to serum from prostate cancer patients prior to the initiation of cancer treatment. 
7.5 Methods 
7.5.1 General Study Design 
After an overnight fast, serum from prostate cancer patients was collected throughout the 
treatment trajectory, prior to initiation of treatment (baseline), following 7, and 33 weeks from 
baseline. Fasting serum was also collected from two separate comparison groups that included an age- 
and BMI-matched group (matched males) as well as a young healthy comparison group (young 
males). These blood samples were collected as part of a larger study described in detail in Study 2 
(Chapter 6); the data presented here has not been previously reported.  Human skeletal muscle 
myoblasts (HSkMM, Lonza, Rochester, NY) were differentiated into myotubes.  Glucose uptake was 
measured following a 24 hour acute conditioning period with serum collected from the cancer 
patients and comparison groups.  The 2-[3H]-Deoxy-D-glucose uptake assay was used a marker of in 
vitro glucose uptake. 
7.5.2 Participants 
Eight high-risk prostate cancer patients (Stage IIB: Gleason score >8, PSA >20ng/mL, or 
Stage >T3A), prior to the initiation of treatment, were recruited for this study. Patients were eligible 
for study participation if their planned treatment included radiation therapy with or without the use of 
androgen deprivation therapy.  Serum was collected from patients prior to initiation of treatment 
(baseline), 7, and 33 weeks from baseline.   For patients, no limits were placed on age, body size, 
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determined by body mass index (BMI), and fitness level; however, patients were excluded from 
participation if their fasting glucose was >7.0 mM, or had any diagnosis of metabolic disease. For the 
comparison groups, the matched males individually corresponded to each prostate cancer patients in 
terms of age (±5 years) and BMI (±3 kg/m2). Matched males were also required to be weight stable, 
have a fasting blood glucose <7.0mM, and no history of metabolic disease. For 3 patients who had a 
BMI >33.0 kg/m2, we were unable to find matches without a history of metabolic disease. These 
patients were matched with the closest age and BMI criteria but met all other criteria. Young males 
were required to be between the ages of 20-30 years, weight stable with normal BMI (18.5-24.9 
kg/m2), active with VO2peak >45 mL/kg/min, fasting blood glucose <6.0mM, and no history of 
metabolic disease. This study was reviewed and received ethical clearance by the University of 
Waterloo Office of Research Ethics (all groups) and by Tri-Hospital Research Ethics Board (prostate 
cancer patients only). 
7.5.3 Cell Culture Procedures 
 Human skeletal muscle myoblasts (HSkMM, Lonza, Rochester, NY) were obtained. The 
donor of these HSkMM line was from the quadriceps muscle of a 19-year old female who had a BMI 
of 19 kg/m2.  According to the manufacturer, these cells have been optimized for cellular 
differentiation and for use in insulin uptake experiments.  The cells were seeded in 100mm 
polystyrene dishes at 3500 cell/cm2.  Cells were grown in 8-10mL of Skeletal Muscle Growth Media- 
2 (SKGM-2) with 10% fetal bovine serum (FBS), 1% L-glutamine, 0.1% human epidermal growth 
factor, 0.1% dexamethasone, and 0.1% Gentamicin/Amphotericin-B (SKGM-2 Bullet Kit, Lonza, 
Rochester, NY).  This media has been specifically developed by the manufacturer to ensure optimal 
growth of the HSkMM cell line. Cell were incubated at 37o C and 5% CO2.  SKGM-2 media was 
replaced every 48 hours and cells were washed with each media change with Dulbecco’s Phosphate-
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Buffered Saline (DPBS; Lonza). Preliminary work revealed growth rates and glucose uptake declined 
at ≥12 cell passages; thus, all experiments were conducted between passages 7-10.  
 Sub-culturing was performed by removing media from the plate and washing the plates 2x 
with DPBS, trypisinzed   at 37oC and 5% CO2 for 5 minutes. SKGM-2 Media was added and cells 
were collected, and centrifuged at 500g for 5 minutes.  Media was aspirated and the pellets was re-
suspended in 2mL of SKGM-2 Media.  Cells were counted a Z2 Coulter Counter (Beckman Coulter) 
to determine cell concentrations for reseeding.   
 For experimentation, HSkMM were seeded into a 12-well polystyrene culture plate a density 
of 50 000 cells per well and were maintained in 1mL of SKGM-2 media per well until ~90% 
confluence was achieved (3-4 days). SKGM-2 media was changed every 48 hours until 
differentiation. To stimulate differentiation, the SKGM-2 media was removed, cells were washed 2x 
with DPBS, and 1 ml of differentiation media was added to each well.  Differentiation media (DM) 
consisted of low-glucose Dulbecco’s Modified Eagle Medium (DMEM), containing 2% horse serum 
(HS) with 1% penicillin streptomycin (P/S).  Cells were maintained at 37oC and 5% CO2, with media 
changed every 48 hours for 4 days. Myotube formation was confirmed using microscopy.   
7.5.4 Incubations with Human Serum 
Fusion and myotube formation are typically observed 3 days following the initiation of 
differentiation in HSkMM (271).  Pilot work also revealed that glucose uptake was highest on day 5 
post-differentiation (Figure 7.1A).  Thus, on day 4 of differentiation, cells were washed 2x with 
DPBS and differentiation media was replaced with experimental media consisting of DMEM with 1% 
P/S and 10% human serum from one participant of the following groups, prostate cancer patients at 
baseline, 7 weeks, and 33 weeks post baseline, matched males, young males, as this concentration of 
human serum was found to have the most robust effects in pilot work (Figure 7.1B).  Cells were 
incubated for 24 hours at 37oC and 5% CO2.  Glucose uptake procedures were conducted on day 5 
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post-differentiation in all cells.  Each set of experiments (1 plate) consisted of 4 technical replicates 
maintained in DM (Control: DM only), 4 technical replicates maintained in human serum 
unstimulated with insulin (Unstimulated: DMEM, 10% human serum, 1% P/S) and 4 technical 
replicates in human serum stimulated with insulin (Stimulated: DMEM, 10% human serum, 1% P/S, 
insulin). Two biological replicates were used for each participant sample, as each set of human serum 
experiments was run in duplicate.  
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Figure 7.1: Results of pilot work.  A.  Y-axis represent insulin-stimulated glucose uptake relative to 
basal glucose uptake levels in cells incubated with DM only for the number of days indicated on the 
x-axis.  Insulin stimulation and glucose uptake procedures are as described in sections 7.5.5 and 7.5.6.  
B.  Y-axis represent insulin-stimulated glucose uptake relative to basal glucose uptake levels in cells 
incubated with DM only (Control) or human serum in the percentages indicated on the x-axis.  Insulin 
stimulation and glucose uptake procedures are as described in sections 7.5.5 and 7.5.6.   
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7.5.5 Insulin Stimulation Procedures 
To wash-out the effects of insulin and other glucose uptake stimulating compounds present in 
the serum, differentiated HSkMM were washed 2x with DPBS and media was changed to serum-free 
DMEM with 1% P/S and incubated for 3 hours at 37oC and 5% CO2.  Longer washout periods were 
not found to have any further benefit in pilot work.  To examine differences in the cells ability to 
respond to insulin some cells were stimulated with serum-free-DMEM 1% P/S supplemented with 3.4 
mM insulin for 30 minutes since this has been shown to be the optimal treatment time for glucose 
uptake (203, 204) and this concentration demonstrated the most potent response in pilot work. 
7.5.6 2-[3H]-Deoxy-D-glucose Uptake Assay 
Following insulin stimulation, media was removed and cells were washed 2x with DPBS.  
Cells were incubated for 10 minutes at room temperature with HEPES buffered solution (HBS) which 
contained 140mM NaCl, 5mM KCl, 20mM HEPES, 2.5 mM MgSO4, 1mM CaCl2, pH 7.4 and 50 μM 
2-[3H]-Deoxy-D-glucose and 50 μM 2-Deoxy-D-glucose.  Cells were then washed with cold 0.9% 
NaCl (w/v) and lysed with 1mL of 0.05M NaOH.  Lysates were collected and added to 5mL of 
scintillation cocktail and was assessed for radioactivity using liquid scintillation counting.  An 
addition of 10 μM Cytochalasin B (CB; Sigma- Aldrich) to one well of each condition was used to 
control for non-specific glucose uptake.  CB inhibits glucose transporters on the cell periphery 
accounting for glucose uptake that does not occur through the GLUT transporters (272). 
7.5.7 Statistics 
Values are presented as mean ± SD.  All statistical calculations were completed using Sigma 
Plot ® version 11.2 (Systat Software Inc.; San Jose, CA).  Statistical significance was determined at p 
< 0.05.  One-way repeated-measures ANOVAs were used to determine differences in measurements 
between each of the time points (baseline, 7, and 33 week post-baseline).   Comparisons between 
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multiple groups (prostate cancer patients, matched males, young males) were determined using One-
way ANOVAs with Tukey’s post-hoc analysis.  
To understand whether traditional markers (glucose, insulin, C-peptide) of glucose 
metabolism were related to glucose uptake, simple univariate linear regression was performed using 
the following parameters: glucose uptake, fasting glucose, insulin, and C-peptide levels, 2-hour 
glucose, insulin, and C-peptide levels during an oral glucose tolerance test (OGTT), and glucose, 
insulin, and C-peptide levels area under the curve (AUC).  This series of data was described in Study 
2 (Chapter 6) and are used here to develop regression analysis to better understand the relationship 
between our in vitro findings with measures from our in vivo studies.  
7.6 Results 
7.6.1 Participants 
Physical characteristics of participants have been described in detail in Study 2 (Chapter 6); 
however, basic physical characteristics (Table 7.1) of participants and factors that may contribute to 
alterations in glucose metabolism can be found in Table 7.2.   
Table 7.1: Physical Characteristics 
Characteristic Prostate Cancer Patients Non-Malignant  
Comparison Groups 
 Baseline 
(n=8) 
7 Weeks 
(n=8) 
33 Weeks 
(n=8) 
Matched 
Males 
(n=9) 
Young 
Males 
(n=10) 
Age (years) 71±6 - - 72±5 26±3* 
Height (cm) 173.5±8.8 - - 174.0±5.2 175.8±4.7 
Weight (kg) 86.1±25.2 85.5±23.8 84.6±21.7 81.8±12.8 72.7±6.5 
Body Mass 
Index (kg/m2) 
28.3±6.6 28.1±6.1 27.8±5.5 27.0±4.0 23.5±1.6* 
% Body Fat 30.8±11.6 23.0±16.2 28.0±8.5 24.4±7.0 16.5±4.7* 
Letters represent significance between Repeated Measures. * indicates significant difference between 
Patients and comparison group; † indicates significant difference between Matched Males and Young 
Males; § indicates a main effect  
 
  105 
 
Table 7.2: Serum Glucose Metabolism Parameters 
Characteristic Prostate Cancer Patients Non-Malignant  
Comparison Groups 
 Baseline 
(n=8) 
7 Weeks 
(n=8) 
33 Weeks 
(n=8) 
Matched 
Males 
(n=9) 
Young Males 
(n=10) 
Fasting Glucose 
(mM) 
4.9±1.2 4.6±0.99 4.5±0.3 4.2±0.5 3.7±0.4* 
2-hour Glucose 
(mM) 
8.7±2.9 6.8±1.5 5.7±2.1a 5.6±1.8* 3.1±0.99a*† 
Glucose AUC 
(mM*min) 
585.5±193.
7 
396.7±113.
7 
354.6±174.3 377.2±261.
9 
104.4±130.0 
Fasting Insulin 
(µIU/mL) 
14.6±5.4 17.8±7.8 14.7±6.1 10.1±4.3 6.2±2.5 
2-hour Insulin 
(µIU/mL) 
105.2±98.2 87.5±57.5 66.2±63.8 51.1±24.3 13.2±9.3 
Insulin AUC 
(µIU/mL*min) 
9502.8±801
3.6 
7427.3±450
5±2 
7965.3±4505.
2 
9765.8±485
0.2 
3691.0±1723.
9 
Fasting C-peptide 
(pmol/L) 
3.3±0.96 2.9±1.0 3.3±0.78 1.8±0.43 0.65±0.31† 
2 hour C-peptide 
(pmol/L) 
11.3±2.9 11.0±3.0 9.8±3.0 7.5±2.6 2.9±1.3 
C-peptide AUC 
(pM*min) 
881.0±269.
4 
742.7±223.
8 
711.1±163.0 637.5±223.
5 
279.6±157.5 
HOMA-IR (AU) 3.3±1.7 3.9±2.1 3.1±1.4 2.0±0.64* 1.1±0.50* 
Letters represent significance between Repeated Measures. a indicates significant difference from 
Baseline; b indicates significant difference between 7 Weeks and 33 Weeks;. Letters represent 
significance between Baseline assessments in Patients and comparison groups.  * indicates significant 
difference between Patients and comparison group; † indicates significant difference between 
Matched Males and Young Males; § indicates a main effect.  
 
7.6.2 Glucose Uptake 
Pilot experiments revealed that the maximum glucose uptake of differentiated HSkMM 
(maintained in differentiation media for 5 day) following acute insulin stimulation was 128.0±13.4%.  
Insulin-stimulated glucose uptake in cells incubated with serum from young males was not 
significantly different from the control-stimulated cells (young males: 134.5±9.3% vs Controls: 
128.0±13.4%, p=0.202).  Thus, glucose uptake of cells incubated with young male serum was found 
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to be optimal and used as the reference point in subsequent analysis.   
 Insulin stimulated glucose uptake in cells incubated with the serum of prostate cancer patients 
at baseline was found to be significantly lower than insulin stimulated glucose uptake of cells 
incubated with young male serum (114.0±6.3% vs 134.5±9.3% of basal glucose uptake respectively, 
p<0.001, Figure 7.2A).  Glucose uptake was also significantly lower in cells incubated with the serum 
of matched males compared to young males (114.8±4.5% vs 134.5±9.3% of basal glucose uptake, 
respectively, p<0.001, Figure 7.2A), with no significant differences in glucose uptake in cells 
incubated with prostate cancer patients at baseline versus matched males.  There were also no 
significant differences in the glucose uptake among cells incubated with serum from prostate cancer 
patients across the treatment trajectory (Baseline: 114.0±6.3%; 7 Weeks; 117.5±10.5%; 33 Weeks: 
119.2 ±9.2% of basal glucose uptake, p=0.366, Figure 7.2A).   
 To investigate the effects of human serum of glucose uptake independent of group, 
unstimulated control cells (maintained in differentiation media) were included in every experiment.  
Comparison of basal glucose uptake between cells exposed to differentiation media and media 
containing serum indicates that  glucose uptake was increased from ~15-23% by the presence of 
human serum alone (Figure 7.2B); however, there were no significant differences between any of the 
groups (Patient baseline: 117.7±13.25%; matched males: 115.3±15.4%; young males 118.7±13.6%, 
p=0.869; Figure 7.2B) or across the trajectory (Baseline: 117.7±13.2%; 7 Weeks; 117.0±7.0%; 33 
Weeks: 123.9±7.9%, p=0.419, Figure 7.2B).  We also examined insulin-stimulated glucose uptake in 
cells incubated with human serum compared to unstimulated control cells (Figure 7.2C).   Insulin-
stimulated glucose uptake tended to be higher in cells incubated with serum from young males 
compared to patients at baseline and matched males when unstimulated control cells were used as a 
reference (Patient Baseline: 135.2±24.0%; matched males: 135.6±22.3%; young males 154.1±15.2%, 
p=0.093; Figure 7.2C).  However, no significant differences in insulin-stimulated glucose uptake 
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were observed across the treatment trajectory when unstimulated control cells were used as the 
unstimulated reference in the analysis (Baseline: 135.2±24.0%; 7 Weeks; 136.7±14.0%; 33 Weeks: 
147.3±14.7%, p=0.362, Figure 7.2C).    When all of these data are considered, age- but not cancer-
related changes in in vitro glucose uptake are revealed. 
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Figure 7.2: Glucose uptake in HSkMM incubated with human serum spiked media and 
differentiation media. * indicates significantly different from all groups. PC-B represents prostate 
cancer patients at baseline, PC-7 represents prostate cancer patients 7 weeks post-baseline, PC-33 
represents prostate cancer patients 33 week post-baseline, MM represents matched males and YM 
represents young males.. A.  Y-axis represent insulin-stimulated glucose uptake relative to basal 
glucose uptake levels in cells incubated with each human serum stimulated group.  B.  Y-axis 
represent insulin-stimulated glucose uptake of cells incubated with indicated human serum to insulin 
stimulated glucose uptake of cells incubated with DM only. C. Y-axis represent basal glucose uptake 
of cells incubated with indicated human serum to basal glucose uptake of cells incubated with DM 
only. 
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7.6.3Does insulin stimulated glucose uptake in human serum condition cells reflect 
traditional markers of glucose uptake? 
 Linear regression modeling was used to examine the relationships between glucose uptake 
measures and traditional markers of glucose metabolism, which were obtained in Study 2 (Chapter 6). 
Regression analysis revealed moderate negative but significant relationships between fasting glucose 
(p=0.010), 2-hour glucose (p=0.009), glucose AUC (p=0.014), fasting C-peptide (p=0.015), 2-hour C-
peptide (p=0.010), C-peptide AUC (p=0.012) and HOMA-IR (p=0.015) and in vitro glucose uptake 
(Table 6.3).  Fasting insulin concentrations e (p=0.064, Table 6.3), 2-hour insulin (p=0.331) and 
insulin AUC (p=0.169) were not related to glucose uptake. Taken together, these data suggest that 
this in vitro model of glucose metabolism reflects changes observed in in vivo models. 
Table 7.3: Simple Univariate Linear Regression Analysis of 
Human Serum Insulin Stimulated Glucose Uptake (Dependent 
Variable) and Glucose Metabolism Parameters 
Parameter (n=43) Co-efficient R R-squared p 
Fasting Glucose  -0.0451  0.387 0.150 0.010 
2-hour Glucose  -0.0168 0.394 0.155 0.009 
Glucose AUC  -0.000177 0.373 0.139 0.014 
Fasting Insulin  -0.00455 0.285 0.081 0.064 
2-hour Insulin  -0.000265 0.152 0.023 0.331 
Insulin AUC  -0.00000446 0.214 0.0457 0.169 
Fasting C-peptide  -0.0328  0.369 0.136 0.015 
2 hour C-peptide  -0.0105 0.387 0.150 0.010 
C-peptide AUC  -0.000146 0.381 0.145 0.012 
HOMA-IR  -0.0245 0.367 0.135 0.015 
 
7.7 Discussion 
This study aimed to develop a new method to explore glucose and insulin signalling using 
cultured human skeletal muscle cells and, subsequently, evaluated glucose uptake in these muscle 
cells after exposure to serum from prostate cancer patients, matched males, and young males. By 
examining the mechanisms that alter glucose metabolism in prostate cancer patients, targeted 
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interventions can be used to ameliorate the negative effects of impaired glucose tolerance.  Three 
major components of this model were novel.  First glucose uptake had never been assessed in 
HSkMM.  Secondly, human serum had never been used as a treatment on any type of muscle cell 
lines, and finally, the effects of prostate cancer on HSkMM has never been investigated in vitro. 
The presence of human serum in the conditioning media had the ability to increase glucose 
uptake by approximately 20% and insulin-stimulated glucose uptake in differentiated HSkMM by 
~30% regardless of which serum was used.   These findings suggest that the administration of human 
serum alone has robust effect on the ability of the cells ability to take-up glucose.  Glucose uptake in 
cells incubated with the serum of prostate cancer patients at baseline was found to be significantly 
lower than the glucose uptake of cells incubated with young male serum.  However, glucose uptake 
was similar between cells incubated with serum from prostate cancer patients at baseline and cells 
exposed to serum from matched males, and similar across the patients’ treatment trajectory (baseline 
vs 7 or 33 weeks). Glucose uptake correlated moderately with both fasting and 2-hour glucose and C-
peptide concentrations, but did not correlate with serum insulin concentration (fasting and 2-hour). 
These findings suggest an age-related, but not cancer-related decline in glucose uptake; thus further 
investigation is warranted.  
7.7.1 Glucose uptake was lower in HSkMM exposed to serum from prostate cancer 
patients compared with young males 
In Study 2 (Chapter 6), we found that prostate cancer patients had greater impairments in 
glucose tolerance during an OGTT compared with matched males; however, they exhibited improved 
glucose tolerance over the treatment trajectory. Given that nutrition intake, physical activity, and 
body composition were similar to matched males and these factors did not change over time, we 
hypothesized that glucose uptake would be lesser at baseline compared with matched males but 
would improve at 7 and 33 weeks. The only significant difference observed in this study was that 
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glucose uptake was greater in young males compared with prostate cancer patients and matched 
males, suggesting that there may not have been any changes in muscle glucose uptake related to 
tumour presence/absence.  Age-related declines in glucose uptake in skeletal muscle occurred as 
expected.  Previous in vivo work using glycemic clamp techniques have revealed that in aged 
individuals, differences in glucose tolerance are attributed to changes in peripheral tissue sensitivity 
to insulin (273, 274). 
There are several perspectives that may explain our results: 1) this method may not be 
sensitive enough to detect changes in glucose uptake beyond a certain threshold, 2) factors that elicit 
significant changes in glucose uptake in prostate cancer patients are not present in fasting serum, 3) 
24 hours of human serum pre-conditioning was not sufficient to induce differences in glucose uptake 
between the group or 24 hours of human serum pre-conditioning was too long and acute changes in 
glucose uptake were blunted due to feedback control mechanisms in the cell, and 4) observed changes 
in glucose tolerance in prostate cancer patients may not occur at the muscle.  Future working 
characterizing the metabolic pathways is warranted to examine if, despite not observing changes in 
glucose uptake, alteration occurs in muscle cell insulin signalling pathways.  
 Most studies use L6 myoblasts to investigate glucose uptake due to their increased ability to 
take-up glucose in vitro and the decreased cell to cell variability; however, primary human skeletal 
muscle cells have been shown to be suitable for examining glucose uptake in culture (9, 10). Previous 
literature has suggested that serum from prostate cancer patients has the ability to induce significant 
changes in prostate cancer cells in vitro (275-277).  While our data demonstrates greater glucose 
uptake for muscle cells exposed to serum from young males compared with either aged participants 
(prostate cancer or matched males), there is large variability in glucose uptake across all participants. 
Consequently, no significant differences were observed between the cancer patients and the matched 
males or across the treatment trajectory. In Study 2 (Chapter 6), we noted large heterogeneity in most 
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metabolic parameters (glucose, insulin, C-peptide, IGF-1, etc.) from the participants, which is 
suspected to have contributed the variability in glucose uptake in in vitro.   
This may be addressed in one of two ways: combining serum from all cancer patients to 
create a single serum stock from each group or through using pre-conditioned media. By combining 
the serum from multiple participants together, you eliminate variability in the concentration of 
various metabolites in the stock serum; however, you lose the ability to examine differences between 
individuals, if any occur.  This method would not guarantee any observed differences between the 
groups, but would rule out metabolite differences as a reason for the variability in glucose uptake.  To 
use pre-conditioned media prior to treating the skeletal muscle cells with media, prostate cancer cells 
are incubated with the experimental serum to create a potent prostate cancer stimulus eliminating the 
variability associated with human serum. This methodology may create a more potent prostate cancer 
related stimulus; however, it would not account for whole body metabolic perturbations that may 
influence glucose metabolism in vivo. Employing both of these models may elucidate what 
contributes to the variability observed in glucose uptake in the current model. 
As part of the Study 2 (Chapter 6), an OGTT was performed and post-prandial blood samples 
were collected from all participants. However, we chose to use fasting serum in all experiments to 
eliminate variation that may occur in the post-prandial state of the OGTT; in other words, fasting 
glucose concentrations fell within a fairly narrow range compared with using serum during the 
OGTT.  However, in Study 2 (Chapter 6), we only observed elevated glucose, insulin, and C-peptide 
during the OGTT in prostate cancer patients compared with matched males and not in fasting 
conditions.  Using serum from non-fasting time-points during the OGTT may help identify an 
impairment in glucose metabolism during the glucose challenge that would also be reflected in 
muscle glucose uptake. Another consideration is that tumour-related factors that induce changes in 
glucose metabolism in vivo may act, to a greater extent on other tissues and their signalling cascades 
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such as liver and not muscle.  Another important consideration is that an OGTT is a whole body 
measure of glucose tolerance, and is unable to distinguish between insulin resistance in liver, adipose 
tissue, muscle, or other tissues. Other invasive measures of insulin resistance such as 
hyperinsulinemic-euglycemic clamps or measures of hepatic glucose production in vivo may elucidate 
complex tissue interactions and facilitate the development of future models to investigate them. 
HSkMM exposure to serum in vitro is significantly different that muscle exposure to whole 
blood in vivo.  Firstly, in vivo, muscle cells are exposed to plasma not serum and the clotting factors 
present in plasma may alter glucose uptake in vitro.  As well, storage of the serum may alter the 
concentrations of some components of the serum such as cytokine, which have a short half-life (278), 
as well as many lipids, which have been shown to degrade with storage (279).  As well HSkMM are 
intrinsically different from muscle cells in vivo.  There is no fascia surrounding the HSkMM, which 
alters the way in which the cells and media can interact.  There is also no fat infiltration, as is often 
observed in skeletal muscle in vivo, which may alter myocyte insulin signalling compared to HSkMM 
in vitro.  Consequently, the insulin stimulation of glucose in vitro may be significantly different than 
that observed in vivo. 
All pilot experiments in this paper used human serum for a 24-hour incubation period, and 
suggesting that this timeframe is sufficient to induce changes in HSkMM. During the experiments, 24 
hours was sufficient to induce age-related changes in glucose uptake, though no cancer related 
changes in glucose uptake were observed. However, in vivo, changes in skeletal muscle that alter 
whole body glucose metabolism may occur over a prolonged period of time. Prostate cancer 
development also occurs over a prolonged period of time, which may convolute the ability to 
optimize this method for this patient cohort. Therefore, longer incubation periods with human serum 
may create a more potent effect.  However, the length of the incubation period is limited as glucose 
uptake in HSkMM decline as the myotubes spend longer time in culture as revealed in pilot work 
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(Figure 6.1A).  However, it is also possible that the 24-hour incubation was too long and acute 
changes in glucose uptake were lost due to negative feedback mechanisms.  Serum from prostate 
cancer patients may have induced acute changes in glucose uptake in the HSkMM, within the first 
minutes to hours of incubation. However, by the time the glucose uptake assay was completed 24 
hours following human serum administration, feedback mechanism within the cells may have been 
initiated to return glucose uptake levels to those of the matched males.    Further investigation of 
earlier time points (i.e. 10 minutes, 1 hours) is needed to elucidate these hypotheses.      
A concentration of 10% human serum was selected to incubate the HSkMM as there was 
little difference between the glucose uptake in other concentrations provided and 10% human serum 
media has been used previously in the literature (280).  However, like the 24-hour incubation period, 
this may not be an appropriate stimulus to detect differences in glucose uptake between the groups. 
7.7.2 Glucose uptake measured in HSkMM was moderately correlated with whole 
body measures of glucose metabolism 
Study 2 (Chapter 6) examined various parameters related to glucose metabolism following an 
overnight fast and during an OGTT. Fasting glucose, 2-hour glucose, glucose AUC, fasting C-
peptide, 2-hour C-peptide, C-peptide AUC, and HOMA-IR were moderately but significantly 
correlated with glucose uptake. Fasting insulin, 2-hour insulin and insulin AUC, were not related to 
glucose uptake. These significant relationships between in vitro glucose uptake and whole body 
markers of glucose metabolism, indicate that this model of in vitro glucose uptake reflects the 
metabolite concentration in the serum samples used in the experiment.   
HOMA-IR, 2-hour glucose, and C-peptide as well as glucose and C-peptide AUC were 
significantly related to glucose uptake.  With the exception of HOMA-IR, these are dynamic 
measures and reflect the body’s ability to respond to a glucose challenge.  We hypothesized that there 
would be no relationship between these dynamic measures and glucose uptake as this model would 
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not be able to account for the transient nature of these measures.  These markers reflect post-prandial 
serum during the OGTT, which was not used in the cell culture model; however, it was in these post-
prandial measures of glucose metabolism that differences in glucose tolerance were observed in Study 
2 (Chapter 6). These data suggest that the 24 hours of incubation with human serum induced changes 
in the HSkMM to moderately reflect whole body glucose metabolism in vivo.  This agrees with the 
hypothesis that observed changes in glucose tolerance in prostate cancer patients in Study 2 (Chapter 
6) may not occur at the muscle.          
There were no relationships observed between 2-hour insulin and insulin AUC and glucose 
uptake; however, the design of the 2-[3H]-Deoxy-D-glucose uptake assay requires that cells are 
provided with exogenous insulin, at significantly greater concentrations than those found in serum.  
Thus, it is not surprising that any potential relationships were washed out. 
While we observed no significant differences in glucose uptake between prostate cancer 
patients and matched males, significant differences were observed in glucose uptake between young 
males and aged males (bothmatched males and prostate cancer patients).  Numerous differences were 
observed between the serum of young males and aged males including lower fasting glucose, c-
peptide and IGFBP-3 concentrations in Study 2 (Chapter 6). Lipid profile components total 
cholesterol, LDL cholesterol and triglycerides were also lower in young male as were many 
inflammatory marker including IL-4, IL-6, IL-8, IL-10, and CRP.  These results suggest that insulin 
secretion, lipid profile, and inflammation may not be mediating the differences in glucose tolerance 
observed in Study 2 (Chapter 6).  Future investigations into these pathways are warranted to 
investigate this hypothesis.   
7.8 Conclusions 
We developed a new model in which to investigate potential changes in insulin stimulated 
glucose uptake in cells conditioned with human serum.  Human serum was found to increase glucose 
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uptake by approximately 20%, and insulin having the ability to stimulate glucose uptake in 
differentiated HSkMM by approximately 30% regardless of serum used.  Serum from aged 
individuals significantly decreases the cells ability to respond to insulin; however, this technique did 
not detect any cancer-related changes in glucose uptake.  However, linear regression revealed that this 
model of glucose uptake related to many traditional moderators of glucose metabolism.   
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Chapter 8 
Integrated Discussion 
Numerous lifestyle factors including obesity (201), physical inactivity (206), high-fat diets 
(281), and metabolic syndrome (160, 174) have been associated with the development of prostate 
cancer.  De Nunzio et al. (174) proposed an integrative model of prostate cancer development in 
which these lifestyle factors create a deleterious metabolic profile resulting in insulin resistance, 
visceral adiposity, pro-inflammation, and hormonal changes that create an environment conducive to 
more aggressive tumour growth (174).  However, much of the current literature fails to characterize 
these features in an integrative manner, choosing epidemiological approaches that focus on few 
parameters using large samples. This thesis aimed to comprehensively characterize the metabolic 
features of prostate cancer patients near the time of diagnosis and to examine changes in this profile 
during acute treatment, immediately and 6-months following radiation therapy.  Specifically, features 
of both metabolic syndrome and glucose metabolism were the primary areas of investigation.  Body 
composition, features of lipid metabolism, adipokines, inflammatory markers, physical activity, and 
nutrition intake were also characterized to better understand the presences of metabolic syndrome and 
impairments in glucose metabolism in the prostate cancer patients.   Figure 8.1 illustrates the 
integrative model of prostate cancer investigated in this thesis.
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8.1 Prostate cancer patients present with a cluster of glucose-related 
metabolic perturbations that may contribute to aggressive prostate cancer 
growth 
Three major metabolic perturbations were identified in patients with the most aggressive 
cancers (indicated by the highest Gleason scores) at the time of diagnosis in Study 1 (Chapter 5). 
First, elevated C-peptide concentrations were observed, suggesting increased insulin secretion; this 
finding was supported by insulin concentrations and HOMA-IR calculations that approached 
significance in patients with the most aggressive cancers. Together, these findings suggest that 
patients with higher Gleason scores may have developed impairments in glucose metabolism and 
insulin resistance, which may relate to with the aggressiveness of their cancer.  C-peptide is an 
important indicator of insulin secretion as elevations in C-peptide concentrations indicate that high 
insulin concentrations are the result of insulin secretion and not poor insulin clearance (281) or 
peripheral insensitivity.   Second, greater visceral adiposity, measured by waist circumference, was 
identified in patients with the higher Gleason scores (4+3 or greater) compared with patients with 
Gleason 3+4. Large waist circumferences are typically observed with insulin resistance in non-
malignant populations (282), and large waist circumference is one of the defining characteristics of 
metabolic syndrome (157). Thirdly, altered adipokine levels (increased leptin, and increased leptin: 
adiponectin ratio) were observed in men with the highest Gleason scores, another phenotype 
commonly observed in insulin resistance (284).  Patients with Gleason score ≥4+3 were significantly 
older than patients with no cancer.   
  These factors were then further considered in men with high-risk prostate cancer relative to 
men without cancer but who were of similar age and body size in Study 2 (Chapter 6). Despite the 
lack of differences in body composition or adipokines between the high-risk cancer patients and the 
matched males, high-risk prostate cancer was associated with a greater magnitude of impaired 
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glucose tolerance during an OGTT compared with the matched males.  Thus, perturbations in glucose 
metabolism in high-risk prostate cancer patients at diagnosis are distinct from those of similar age and 
size who do not have cancer, and these perturbations may also contribute to the development of 
aggressive prostate cancer.  This also suggests that the increased age of patients with Gleason score 
≥4+3 in Study 1 cannot fully account for the metabolic perturbation observed. 
8.1.1 Impaired glucose metabolism is associated with aggressive prostate 
cancer 
Fasting glucose concentrations were not different between patients with different Gleason 
scores (Study 1, Chapter 5), nor were they different in treatment-naïve high-risk prostate cancer 
patients compared with matched males (Study 2, Chapter 6).  However, fasting glucose measures may 
not be sensitive enough to depict impairments in glucose metabolism in these patients (285).  The 
examination of fasting C-peptide, insulin, and HOMA-IR as well as OGTT measures including 
glucose, insulin, and C-peptide, demonstrate impairments in glucose metabolism in prostate cancer 
patients with high Gleason scores, compared to patients with lower Gleason scores (Study 1, Chapter 
5) and matched males (Study 2, Chapter 6).    Despite that fasting glucose is often used to identify 
impaired glucose metabolism it may not be the best biomarker, as it reflects the net balance of 
glucose metabolism and long-term ability of the body to metabolize glucose (285).  
Elevated fasting C-peptide concentrations have been associated with high-grade prostate 
cancer as well as increased likelihood of prostate cancer-specific death (128, 286); however, other 
studies demonstrate no association between C-peptide concentrations and prostate cancer risk (138, 
225). Insulin has been implicated in prostate cancer development through two major pathways to 
promote tumour growth: 1) MAPK signalling resulting in an anti-apoptotic effect via STAT3 
signalling, and 2) PI3K/Akt pathway, promoting proliferation, cell cycle progression and anti-
apoptotic effects via activation of BAD, Bcl, and FOXO complexes (287, 288).  PI3K/Akt also has 
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the ability to stimulate mTOR signalling, consequently promoting protein synthesis and promoting 
cell proliferation in the tumour (287, 288).   
Insulin and IGF-1 act through the same metabolic pathways to promote prostate cancer; 
however, fasting IGF-1, IGFBP-3, and the molar ratio IGF-1:IGFBP-3 were not significantly different 
between any of the groups in Study 1 (Chapter 5) or between the cancer patients and the matched 
males in Study 2 (Chapter 6). Since IGF-1 has similar functions with insulin, IGF-1 has been 
associated with increased risk of prostate cancer development (93, 289).   IGF-1 may be linked to 
early stage prostate cancer initiation, however, multiple studies have characterized a decrease in IGF-
1 action and a subsequent down-regulation of the IGF-1 receptors in advanced and metastatic disease 
(290, 291).  This down-regulation facilitates survival of the cancer cells once they enter circulation 
(290, 291), which may explain the lack of difference observed in the aggressive prostate cancer 
patients compared with matched males and throughout the trajectory in this thesis.   
Obesity may contribute to the relationship between impairments in glucose metabolism and 
aggressive prostate cancer as is associated with hyperinsulinemia, insulin resistance, and type 2 
diabetes.   Obesity is also association with increases in bioactive IGF-1 concentrations (292, 293). 
Bioavailability of IGF-1 is regulated through the IGFBPs, with IGFBP-3 identified as having the 
largest capacity to reduce IGF-1 bioavailability (294).  Higher IGFBP-3 resulting in lower active IGF-
1 has been associated with decreased risk of prostate cancer (93).  IGFBP-3 may not be an ideal 
biomarker to relate obesity with prostate cancer development.  While increased bioactive IGF-1 is 
associated with obesity, serum IGFBP-3 concentrations have not been associated with obesity (295, 
296). This increase in free IGF-1 was related to decreased IGFBP-1 and IGFBP-2 in obese versus 
normal weight subjects, not IGFBP-3 (296).   
 Despite matching age and BMI for males in Study 2 (Chapter 6), high-risk prostate cancer 
patients’ demonstrated impaired glucose tolerance to a greater extent than matched males without 
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cancer and thus, these collective perturbations in glucose metabolism of high-risk prostate cancer 
patients may be distinctly related to presence of the tumour. This hypothesis is further supported by 
the significant improvements observed in glucose concentrations during the OGTT performed 
immediately following treatment (7 weeks) and was maintained at the 33-week follow-up.  There 
were no significant changes in lifestyle factors, such as body composition, physical activity, and 
nutritional intake over the course of Study 2 (Chapter 6), despite that these factors usually contribute 
to changes in glucose metabolism in non-malignant populations (123, 297, 298).  However, it is 
possible that if the tumour contributes to impairments in host glucose metabolism, then radiation 
therapy to mitigate the tumour would also account for the observed improvements in glucose 
tolerance following radiation therapy.  We noted no significant differences in insulin and C-peptide 
response following radiation therapy, which suggest increased insulin sensitivity in peripheral tissues 
(such as skeletal muscle) for glucose clearance.   
 To better understand possible effects of treatment on peripheral glucose uptake, muscle 
biopsies would be needed.  Muscle biopsies would allow thorough examination (expression, 
regulation, activation) of numerous proteins involved in peripheral glucose uptake, including 
components of the insulin and IGF-1 signalling cascades to determine where potential impairments in 
glucose uptake are occurring. However, it was not feasible to obtain muscle biopsies for this thesis. 
Thus, to investigate potential mechanisms for the observed improvements in glucose metabolism 
following treatment, a novel cell culture model was developed which incubated human skeletal 
muscle cells and serum collected for prostate cancer patients to examine how systemic factors found 
in the serum may influence glucose metabolism in the muscle. While no previous literature has 
examined interactions between prostate cancer and skeletal muscle in vitro, the idea was conceived 
from studies that have used serum from prostate cancer patients prior to and following lifestyle 
interventions to induce changes in prostate cancer cell proliferation (275-277, 299-303).  These 
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studies demonstrated that human serum has the potential to induce significant change in in vitro 
models using prostate cancer cells (275-277, 299-303).  We hypothesized that it may be possible to 
induce changes in HSkMM using serum from prostate cancer patients to understand tumour– skeletal 
muscle interactions. 
   Tumour resection has been shown to significantly improve glucose metabolism (304), 
suggest that the tumour itself may contribute to changes in glucose tolerance.  Peripheral insulin 
resistance has also been shown to contribute to alterations in glucose metabolism in pancreatic cancer 
patients due to changes in glucose transport in to skeletal muscle as well as alterations in PI3K 
activity (270).  These peripheral effects may occur though a tumour derived factor.  Basso et al (205) 
identified a putative pancreatic cancer factor, present in the serum of patient capable of inducing 
impairments in glucose metabolism.  Thus, this model was designed to examine if systemically driven 
cancer-related changes in glucose uptake could be observed in cultured human skeletal muscle cells.  
With this model it was found that skeletal muscle cells incubated with serum from high-risk 
prostate cancer patients at baseline and the matched males demonstrated significantly lower glucose 
uptake compared to the cells incubated with serum from young males.  This suggested an age and 
body size-related, but not cancer-related, decline in glucose uptake. There were no significant 
differences in glucose uptake in cells incubated with serum for prostate cancer patients at baseline, 
following radiation therapy (7 weeks) and at 33 weeks post-baseline.  
8.1.1.1 Limitation to the novel model 
The novel cell culture model was unable to detect significant differences in glucose uptake 
between HSkMM incubated with serum from cancer patient and serum form matched males. 
Hypothesized reasons for the inability of the model to detect these differences include the use of 
fasting serum, insensitivity of the model, length of the incubation time, and the use of skeletal muscle 
as the experimental tissue cells.  First, fasting serum was used in all experiments to eliminate the 
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influence of variable post-prandial hormone levels on HSkMM in vitro. Study 2 (Chapter 6) reveal no 
significant differences in fasting glucose, insulin, C-peptide, and other glucose-related parameters 
between the high-risk prostate cancer patients and the matched males and impaired glucose tolerance 
was revealed in the prostate cancer patients through the glucose challenge of the OGTT.  
Consequently, fasting serum may not contain the factors necessary to induce significant changes in 
HSkMM and alter glucose uptake in vitro.   
Second, previous work has shown that human skeletal muscle myoblasts are suitable for 
examining glucose uptake in culture (203, 204) and pilot work suggested it may be possible to detect 
differences between prostate cancer patients and the matched males; however, once glucose uptake 
was averaged over numerous participants, there were no significant differences between the cancer 
patients and the matched males.  Thus, it is possible that the method was not sensitive to detect 
differences in glucose due to variability in the human serum.  Perhaps a more potent stimulus through 
the use of pre-conditioned media, concentrating the systemic factors released from the prostate cancer 
cells is required to induce changes in skeletal muscle in vitro.  Not only would the use of pre-
conditioned media create a more potent prostate cancer stimulus but it may eliminate the variability 
observed when using human serum. 
Third, the lack of differences observed between cancer patients and the matched males may 
be related to incubation time.  Either, 24 hours of incubation may not be long enough to induce 
cancer-specific changes in glucose uptake or it was too long of an incubation time and acute changes 
in glucose uptake were lost due to negative feedback mechanisms. However, it is important to note 
that 24 hour incubation period was sufficient to induce age and body size related changes in glucose 
uptake.  Conversely, 24 hours of incubation may have too long and acute changes in glucose uptake 
were lost due to negative feedback mechanisms.  Serum from prostate cancer patients may have 
induced acute changes in glucose uptake in the HSkMM, within the first minutes to hours of 
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incubation.  However, by the time the glucose uptake assay was completed, 24 hours following 
human serum administration, feedback mechanism within the cells may have been initiated to return 
glucose uptake levels to those of the matched males.   
Finally, changes in glucose tolerance in prostate cancer patients may not occur in skeletal 
muscle.  Skeletal muscle accounts for the largest proportion (~80%) of insulin stimulated glucose 
disposal in the human body (202), and was therefore chosen as the tissue of investigation.  However, 
the in vitro studies examining insulin resistance and pancreatic cancer were conducted in hepatocytes 
(205), suggesting that the liver may be a potential area of investigation.  It might only be possible to 
address the improvements in glucose clearance following treatment in vivo, using more invasive 
techniques such as hyperinsulinemic-euglycemic clamp or by measuring hepatic glucose production 
(via artiovenous-difference techniques, isotope dilution techniques, or labeled nuclear MR 
spectroscopy). These methods may provide a better indication of where insulin resistance is occurring 
and where improvements were occurring post-treatment.  Given the invasiveness and burden of these 
methods may be too high for a proper research study in cancer patients, an animal model may be a 
better choice to examine interactions between glucose metabolism and prostate cancer. 
8.1.2 Poor glucose tolerance may contribute to the development of secondary disease 
states in cancer survivors 
Patients with aggressive prostate cancer usually receive androgen deprivation therapy (ADT) 
as part of their treatment (305).  While acute treatment and specifically, radiation therapy, was the 
focus of this thesis, 4 of 9 patients received ADT during the study and more may have received ADT 
following study conclusion (Chapter 6).  ADT reduces androgens to castrate levels, essentially 
eliminating the primary anabolic stimulus for maintaining or gaining muscle (29). Consequently, 
patients lose significant amounts of skeletal muscle and gain adipose tissue (29, 145, 146), which is 
associated with significant metabolic perturbations leading to cardiovascular disease and diabetes (9).  
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Obesity has also been associated with increased risk of advanced disease (10, 11, 21, 22, 57, 58); 
consequently, obese patients already possess a potent risk factor for diabetes, which are further 
exacerbated due to treatment. Collier et al, have suggested that prostate cancer patients should be 
screened for symptoms relating to cardiovascular disease, diabetes and metabolic syndrome prior to 
ADT use to help mitigate the negative metabolic consequences of this treatments (25).  
Beyond ADT, there is emerging evidence suggesting that prostate cancer patients who 
receive other forms of treatment may be at risk of diabetes as well.  Thong et al examined incidence 
of diabetes following prostate cancer diagnosis and demonstrated that 50.2% of patients had received 
radical prostatectomy, 21.4% received radiation therapy, 12.1% received hormone therapy and 16.3% 
were undergoing active surveillance as their primary treatment type (108).    These data suggest that 
all prostate cancer patients, not just those who receive ADT, are at risk of developing diabetes in 
survivorship. 
The mechanism that drives the accelerated development of diabetes in men receiving ADT is 
largely unknown (306).  However, there is evidence to suggest that the development of diabetes may 
be related to observed changes in body composition (101).  ADT is primarily used to treat more 
aggressive forms of prostate cancer, which as noted in this thesis are associated with greater 
metabolic perturbations, like hyperinsulinemia, increased leptin, decreased adiponectin, inflammation 
and visceral adiposity (Chapter 5 and Chapter 6). No significant changes in body composition were 
observed over the acute treatment trajectory in Study 2 (Chapter 6); however, insulin and C-peptide 
response to the OGTT suggests increased insulin secretion despite normal fasting glucose and insulin 
levels.    Hyperinsulinemia, reflective of peripheral insulin resistance, has been shown linked to the 
development of insulin resistance in non-malignant populations (261, 307).  Peripheral tissues are 
unable to response to insulin and take-up circulating glucose resulting in hyperglycemia (261, 307). 
Hyperglycemia stimulates further insulin secretion, exacerbating this cycle and eventually resulting in 
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diabetes (261, 307).  Prolonged elevation in insulin secretion such as those observed during the 
OGTT in patients following 7 and 33 weeks following treatment many contribute to the development 
of insulin resistance and ultimately diabetes in prostate cancer survivors.  
8.1.3 Obesity, specifically visceral adiposity, and its associated metabolic sequelae 
may contribute to impairments in glucose metabolism observed in prostate cancer 
patients  
Obesity causes many metabolic perturbations including changes in the IGF-1 and insulin 
signalling axis as well alterations in adipokine production, sex hormones and inflammation in non-
malignant populations (308), which may contribute to aggressive cancer development.  However, 
obesity in most cases has been associated with increased risk of prostate cancer (10, 11, 21, 22, 57, 
58).  The literature that links obesity to prostate cancer risk in humans remains inconclusive because 
numerous obesity-related metabolic perturbations have also been linked to prostate cancer 
development, including insulin, IGF-1, leptin and sex hormones (308).   
 Based on average BMI, participants in both Studies 1 (Chapter 5) and 2 (Chapter 6) were 
classified as overweight.  While BIA, which provides fat and fat free mass distributions classified 
these patients at obese (% body fat >24% in male; 64). In Study 1 (Chapter 5), patients with Gleason 
score ≥3+4 had 33.9±8.0% body fat, which was the highest among any of the groups, but was similar 
to the high-risk prostate cancer patients in Study 2 (30.6±10.9%; Chapter 6).   Animal models 
demonstrate that excessive energy intake may stimulate prostate tumour growth directly and through 
increased angiogenesis by altering the expression of many angiogenic growth factors, specifically one 
of the most potent factors, vascular endothelial growth factor (310).  
The adipokine profile of prostate cancer patients is thought to link obesity and prostate cancer 
development.  Elevated leptin and decreased adiponectin levels have been associated with increased 
risk of prostate cancer (132).  Leptin primarily functions as a satiety signal, inhibiting lipogenesis and 
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stimulating lipolysis (311), and leptin concentrations are significantly elevated in obese versus normal 
weight humans (312).  Conversely, adiponectin, stimulates fatty acid uptake and increases fatty acid 
oxidation (311), and it has been shown to decrease in obese subjects (313). Leptin acts as a growth 
factor in pathological conditions stimulating cancer cell growth and angiogenesis (132), while 
adiponectin has been shown to modulate proliferation resulting in decreased growth (230).  In Study 1 
(Chapter 5), we observed significant increases in leptin and leptin to adiponectin ratio in patients with 
the most aggressive cancers.  However, in Study 2 (Chapter 6), prostate cancer patients were matched 
to individuals of similar BMI and thus had no differences in body composition, which may explain 
the similar adipokine profiles between these two groups.   
In Study 2 (Chapter 6), the leptin levels of the prostate cancer patients were significantly 
higher than the young males; however, there were no differences across the trajectory or with the 
matched males.  This adipokine profile, (elevated leptin, decreased adiponectin) may contribute to 
hyperinsulinemia and the development of diabetes in prostate cancer survivors.  Adiponectin has 
potent insulin sensitizing effects, activating AMPK and PPAR-α (314), while leptin resistance, 
observed with rising leptin levels, and has the opposite effect. Under normal conditions, leptin 
inhibits appetite, increases fatty acid oxidation, decreases glucose and ultimately reduces body weight 
and fat; however, in leptin resistance obesity, decreased fatty acid oxidation and increased glucose 
concentrations are observed, which may result in hyperinsulinemia and insulin resistance (314).  
Increased leptin and decreased adiponectin are associated with most aggressive forms of prostate 
cancer (as demonstrated in Study 1, Chapter 5); this may be of particular concern as these patients 
are most likely to receive ADT.  ADT is also associated with increased adipose tissue (29, 145, 146), 
which may further exacerbate the negative effects of elevated leptin and decreased adiponectin in 
circulation.  
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 Sex hormones, in particular testosterone, are hugely implicated in prostate cancer 
development.   Free testosterone enters the prostate cell and it is converted into dihydrotestosterone 
(DHT) by the 5α-reductase enzyme, which binds to the androgen receptor (AR).  This causes 
dissociation from heat-shock proteins and phosphorylation of the AR (258).  The AR dimerizes, and 
then enters the nucleus and binds to the androgen responsive elements in the promoter regions of 
numerous genes that increase PSA levels, cell growth and survival (258). However, testosterone 
levels decline with obesity, which would appear to be beneficial for prostate cancer patients. It is 
possible that free testosterone levels may not be a good biomarker of prostate cancer development 
(315).  Kaaks and Stattin suggest that sex hormone-binding globulin (SHBG), a carrier protein that 
binds to testosterone and DHT and reduces the bioavailability of these hormones, may be a better 
biomarker (315).  SHBG is inversely correlated with BMI, thus, obese individual has more 
bioavailable testosterone to facilitate prostate cancer growth (315). SHBG levels have been inversely 
associated with prostate cancer risk (316).  In addition to the potential role of SHBG, the majority of 
interprostatic DHT is formed locally, and has little correlations with circulating testosterone levels; 
therefore, the declining testosterone levels observed in obesity are of less consequence than the 
interprostatic DHT and 5α-reductase levels, key regulators of androgen action on prostate cancer 
(315).  Evidence for this relationship comes from examining the relationship between finasteride, a 
5α-reductase inhibitor, and prostate cancer risk.  Data from the Prostate Cancer Prevention Trial 
demonstrated a 22% reduction in risk of high-grade cancers in patients received finasteride and even 
higher reductions in patients with low-grade tumours (317).  Despite these hypotheses, the role for 
androgens has not been completely eliminated (318).  Here, higher testosterone levels were identified 
in the prostate cancer patients compared to the matched males, despite similar body composition; 
however, SHBG was not assess and therefore it was not possible to determine the bioactivity of 
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testosterone in our patients.  The interprostatic DHT and 5α-reductase levels were also not 
characterized and therefore were unable to investigate this relationship further.   
 Inflammation had also been identified as a potential link between obesity and aggressive 
prostate cancer growth, specifically through increases in IL-6 and TNF-α.  Obesity is associated with 
low-grade systemic inflammation, which facilitates cancer growth through several transcription 
factors including NF-κB and STAT3, to promote cell proliferation, survival, angiogenesis, tumour-
cell migration and metastasis (319).  There were no significant differences in CRP between any of the 
Gleason score groups in Study 1 (Chapter 5); however, CRP, IL-4, IL-6, IL-8, and IL-10, were 
significantly greater in the prostate cancer patients than the young males, which is indicative of a pro-
inflammatory environment.  Compared to the prostate cancer patients, young males had significantly 
lower fat mass and % body fat, which suggests that the observed increases in inflammatory marker 
may be related to increased adiposity. There were no significant differences in inflammatory profile 
between the cancer patients and the matched males, who demonstrated similar body composition.   
Systemic inflammation is also implicated in the development of obesity and insulin resistance in non-
malignant populations.  Obesity activates the IKKβ/NF-κβ and JNK pathways in various tissues. JNK 
activation phosphorylates of serine residues in the IRS-1 complex.  This phosphorylation prevents 
normal activation of the IRS-1 complex via the insulin receptor and its tyrosine kinases cascade 
(253).   IKKβ activation cause the translocation of NF-κβ, which stimulates the transcription of 
numerous genes associated with the development of insulin resistance including IL-6, IL-8, IL-10, 
and TNF-α (253).  This creates a cycle of further JNK and NF-κβ activation leading to insulin 
resistance.   
 Visceral adiposity may be specifically related to aggressive prostate cancer development 
(320, 321) and has be previously associated with higher Gleason score (321, 322).   Study 1 (Chapter 
5) also noted increased abdominal adiposity, measured by waist circumference, in patients with 
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Gleason ≥4+3.   Numerous hormonal changes occur as a result of increased visceral adiposity 
including decreased adiponectin, increased leptin, and hyperinsulinemia (323). Changes in adipokine 
profiles (increase leptin, decreased adiponectin) increase cancer cell proliferation and angiogenesis 
(132, 230), as described above. We observed increase leptin and decreased adiponectin levels in 
patients with the most aggressive cancers in Study 1 (Chapter 5), who also had the largest waist 
circumferences.  Visceral fat increases hyperinsulinemia by increasing the liver’s exposure to non-
esterified fatty acids (NEFA; 324).  Increased NEFA exposure can decrease the liver’s ability to 
respond to insulin and consequently results in increased gluconeogenesis and systemic 
hyperinsulinemia (324).  Systemic hyperinsulinemia may increase peripheral insulin resistance, 
consequently increasing circulating glucose levels and insulin release from the pancreas (261, 307).  
In Study 1 (Chapter 5), increased C-peptide, suggesting increased insulin secretion, was demonstrated 
in patients with the most aggressive cancers, who also demonstrated the largest waist circumferences.  
In Study 2 (Chapter 6), there were no direct measures of visceral adiposity, however, patients were 
categorized as overweight based on BMI and obese based on % body fat; these patients demonstrated 
impaired glucose tolerance following an OGTT which suggests impairments in the peripheral tissues’ 
ability to respond to insulin.  Taken together, visceral adiposity may be contributing to not only 
aggressive prostate cancer developments but a cluster of obesity-related metabolic perturbations that 
facilitate prostate cancer growth.   
8.2 Future Directions  
8.2.1 There are significant metabolic sequelae associated with aggressive prostate 
cancer: Does the relationship between glucose metabolism and aggressive prostate 
cancer change depending on geographical location? 
 Much of the literature that attempts to relate metabolism and lifestyle factors to prostate 
cancer remain inconclusive, often with contrasting results from various studies depending of the 
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variable of interest, such as glucose (83-85), insulin (73, 74, 325) or obesity (10, 11, 21, 22, 57, 58).  
One hypothesis to explain the heterogeneity of results considers differences in the geographical 
location of the studies.  Firstly, there are widely different prostate cancer screening protocols in 
different countries (43, 44, 326 ).  For example, PSA screening is widespread in North America, 
which consequently, results in a large number of prostate cancer diagnoses.  Cancers are usually 
identified early and are therefore highly treatable.  Thus, the 5-year survival rates for non-metastatic 
diseases in both Canada and the US are almost 100% (2, 327).  PSA screening is not as widespread in 
other counties, such as those in Europe, where prevalence of new cases of prostate cancer is highly 
different (43, 326).  The diversity in screening may contribute to a large range if metabolic 
disruptions observed between cohorts from North America and Europe. The second major difference 
between different geographical locations is diet and physical activity levels vary significantly 
between countries, which potentially results in significantly different metabolic profiles of prostate 
cancer patients.  The studies in this thesis use small, single-site Canadian populations, who typically 
undergo more frequent PSA screening, and may consume higher saturated fats, fewer vegetables and 
may be less active than Mediterranean and Scandinavian men (328, 329).  As such, future multi-
centre work should examine the metabolic diversity across difference geographic regions. 
8.2.2 Glucose tolerance improves immediately following radiation therapy: What 
changes occur during other forms of acute treatment?    
 In this thesis, high-risk prostate cancer patients demonstrate significant improvements in 
glucose tolerance immediately following radiation therapy. Patients with aggressive cancer present 
with a poor metabolic profile (obesity, increased insulin secretions, increased leptin decreased 
adiponectin; Chapter 6) and these patients are also most likely to receive ADT (305), which will 
likely exacerbate this poor metabolic profile.  Understanding what is happening in the early stages of 
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the treatment trajectory, before significant metabolic changes occur will allow for the development of 
optimal lifestyle interventions to combat these metabolic perturbations.   
 As well, investigation into the acute treatment trajectory must go beyond hormone therapy. 
The literature focuses on ADT; however, there are numerous other forms of prostate cancer treatment 
including radiation therapy, prostatectomy, and chemotherapy.  There is little literature on the 
metabolic health of patients who receive other forms of treatment.  Here, a combination of radiation 
therapy with or without ADT was examined and contrary to our hypothesis observed significant 
improvements in glucose tolerance immediately following 7 weeks of radiation therapy.  This 
demonstrates that, early in the treatment trajectory, radiation treatment with or without ADT has a 
unique metabolic response. Thong et al also demonstrated that patients who receive multiple types of 
treatment are diagnosed with diabetes in survivorship, not just those who receive hormone therapy 
(108).  Each treatment type possesses its own metabolic implications for survivors and understanding 
the impact of each treatment will facilitate the individualized interventions for different treatment 
types and improve quality of life for prostate cancer survivors.    
8.2.3 Immediately following treatment may be the best time for lifestyle interventions 
to combat the negative metabolic implications of prostate cancer 
 Both Study 1 and Study 2 (Chapter 5 and 6) demonstrate that prior to treatment, prostate 
cancer patients demonstrate significant metabolic disruption, including increased insulin secretion, 
impaired glucose tolerance, obesity, increased leptin, and decreased adiponectin concentrations 
(Chapter 5, 6).   However, glucose tolerance is improved with radiation treatment, despite no changes 
in many of the other metabolic markers examined such as body composition, physical activity and 
nutrition intake.  There is a significant body of literature looking to mitigate the detrimental changes 
in body composition that contribute to these metabolic disruptions and secondary disease state 
(cardiovascular disease, diabetes) via diet and exercise in patients who receive ADT (Reviewed: 330-
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332). Significant improvements in glucose tolerance were noted immediately following radiation 
treatment, suggesting this may be an ideal time to intervene to not only combat changes in body 
composition but to also exploit the improved metabolic profile of prostate cancer patients at this time 
during the acute treatment trajectory.  Investigating early versus later lifestyle interventions will help 
identify if it is possible to exploit improvements in glucose metabolism immediately following 
radiation therapy.  If it is possible to mitigate or even prevent changes in metabolism and body 
composition in prostate cancer, it may be possible to mitigate the long-term consequences of prostate 
cancer treatment such as the development of cardiovascular disease and diabetes as has been 
demonstrated in non-malignant populations (333, 334).   
8.2.4 Glucose metabolism is significantly altered in prostate cancer patients: What are 
the mechanisms? 
This thesis has demonstrated that there are specific metabolic sequelae that occur in prostate 
cancer; however, the mechanisms that cause these disruptions in metabolism are unknown in this 
population. In this thesis, an OGTT was used to examine the body’s ability to clear glucose from the 
blood, but the use of clamp techniques may provide further insight.  A hyperglycemic clamp acutely 
raises plasma glucose concentrations above fasting levels, via a continuous glucose infusion, which 
can be used as an index of insulin secretion (273). A hyperinsulinemic-euglycemic clamp, reflective 
of insulin sensitivity raises insulin concentration to 100μU/mL, while glucose concentrations are held 
at fasting levels via continuous infusions until homeostasis is achieved (273). Further details about 
hepatic and skeletal muscle insulin sensitivity could be revealed via artiovenous-difference techniques 
(335-333), isotope dilution techniques (339), or labeled nuclear MR spectroscopy (340); however, 
these techniques are invasive and a difficult to perform in cancer population due to the high patient 
burden.   The use of human skeletal muscle biopsies would also allow the characterization of the 
metabolic pathways involved in prostate cancer-induced impairments in glucose tolerance, but again 
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there is a high-burden associated with these techniques.  The use of tracer methodology for both 
glucose and lipid kinetics may also provide valuable insight into alteration in these processes. The 
development of novel models to investigate the relationship between insulin resistance and prostate 
cancer are warranted to help elucidate the complex interactions between insulin signalling and 
aggressive prostate cancer development.   
 Study 3 attempted to develop a model in which to investigate these interactions; however, it 
did not detect cancer related change in glucose metabolism.  Thus, the development of other models, 
both cell and animal, to investigate these interactions in necessary.  This thesis has demonstrated that 
there is a complex series of interactions between glucose metabolism, obesity, and prostate cancer 
development and progression.  Understanding the mechanism of these interactions will help at 
numerous time points across the treatment trajectory, including reducing occurrence, preventing 
cancer recurrence, and decreasing the risk of secondary disease states for prostate cancer survivors.  
There is a significant disconnect in the literature between what factors are associated with prostate 
cancer through observational studies and the physiological mechanism that drive these associations. 
Understanding these physiological mechanisms will allow the development of the most appropriate 
interventions for prostate cancer patients to create the best outcomes.     
8.3 Conclusions 
With this thesis I aimed to create a comprehensive metabolic profile of prostate cancer 
patients at the time of diagnosis to examine which metabolic factors may contribute to the most 
aggressive forms of prostate cancer.  I also sought to examine how this metabolic profile changed 
during the acute treatment trajectory in patient with the more aggressive cancer.  Patients with higher 
Gleason scores were found to have higher C-peptide levels, suggesting increased insulin release.  
These patients also had greater abdominal adiposity, measured by waist circumference and a 
disrupted adipokines profile compared with patients with lower Gleason scores.  All of these 
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metabolic perturbations are not only associated with the most aggressive forms of prostate cancer as 
well as the development of insulin resistance.  The metabolic profile of high-risk prostate cancer 
patients across the acute treatment trajectory, prior to treatment, demonstrated impaired glucose 
tolerance which improved following radiation treatment and this improvement was maintained 33 
weeks post-baseline, independent of changes in traditional moderators of glucose metabolism.  This is 
beneficial for these patients as they are the patients most likely to receive ADT as part of their cancer 
treatment.  ADT is associated with numerous body composition and metabolic changes that increase 
the risk of secondary disease states including diabetes in survivorship.  Thus, prostate cancer patients 
have a poor metabolic profile at the time of diagnosis, which can increase the risk of prostate cancer 
recurrence and secondary disease states in survivorship including diabetes.  This profile improves 
following treatment; however, these men are susceptible to the metabolic consequences of ADT, 
which will exacerbate these metabolic sequelae and lead to the development of secondary disease 
states such as diabetes.  Combating the changes in the metabolic profile of prostate cancer patients 
throughout the acute treatment trajectory may mitigate the development of secondary disease states in 
prostate cancer survivors. 
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Appendix A 
Glossary of Relevant Medical Terms 
5-year Survival Rate: the percentage of patients alive 5 years following diagnosis.  Used to estimate 
prognosis of a particular disease. 
 
Androgen Deprivation Therapy (ADT): any treatment that reduced the levels of androgen in the 
body to prevent them from reaching prostate cancer cells and stimulating growth.  There are two 
primary types of ADT, chemical and surgical.  An orchiectomy, surgical removal of the testicles, 
luteinizing hormone-releasing hormone analogs, luteinizing hormone-releasing hormone 
antagonists, anti-androgen are common forms of ADT.  All serve to reduce androgen to castrate 
levels. 
 
Cancer Survivor: An individual who has completed primary treatment. 
 
Digital Rectal Exam (DRE): physical medical examination involving the insertion of a digit (finger) 
into the rectum to palpate for abnormalities in the prostate and surrounding tissue. 
 
Metastasis: the spread of cancer from one organ or tissue to distant, non-adjacent organs or tissue. 
 
Prostate Specific Antigen (PSA): a serine protease produced by the prostate, used as a blood 
biomarker for prostate cancer. In non-malignant tissue it is secreted in seminal fluid, while in 
malignant tissue, it leaks into the blood stream raising circulating levels. 
 
PSA Failure: elevation of circulating PSA levels following prostate cancer treatment, indicating 
cancer recurrence. 
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Appendix B 
Gleason Scores 
Use of Gleason Scores as a Pathology Marker of Prostate Cancer 
The Gleason scores is most common pathology marker used to assess prostate cancer 
severity. The pathologist evaluates the patterns of the cells within the biopsy core and subsequently 
assigns 2 scores (each score ranges from1-5) to the tissue, based on the pattern of cell growth. The 
first score is the most common cell pattern and the second score is the second most common cell 
pattern. These scores are then added together to determine Gleason score (a total score ranging from 
2-10). A Gleason score of 1 indicates small uniform, tightly packed gland cells (Figure 1A), while 
larger more spaced cells with loosely defined edges indicates a Gleason score of 2 (Figure 1B).  With 
a Gleason score of 3 the cells begin to take on irregular shapes and spacing (Figure 1C); a Gleason 
score of 4 indicates that the glands have begun to fuse into cords or sheets (Figure 1D).  Finally, a 
score of 5 indicates that the cells have taken on a ragged sheet like appearance (Figure 1E) (Gleason, 
1992).  Generally, the higher the Gleason score, the more 
severe the cancer; however, a Gleason score of >7 is 
often defined in the literature as the cut point between 
moderate and severe prostate cancer diagnosis.   
Figure 1: Standardized drawing of prostatic 
adenocarcinoma histological patterns.  A.  Gleason 1: 
Small uniform, tightly packed gland cells. B.  Gleason 2: 
Larger, more spaced cells.  C. Gleason 3: Irregular shape 
and spacing.  D. Gleason 4: Cells have fused into sheets.  
E. Gleason 5: Ragged sheet like appearance. 
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Appendix C 
Detailed Methodology 
Biochemical Analysis 
Serum Glucose 
Serum glucose was measured using a spectrophotometer (Shimadzu UV160U UV-Visible 
Recording Spectrophotometer; Columbia, MD) and peroxidase/glucose oxidase enzymatic reaction.  
Test tubes were filled in triplicate with 10 L distilled water (blank), glucose standard or serum 
sample.  We added 2.5 mL of a reagent solution containing peroxidase, glucose oxidase and o-
dianisidine dihydrochloride to each tube.  Tubes were then vortexed and incubated at 37 C for 30 
minutes.  During the incubation period, glucose in the blanks, standards and samples reacts with 
glucose oxidase, releasing hydrogen peroxide.  Peroxidase then catalyzes a reaction between the 
liberated hydrogen peroxide and o-dianisidine dihydrochloride, forming oxidized o-dianisidine.  
Oxidized o-dianisidine produces a colour that can be read at 450 nm by the spectrophotometer.  The 
intensity of the colour in the samples in comparison to the intensity of the colour in the standards 
provides an indication of glucose concentration.  
 
Serum Insulin  
Serum insulin was measured in duplicate using the Coat-A-Count Insulin Radioimmunoassay 
kit (Study 1,Siemans Healthcare Diagnostics; Deerfield, IL) or the Millipore Human Insulin Specific 
Radioimmunoassay kit (Study 2, EMD Millipore, Billerica, MA) as the Coat-A-Count assay was 
discontinued.   
For the Coat-A-Count kit, 200 L of blank, standard or sample was added to polypropylene 
tubes pre-coated with insulin antibody.  To all tubes 1.0 mL of 125I-labeled insulin was added.  Tubes 
were vortexed and incubated at room temperature for 24 hours.  During the incubation period, 125I-
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labeled insulin competes with insulin in the sample or standard for binding sites on the insulin 
antibody molecules, which are fixed to the polypropylene tube walls.  After 24 hours, the supernatant 
was aspirated and tubes were counted for 1 minute using a gamma counter (Wallac Wizard 1470 
Automatic Gamma Counter; PerkinElmer Life and Analytical Sciences; Woodbridge, ON).  Samples 
or standards with high concentrations of insulin bind less 125I-labeled insulin and are less radioactive.  
For the Millipore kit, 100μL of assay buffer was added to each of the glass test tubes 
required, followed by 100μL of sample, standard, or blank, 100μL of hydrated 125I-labeled insulin and 
100μL of human insulin antibody.  Tubes were vortexed, covered and left to incubate over-night (24 
hours) at room temperature.  The following day 1mL of cold precipitating reagent was added to all 
tube.  The tubes were vortexed and incubated for 20 minutes at 4oC.  Tubes were then centrifuged at 
3000g for 20 minutes, after which the supernatant was aspirated and the precipitate was counted using 
the same gamma counter for 1 minutes.  This assay works under the same principle as the Siemens 
assays; samples or standards with high concentrations of insulin bind less 125I-labeled insulin and are 
less radioactive.  
 
Serum C-peptide 
Serum C-peptide was assessed in duplicate using a C-peptide Double Antibody 
Radioimmunoassay kit (Siemans Healthcare Diagnostics; Deerfield, IL).  During the assay, 25 L of 
standard or serum was combined with 100 L 125I-labeled C-peptide and 100 L C-peptide antibody 
in polypropylene tubes.  The tubes were vortexed and incubated for 4 hours at room temperature.  
During the incubation, C-peptide in the standard and sample competed with 125I-labeled C-peptide for 
binding sites on the C-peptide antibody.  After the 4-hour incubation, 1.0 mL of cold (4 C) 
precipitating solution was added to each tube.  The tubes were vortexed and then centrifuged at 3000g 
for 15 minutes.  After centrifugation, the supernatant was aspirated and the tubes were counted for 1 
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minute in a gamma counter.  Radioactivity is inversely correlated with C-peptide concentration.  
Concentration of C-peptide was determined by interpolating samples from a graph of known C-
peptide concentrations.  
 
Glycated Hemoglobin (HbA1C) 
 Glycated hemoglobin was determined from fresh whole blood samples using the 
commercially available A1CNow+ kit (Bayer Healthcare LLC, Sunnyvale, CA), which uses 
immunological reactions to determine glycated hemoglobin and a chemical reaction to determine total 
hemoglobin.  These values are then used to calculate the percentage of glycated hemoglobin.  For the 
assay, 5 μL of whole blood was added to the blood collector provided by the manufacturer. Once 
collected, the blood collector is than combined with the manufacturer sampler body and shaken to 
adequately dilute the sample.  The diluted sample was then added to the test cartridge where blue 
microparticles conjugate to the anti-HbA1c antibodies and migrate along reagent strips to the 
detectors. The amount of blue microparticles present on the strip is proportional to the amount of 
HbA1C in the sample. Total hemoglobin is measured using basic chemistry.  The sample diluent 
reacts with the hemoglobin present in the sample and converts hemoglobin to met-hemoglobin, which 
is red-brown in colour.  The intensity of the red-brown is measured on the reagent strips and is 
proportional to the concentration of hemoglobin.  Quantification of both forms of hemoglobin 
occurred using reflectance photometry and two LED lights.  The monitoring device than provided a 
reading of the percent of glycated hemoglobin. 
 
Perchloric Acid (PCA) Extraction for Serum Lactate 
Serum contains many extraneous proteins that may interfere with the reading of certain 
metabolites such as lactate.  To remove these extra proteins, a solution of 0.6 M perchloric acid was 
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prepared by combining perchloric acid stock solution and water.  Following which 500 L of this 
solution was combined with 100 L of serum in an eppendorf tube.  All tubes and solutions were kept 
on ice throughout the procedure.  Tubes were vortexed and centrifuged at 4 C at 15 000g for 2 
minutes.  After centrifugation, 250 L of 1.25 M potassium bicarbonate was added to each tube.  
Tubes were incubated on ice for 10 minutes, and centrifugation was repeated. The supernatant was 
extracted, transferred to new eppendorf tubes and stored at -80 °C until use.  A dilution factor of 8.5 
is introduced with the PCA extraction; the dilution factor was taken into account when calculating 
final concentrations of lactate.  
 
Serum Lactate following PCA Extraction 
Serum lactate was measured using a spectroflourophotometric assay similar that described by 
(1).  A reagent solution was first prepared containing 15 mL of hydrazine, 15 mL glycine, and 1500 
μL of NAD+, brought to a volume of 150 mL with distilled water and the pH was adjusted to 10.0.  
Lactate dehydrogenase (5200 U/mL) was diluted by combining 250 uL of lactate dehydrogenase 
(Sigma-Alderich, St. Louis, MO) with 1 mL of the reagent.  Subsequently, 25 μL of dilute blank, 
standard, and sample was added to glass test tubes in triplicate.  Dilute reagent was added to each test 
tube at a volume of 1 mL and test tubes were vortexed.  Baseline readings were taken on the 
spectroflourophotometer (RF-1501; Chimadzu, Columbia, MD) with the absorbance set between 365 
nm and 455 nm.  After baseline readings, 25 μL of dilute lactate dehydrogenase was added to each 
test tube.  Tubes were vortexed and incubated in the dark for 120 minutes.  Following incubation, a 
final reading of each tube was completed and the final absorbency of each tube was determined by 
subtracting the baseline reading from the final reading.  During the incubation, lactate present in the 
tubes reacts with NAD+ to form pyruvate and NADH as catalyzed by lactate dehydrogenase.  
Pyruvate then reacts with the hydrazine present in the reagent to drive the first reaction to completion.  
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The fluorescence of NADH – created from the reduction of NAD+ - is directly proportional to the 
concentration of each sample.  
 
Serum Triglycerides 
Fasting triglycerides concentrations were measured using a commercially available 
triglyceride-GPO regent set (Pointe Scientific, Canton, MI).  Triglyceride reagent (active ingredients:  
ATP 1.0mM, Magnesium Sale >5.9mM, 3-hydroxy-2,3,4-tribomobenzoic acid (TBHB) 2.0mM, 
glycerol phosphate oxidase (GPO) >2000 U/L, lipase >200 000 U/L, glycerol kinase (GK) 1000 U/L 
peroxidase >500 U/L) was prepared according to the manufacturer’s instructions, after which 1 mL 
was pipetted into required glass test tubes and incubated at 37oC for 5 minutes.   For the assay, 10 μL 
of blank, standard or sample was added to each tube and incubated again for 5 minutes at 37oC.  
During incubation, lipase catalyzes the degradation of triglycerides into glycerol and non-esterified 
free fatty acids (NEFAs).  GK then catalyzes the reaction between glycerol and ATP to form glycerol-
3-phosphate (G3P) and ADP.  The newly formed G3P reacts with oxygen in the presence of GPO to 
form hydrogen peroxide and dihydroxyacetone phosphate.  Peroxidase than catalyzes the reaction 
between hydrogen peroxide and TBHB to produce a red coloured quinoneimine dye. The absorbance 
of each tube was read at 540 nm on the spectrophotometer (Spectramax Plus 384; Molecular Devides, 
Sunnvale, CA).  The increase in absorbance at 540nm is directly proportional to the concentration of 
triglyceride in the sample.   
 
Total Cholesterol  
Fasting serum cholesterol will be evaluated using a commercially available cholesterol 
reagent set (Pointe Scientific, Canton, MI).  The cholesterol reagent (active ingredients:  4-
aminoantipyrine 0.6mM, sodium cholate 8.0mM, cholesterol esterase >150 U/L, cholesterol oxidase 
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> 200 U/L, horseradish peroxidase 1000 U/L, ρ-hydroxybenzene (ρ-HBS) sulfonate 20mM) was 
prepared according to the manufacturer’s instructions and 1mL was added to glass test tubes as 
required.  Reagent was pre-warmed at 37oC for 5 minutes.  Sample, standard or control was added to 
each tube in a volume of 10μL.  Tubes were incubated at 37oC for 5 minutes.  During the incubation, 
free cholesterol and fatty acids are liberated from cholesterol esters via cholesterol esterase.  
Cholesterol oxidase than catalyzes the reaction of free serum cholesterol to cholestol-3-one and 
hydrogen peroxide.  Hydrogen peroxide couples with 4-aminoantipyrine and ρ-HBS in the presence 
of peroxidase to produce quinoneimine and water. The absorbance of each tube was read at 520 nm 
on a spectrophotometer (Spectramax Plus 384; Molecular Devides, Sunnvale, CA).  The amount of 
quinonemine is directly proportional to the concentration of total cholesterol in the sample.   
 
High-density Lipoprotein (HDL) 
Fasting serum HDL cholesterol will be measured using the HDL Cholesterol Precipitating 
Reagent Set (Dextran Sulfate) and the cholesterol reagent set (Pointe Scientific, Canton, MI).  This 
two-part assay involves first removing LDL and VLDL cholesterol fractions and leaving the HDL 
fraction in solution.  The HDL concentration is then determine in the supernatant using the 
cholesterol reagent set as described above.  
The HDL cholesterol precipitating solution was prepared using the manufacturer’s 
instructions (active ingredients:  dextran sulfate (50 000MW) 10g/L, Magnesium ions 500mM).  
Samples and controls were diluted 1:1 with saline, after which 500μL of diluted sample and controls 
were added to each tube.  Then, 50μL of reagent was added and the tubes were vortexed and 
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incubated for 5 minutes at room temperature.  Tubes were vortexed again and centrifuged at 2000g 
for 5 minutes.  The supernatant was then used in the cholesterol assay described above.   
 
Low-density Lipoprotein (LDL) 
Fasting serum LDL was assessed indirectly using the procedures described by Friedewald et 
al (2). Total cholesterol, HDL and TG was assessed using the procedures described above.  LDL 
concentrations was then estimated based on the following equation (2). 
𝑳𝑫𝑳 (𝒎𝒎𝒐𝒍 𝑳) = 𝒕𝒐𝒕𝒂𝒍 𝒄𝒉𝒐𝒍𝒆𝒔𝒕𝒆𝒓𝒐𝒍 (𝒎𝒎𝒐𝒍 𝑳⁄ ) − 𝑯𝑫𝑳(𝒎𝒎𝒐𝒍 𝑳⁄ ) − (𝑻𝑮(𝒎𝒎𝒐𝒍 𝑳⁄ )  ×  𝟐. 𝟐)⁄  
 
Serum TNF-α, IL-6, IL-4, IL-8, IL-10 
Serum cytokines were analyzed using the BD Cytometric Bead Array Human Soluble Protein 
Master Buffer Kit and BD FACSCalibur flow cytometer (BD Biosciences; Mississauga, ON).  The kit 
provides 6 types of capture beads coated with an antibody specific to TNF-α, IL-1β, IL-6, IL-4, IL-8 
or IL-10.  Each bead has a matching detection reagent that fluoresces at a specific activity.  Prior to 
beginning the assay, all beads were combined into a single tube and vortexed and all detection 
reagents were combined into single tube.  Serum samples were diluted in a 1:4 ratio with serum 
diluent provided by the manufacturer. 
During the assay, 50 L of each standard or diluted sample was added to appropriately 
labelled tubes and 50 L of the Mixed Capture Beads was then added to each tube. Tubes were 
vortexed and incubated at room temperature for 1 hour.  During the incubation, the beads form 
complexes with the cytokines matching their antibodies.  After 1 hour, 50 L of Mixed Detection 
Reagents was added to each tube, tubes were vortexed and then incubated for 2 hours at room 
temperature.  During the 2-hour incubation, the detection reagent specific to each bead associates 
with the bead/cytokine complex, forming a sandwich structure.  After 2 hours, 1 mL of wash buffer 
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was added to all tubes.  Tubes were vortexed and centrifuged at 200g for 5 minutes, after which time 
the supernatant was aspirated.  Each pellet was re-suspended with 300 L wash buffer and acquired 
on the flow cytometer.  Each of the 6-bead/cytokine/detection reagent complexes is reflected as a 
different population.  Concentrations were determined by comparing the mean fluorescence of the 
population to the standard curve for each cytokine.   
 
Serum C-reactive Protein (CRP) 
Serum CRP will be measured using an enzyme-linked immunosorbant assay (ELISA) (R&D 
Systems Inc, Minneapolis, MN).  Wells of the ELISA plate are pre-coated with monoclonal antibody 
specific for human CRP.  All regents were prepared according to manufacturers’ specifications and 
samples were diluted 100-fold. To prepare, 100μL of assay diluent was added to each well, followed 
by 50μL of standard, control or diluted sample.  The plate was incubated at room temperature for 2 
hours, following which the plates was aspirated and washed 4 times with the manufacturer’s wash 
buffer.  200μL of CRP conjugate was added to each well and incubated again for 2 hours at room 
temperature.  The wash process was repeated and 200μL of substrate solution was added to each well.  
A third 30 minute incubation followed protecting the plate from light, followed by the addition of 50 
μL of stop solution.  Optical density was determined using a microplate reader at 450nm.  The 
amount of colour is directly proportional to the concentration of CRP in the sample.   
 
Serum Adiponectin 
Serum adiponectin was measured using an enzyme-linked immunosorbant assay (ELISA) 
(R&D Systems Inc, Minneapolis, MN).  Wells of the ELISA plate are pre-coated with a monoclonal 
antibody specific to the adiponectin globular domain.  All regents were prepared according to 
manufacturers’ specifications and samples were diluted 100-fold. To prepare, 100μL of assay diluent 
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was added to each well, followed by 50 μL of standard, control or diluted sample.  The plate was 
incubated at room temperature for 2 hours, following which the plate was aspirated and washed 4 
times with the manufacturer’s wash buffer.  200μL of adiponectin conjugate was added to each well 
and incubated again for 2 hours at room temperature.  The wash process was repeated and 200μL of 
substrate solution was added to each well.  A third 30 minute incubation followed, protecting the 
plate from light, followed by the addition of 50 μL of stop solution.  Optical density was determined 
using a microplate reader at 450nm.  The amount of colour is directly proportional to the 
concentration of adiponectin in the sample.   
 
Serum Leptin 
 Serum leptin will be measured using the Human Leptin sandwich enzyme ELISA 
immunoassay (R&D Systems Inc, Minneapolis, MN).  Wells of the ELISA plate are pre-coated with 
human specific monoclonal leptin antibody. Prior to the assay samples were diluted 50-150-fold and 
all regents were prepared as instructed by the manufacturer.  For the assay, 100 L of Assay Diluent 
was added to each well and 100 L of either standard, control, and sample.  The plate was incubated 
at room temperature for 2 hours.  During the incubation period, leptin in the standards or samples 
becomes bound to the antibody-coated microwells. The plate was then washed and 200 L of Leptin 
Conjugate was added and the plate was incubated for 1 hour at room temperature. During the second 
incubation period, the immunoconjugate binds to the leptin-antibody complex affixed to the wells.  
After the incubation, the plate was washed again and 200 L of Substrate Solution was added to each 
well.  The plate will again be incubated at room temperature for 30 minutes, protected from light, 
during which time a blue colour will develop as the TMB reacts with hydrogen peroxide. Finally, 50 
L of stop solution was added to each well causing the colour of the well to change from blue to 
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yellow. The plate was then read at a wavelength of 450 nm. The amount of colour is directly 
proportional to the concentration of leptin in the sample.   
 
Insulin-like Growth Factor -1 (IGF-1) 
IGF-1 was measured using a commercially available enzyme-linked immunosorbent ELISA 
kit (R&D Systems Inc, Minneapolis, MN).  Prior to the start of the assay, samples were extracted and 
diluted 100-fold to liberate IGF-1 from its binding proteins.  For the extraction, 380μL of an acidic 
dissociation solution was combined with 20μL of sample and incubated for 10 minutes at room 
temperature.  Following which, 50 uL of this solutions was added to 200μL of buffered proteins and 
were assayed immediately. All regents were prepared according to manufacturers’ specifications. To 
begin, 150μL of assay diluent was added to each well, followed by 50 μL of standard, control or 
liberated sample.  The plate was incubated at 2oC for 2 hours, following which the plate was aspirated 
and washed 4 times with the manufacturer’s wash buffer.  200μL of cold IGF-1 conjugate was added 
to each well and incubated again for 1 hours at 2oC.  The wash process was repeated and 200μL of 
substrate solution was added to each well.  A third, 30 minute incubation followed, protecting the 
plate from light, followed by the addition of 50 μL of stop solution.  Optical density was determined 
using a microplate reader at 450nm.  The amount of colour is directly proportional to the 
concentration of IGF-1 in the sample.   
 
Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) 
IGFBP-3 was measured using a commercially available enzyme-linked immunosorbent 
ELISA kit (R&D Systems Inc, Minneapolis, MN).  Wells of the ELISA plate are pre-coated with 
human specific monoclonal IGFBP-3 antibody. Prior to the assay samples were diluted 100-fold and 
all regents were prepared as instructed by the manufacturer.  To begin, 100μL of assay diluent was 
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added to each well, followed by 100 μL of standard, control or diluted sample.  The plate was 
incubated at 2oC for 2 hours, following which the plate was aspirated and washed 4 times with the 
manufacturer’s wash buffer.  200μL of cold IGFBP-3 conjugate was added to each well and 
incubated again for 1 hour at 2oC.  The wash process was repeated and 200μL of substrate solution 
was added to each well.  A third, 30 minute incubation followed, protecting the plate from light, 
followed by the addition of 50 μL of stop solution.  Optical density was determined using a 
microplate reader at 450nm.  The amount of colour is directly proportional to the concentration of 
IGFBP-3 in the sample.   
 
Serum Testosterone 
Testosterone was measured using the commercially available Testosterone Parameter assay 
(R&D Systems Inc, Minneapolis, MN).  The assay is based on the competitive binding technique and 
the intensity of the colour at the end of the assay is inversely proportional to the concentration of 
testosterone in the sample.  The supplied microplate comes coated with a goat anti-mouse antibody to 
which monoclonal antibody specific for testosterone binds.  The testosterone in the sample competes 
with a fixed amount of horseradish peroxidase labelled testosterone for sites on the monoclonal 
antibody. Samples were diluted 10-fold prior to the assay and all regents were prepared according to 
the manufacturer’s instructions.  To begin, 50μL of primary antibody solution was added to each well 
and incubated at room temperature for 1 hours on a horizontal orbital microplate shaker at 500 rpm.  
The plate was aspirated and washed 4 times with the manufacturer’s wash buffer and 100μL of 
standard, control, diluted sample, or blank was added to each well.  Following which, 50μL of 
testosterone conjugate was added to each well.  The plate incubated at room temperature for 3 hours 
on a horizontal orbital microplate shaker at 500 rpm.  Washing procedures were repeated and 200μL 
of substrate solution was added to each well.  The plate was incubated for 30 minutes at room 
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temperature protected from light.  Stop solution was added in a volume of 50μL to each well and 
optical density was determined at 450 nm using a microplate reader. 
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